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ABSTRACT 
Oesophagectomy is a highly invasive procedure characterised by an intense metabohc 
inflammatory response. Previous attempts to characterise surgical stresses that are associated 
with oesophagectomy have relied on the quantification of cytokines and acute phase proteins, 
yielding variable and sometime contradictory results. By accepting this conventional 
approach, the potentially powerful resource offered by gas- and fluid-phase metabolic 
profiling has been overlooked. 
The objective of this PhD was to delineate those metabolic alterations associated with 
transthoracic oesophagectomy. Towards this goal a modem mass-spectrometry based 
approach was adopted to explore both fundamental aspects of breath analysis in the clinical 
setting and the expiratory phenotype of patients during the perioperative period. Fluid-phase 
NMR-base metabonomics was also used to assess serum and urine response to these 
injuries. 
Initial studies provide strong evidence that the concentration of selected volatile metaboUtes 
within exhaled breath are influenced by sampling methodology including, variation of 
expiratory flow rate and minute ventilation. SIFT-MS studies determined that surgery was 
responsible for significant changes in the levels of prominent breath metabolites, including 
acetone, isoprene and hydrogen cyanide, that were associated with (patho)physiological 
processes. In particular, the extent of surgical trauma and the development of postoperative 
pneumonia were linked to specific changes in breath metabolites. The finding of lower 
hydrogen cyanide within the breath of patients who developed postoperative pneumonia was 
supported by an equivalent observation in non-surgical patients with pneumonia. 'H NMR 
analysis of serum and urine samples from patients undergoing oesophagectomy revealed 
significant changes in the global metabolic phenotype. Assigned determinants of these 
metabolic responses were, for the most part, known intermediates of prominent intracellular 
energy pathways. 
These findings represent an advancement of our understanding of factors influencing breath 
gas analysis in human subjects. Clinical studies have yielded important insight into the 
metabohc pathways altered in response to surgical stress. 
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Literature review 
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1. LITERATURE REVIEW 
1.1 Oesophagectomy for the management of oesophageal cancer 
1.1.1 Epidemiology of oesophageal cancer 
Oesophageal cancer is ranked within the top ten most common malignancies worldwide [1] 
and is the sixth most common cause of cancer related death [2], There are two main 
histological types of oesophageal cancer, squamous cell carcinoma and adenocarcinoma, the 
former accounting for greater than 90% of all oesophageal tumours [3], However, in the last 
30 years the incidence of oesophageal squamous cell carcinoma has declined in some 
western countries, whilst at the same time there has been a dramatic rise in the incidence of 
adenocarcinoma [4-12], such that it is currently the most rapidly increasing cancer in the 
United States [7]. 
Oesophageal cancer has a bleak prognosis, with an overall five-year survival rate that is often 
less than 10% [13]. The poor prognosis of oesophageal cancer is largely due to the advanced 
stage at which many patients present to medical attention [14]. This is reflected by the 
Surveillance Epidemiology and End Result (SEER) data from the United States where 
between the years 2001-2005 the median age at which patients were diagnosed with 
oesophageal cancer was 69 years, whilst during the same period the median age of death 
from this disease was 70 years [11]. 
1.1.2 Oesophagectomy 
In the absence of contraindication, surgery remains the mainstay of treatment for patients 
with localised oesophageal cancer [15]. Notwithstanding, five-year survival after 
oesophagectomy seldom exceeds 25% [16-17]. In England approximately 2000 
oesophagectomies are performed each year [18], roughly correlating to one third of all 
patients diagnosed with oesophageal cancer [19]. Recent figures taking in to account global 
experiences, have suggested that 15% to 20% of all patients presenting with a diagnosis of 
oesophageal cancer are ultimately suitable for curative resection [14]. There also remains 
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considerable debate as to the most appropriate surgical treatment for oesophageal cancer. The 
most common surgical approaches for potentially curative resection of oesophageal cancer 
are transthoracic and transhiatal oesophagectomy [15]. 
1.1.2.1 Transthoracic oesophagectomy 
Transthoracic oesophagectomy, successfully performed for the first time by Franz Torek in 
1913 [20], typically combines a laparotomy and right sided thoracotomy with 
oesophagogastric anastomosis either within the chest (two-stage technique) or neck (three-
stage technique). The main advantage of the transthoracic approach is the opportunity for 
superior visualisation of the operative field allowing more thorough dissection of the tumour 
and lymphatics [14, 21], whilst at the same time, reducing the risk of injury to adjacent 
structures including the azygos vein, aorta, thoracic duct and large airways [15]. The 
transthoracic approach is often associated with higher rates of postoperative morbidity and 
mortality [16-17]. 
1.1.2.2 Transhiatal oesophagectomy 
Transhiatal oesophagectomy, first reported by Grey Turner in 1931 [22] and later 
repopularised by Orringer in the late 1970's [23-24], requires laparotomy, blind dissection of 
the thoracic oesophagus and formation of a cervical anastomosis, thus avoiding formal 
thoracotomy. Many surgeons prefer the less invasive transhiatal approach for older patients 
and patients with greater comorbidity [16]. Whilst limiting the degree of surgical stress, 
critics argue that this approach is contra to basic surgical principals of adequate exposure and 
haemostasis and that the oncological quality of the resection is compromised by inadequate 
mediastinal clearance. 
1.1.2.3 Lymphadenectomy 
Approximately 80% of patients who undergo surgery for oesophageal cancer have lymph 
node metastasis [15]. An increased number of positive regional lymph nodes is predictive of 
decreased survival following oesophagectomy [25-26]. There is however little doubt that for 
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some patients with lymph node metastasis, curative resection may still be achieved by 
oesophagectomy and radical lymphadenectomy. Several studies provide strong evidence that 
an increased extent of lymphadenectomy is associated with improved survival following 
oesophagectomy [25-32], Formal lymphadenectomies routinely carried out for tumours of 
the oesophagus are; single-field, involving dissection of abdominal lymph nodes; two-field, 
involving dissection of abdominal and mediastinal lymph nodes; and three-field, involving 
the first and second fields as well as dissection of lymph nodes in the neck. Many surgeons 
still however question the benefit of radical lymphadenectomy and as a result do not carry 
out formal lymph node dissection during oesophagectomy. 
1.2 Clinical outcomes of oesophagectomy 
Oesophagectomy is widely considered a high risk surgical approach [33], Whilst 
improvements in surgical technique, perioperative monitoring and postoperative care have 
led to a reduction in mortality following oesophagectomy [34-37] [Figure 1.1], early 
mortality still remains between 5% and 10% [34]. Moreover, postoperative complications, 
involving predominantly the cardiorespiratory system, occur in approximately 50% of 
patients undergoing oesophagectomy [38-41]. Preoperative malnutrition, advanced patient 
age and high rates of comorbidity, together with the extent of surgical trauma and frequent 
requirement for periods of one-lung-ventilation (OLV) are all expected to contribute to the 
high risk that is associated with oesophagectomy. 
Overall mortality following oesophagectomy is higher in Western series compared to those 
firom the East [34, 36-37], The findings of the last major review of the world literature for 
oesophagectomy demonstrated higher rates of overall mortality (8.9% vs. 5.2%), anastomotic 
leak (10.2% vs. 5.5%) and lower 5-year survival (23,0% vs. 30.5%) in Western compared to 
Eastern series [34]. The superior outcomes of Eastern centres, particularly those in Japan, are 
attributed to meticulous surgical technique, radical lymphadenectomy and the different 
characteristics of patient cohorts [34]. 
Two previous systematic reviews published in 1999 and 2001 concluded there to be no 
significant difference in long term survival between patients undergoing transthoracic and 
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Figure 1.1 Postoperative mortality following oesophagectomy 
There have been four reviews of the world's literature reporting postoperative 
mortality following oesophagectomy [34-37], The most recent, published by 
Jamieson et al. in 2004, reporting data from the period 1990-2000, found that die 
overall mortality rate following oesophagectomy was 6.7%, witli rates in the Eastern 
and Western centres of 5.2% and 8.9% respectively [34]. 
transhiatal oesophagectomy [16-17]. Whilst postoperative mortality was higher in patients 
undergoing transthoracic resection, rates of anastomotic leak, anastomotic stricture and 
recurrent laryngeal nerve palsy were greater in the transhiatal group [16-17], Hulscher el al., 
who reviewed the literature from 1990 to 1999 also found that intraoperative blood loss, 
operative time and intensive care and hospital stay were significantly greater in the 
transthoracic group [16], 
There is evidence that surgeon case load [42-48] and hospital volume [42, 44, 49-71] are 
both predictors of patient outcome after oesophagectomy. Recent reports have suggested that 
in experienced centres complete resection of oesophageal cancer can be achieved in greater 
than 70% of cases, with an associated mortality of less than 5% [72-73]. Rates of 
postoperative morbidity and 5-year survival are also more favourable for patients undergoing 
oesophagectomy in expert centres [74-75]. Five-year survival rates reported by one expert 
centre were 84%, 49%, 27%, and 17% for stage I (T1 NO), stage HA (T2-T3 NO), stage IIB 
(T2-T3 Nl) and stage III (T3-T4 Nl) disease respectively [76-77]. This has prompted the 
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recommendation that patients indicated for surgical management of oesophageal cancer 
should be referred to high volume, expert centres [55]. 
1.3 Metabolic inflammatory response to surgical stress 
1.3.1 General metabolic response to surgical stress 
1.3.1.1 Normal physiological response 
The normal stress response to injury was first described by Cuthbertson in the early 1930's 
[78]. Although further details have since been added, Cuthbertson's original observation of a 
biphasic immune, inflammatory and metabolic response is still upheld, hi the context of 
surgical trauma the initial 'shock' phase, occurring in response to anaesthesia and tissue 
injury, is principally characterised by haemodynamic instability. Specific features of the 
'shock' phase include; a hypometabolic state, decreased energy expenditure, hypothermia, 
normal glucose production, raised blood glucose, raised catecholamines, raised 
glucocorticoids, low cardiac output and poor tissue perfusion [79-80]. Careful fluid 
resuscitation and inotropic support, guided by anaesthetic monitoring, however help to limit 
the magnitude and duration of these effects. Subsequent to the early 'shock' phase is a period 
of hypermetaboHsm, during which proteins and fats are consumed and body water and salts 
are conserved [81]. Additional features of this second phase include; increased metabolic 
rate, increased energy expenditure, hyperthermia, increased glucose production, profound 
protein catabolism, raised or normal blood glucose, raised or normal catecholamines, raised 
or normal glucocorticoids, increased cardiac output and normal tissue perfusion [79-80], 
1.3.1.2 Metabolic picture 
The normal metabolic response to surgical trauma is coordinated by a complex neuro-
endocrine flux, which accompanies the release of inflammatory mediators firom activated 
white blood cells [80]. Expected initiators of this response during oesophagectomy include 
tissue damage and ischaemia reperfusion injury. 
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After major surgery there can be a dramatic rise in resting energy expenditure and oxygen 
consumption [79-80, 82], that is proportional to the degree of surgical stress [79]. Previously, 
Sato et al. have reported that resting energy expenditure is significantly increased on days 1, 
3, 5 and 7 following transthoracic oesophagectomy [83]. The same group also demonstrated 
that the resting energy expenditure of patients who had undergone transthoracic 
oesophagectomy was significantly higher on postoperative day 7 than that of other patients 
who underwent, less invasive, transhiatal resection [83]. 
1.3.1.2.1 Glucose metabolism 
Hyperglycaemia is a central feature of the early response to trauma. The demands of tissues 
and activated white blood cells, leads to a rapid depletion of glucose stores, prompting de 
novo synthesis of this important metabolite. Whilst glycogenolysis may sustain glucose 
requirements for a short period, long term gluconeogenesis is maintained by proteolysis, 
hpolysis and conversion of lactate that is produced by anaerobic tissue metabolism [81]. 
1.3.1.2.2 Protein metabolism 
Cuthbertson was the first to demonstrate an association between injury and protein 
metabolism, through the observation of increased nitrogen losses from patients who had 
sustained orthopaedic trauma [78]. Cuthbertson and subsequent other authors attributed this 
negative nitrogen balance to the breakdown of skeletal and visceral muscle protein in order to 
meet the requirements of wound healing [78, 84]. One study demonstrated a 16% loss of 
body protein stores, during the first three weeks after major trauma [81]. Two-thirds of the 
protein that is lost was found to be derived from skeletal muscle. Other studies have 
demonstrated inhibition of protein synthesis after orthopaedic and abdominal surgery, whilst 
protein catabolism remained unchanged [85-86]. Tashiro et al., found evidence of enhanced 
skeletal muscle breakdown in patients following oesophagectomy [87]. 
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1.3.1.2.3 Fat metabolism 
Stimulated by the sympathetic nervous system and the hormonal milieu, lipolysis is 
accelerated following trauma [81]. In the absence of nutritional support the increased 
turnover of free fatty acids and glycerol acts as a major energy source for the body's tissues 
after injury. A previous study which investigated the contribution of substrates to energy 
metabohsm in patients who had undergone transthoracic oesophagectomy, did however find 
that the caloric contribution of fat decreased after the first postoperative day [88]. 
1.3.1.3 Inflammatory response to oesophagectomy 
1.3.1.3.1 Cytokines and inflammatory mediators 
Surgery is associated with the induction of an acute phase response that reflects the extent 
and severity of the surgical insult. Major components of the acute phase response are the 
activation of cytokine networks and the release of inflammatory mediators, which may in 
turn support the propagation of a systemic inflammatory response. It is predicted that the 
dissemination of this inflammatory response following oesophagectomy is a major factor 
contributing to the development of lung injury and other postoperative complications. 
1.3.1.3.1.1 Serum cytokines 
It is recognised that the levels of cytokines within the serum of patients undergoing elective 
surgery mirrors the development of an acute phase response and correlates with the degree of 
surgical stress sustained [89-90]. The pleiotrophic cytokine, interleukin (IL)-6, is particularly 
noted for its pivotal role in such processes [89, 91-93] with many authors reporting that its 
levels are correlated with postoperative rates of morbidity and mortality [94-95]. Cytokines 
elevated in the serum of patients following oesophagectomy include IL-6, IL-1, IL-lra, IL-2, 
IL-8, XL-10, TNFa, and MCP-1 [96-111]. Yamada and co-workers identified that the serum 
of patients who had undergone oesophagectomy contained higher levels of IL-6 and IL-8 and 
that both these cytokines were highest in the serum of patients who developed pulmonary 
complications [99]. This finding lends support to the theory that perioperative 
hypercytokinaemia is a precipitating factor for the development of postoperative respiratory 
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complications. Furthermore administration of steroids and the adoption of lung protective 
ventilation sttategies have both been independently shown to reduce postoperative serum 
cytokine levels and to improve pulmonary function [110, 112]. 
1.3.1.3.1.2 Serum Inflammatory mediators 
Several studies have reported finding increased levels of serum inflammatory mediators 
following oesophagectomy including: hepatocyte growth factor (HGF), nitric oxide (NO), C-
reactive protein (CRP), neutrophil elastase (NE) and high-mobility group box chromosomal 
protein-1 (HMGB-1) [97, 99, 101, 106, 108, 113-117]. In particular, high levels of serum 
HGF, NO and HMGB-1 have been linked with the development of postoperative respiratory 
complications [99, 117]. 
1.3.1.3.2 Inflammatory cell response 
There remains uncertainty as to the precise nature of the cellular response to 
oesophagectomy. As discussed, oesophagectomy induces a postoperative systemic 
inflammatory response, characterised by hypercytokinaemia and the release of pro-
inflammatory mediators from immunocompetent cells. This response, however, is often 
responsible for triggering a compensatory anti-inflammatory response, which itself is 
characterised by the release of anti-inflammatory cytokines (e.g. IL-10) and disruption of cell 
mediated immunity. Consequently, whilst several authors have reported evidence of the 
activation of inflammatory cells in response to oesophagectomy, others have observed a 
significant reduction in normal cellular immunity. 
1.3.2 Postoperative respiratory complications following oesophagectomy 
Postoperative respiratory complications following oesophagectomy are of particular interest, 
both because of their prevalence as well as their impact on in-patient mortality and length of 
hospital stay [118]. The findings of a confidential enquiry into perioperative deaths 
(CEPOD), revealed that respiratory complications were the most frequent cause of early 
morbidity following oesophagectomy [119]. Muller and colleagues in their review of the 
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literature identified that the most commonly reported respiratory complications following 
oesophagectomy were pneumonia, respiratory insufficiency and atelectasis, and that the 
incidence of each of these complications was greater following transthoracic compared to 
transhiatal resections (26% vs. 21%; 27% vs. 13%; 23% vs. 10% respectively) [37]. Tandon 
et al, also reported that 23.8% of patients who had undergone oesophagectomy developed 
respiratory failure, defined as those patients who both met the criteria for acute lung injury 
(ALI) [120] and required ventilator support for greater that 48 hours after surgery [121]. In 
the same report the acute respiratory distress syndrome (ARDS) complicated the 
postoperative recovery of 14.5% of patients and was associated with 50% mortality. Other 
authors have reported rates of ARDS following oesophagectomy ranging between 2.6% and 
33% [121-125]. 
A literature review reveals that a variety of approaches have been employed to both define 
and characterise the extent of lung injury in patients following oesophagectomy. Published in 
1994, the American-European consensus conference definitions of ALI and ARDS have 
been increasingly adopted for this purpose [120]. Whilst the gas exchange criteria upon 
which the 1994 consensus conference definitions are partly based offers a reliable measure of 
lung injury after oesophagectomy, radiological criteria are weakened by the fact that 
thoracotomy invariably alters the appearance of plain chest X-rays rendering their 
interpretation subjective [18]. Baudouin suggests that alternative definitions based on 
inflammatory characteristics and changes in permeability may serve to improve the diagnosis 
of lung injury following oesophagectomy, although he recognises that such measures are not 
at the present time universally available [18]. 
1.3.2.1 Pulmonary cytokines 
Lung tissue is acknowledged to be a major source of cytokines during the early postoperative 
period following oesophagectomy. Sakamoto et al., who investigated the cytokine response 
to surgical trauma identified that within the first 24 hours after oesophagectomy the levels of 
IL-6 and IL-8 within drainage fluid from the thoracic cavity were 100-fold greater than in 
peripheral blood samples [90]. During the same period the prominent inflammatory cytokines 
IL-ip and TNFa were virtually undetectable in both the drainage fluid and blood. Further 
27 
investigations demonstrated that the expression of IL-6 and IL-8 mRNA within leukocytes 
originating from thoracic drainage fluid, but not peripheral blood, was also elevated during 
the postoperative period. Abe and co-workers later gave support to the findings of Sakamoto 
et al, identifying that the production of IL-6 was significantly greater in lung tissue samples 
following transthoracic ©esophagectomy and that IL-6 mRNA expression within the same 
samples was also elevated [103]. Furthermore, the increased production of IL-6 within the 
lungs correlated with an observed peak plasma IL-6 levels. Immunohistochemical staining 
revealed the source of IL-6 production within the lung tissue was alveolar and bronchial 
epitheUal cells and not alveolar macrophages as anticipated. 
Two studies have however reported finding lower levels of IL-6 in bronchoalveolar lavage 
fluid (BALF) compared to plasma taken from patients following oesophagectomy [104, 126]. 
The same studies also identified higher IL-8 levels within BALF compared to plasma. Levels 
of IL-8 within BALF were correlated with the development of respiratory complications 
[104, 127]. 
1.3.2.2 Pulmonary inflammatory mediators 
Changes in pulmonary inflammatory mediators are also recognised in patients who have 
undergone oesophagectomy. Early experiments in both animals and humans identified that 
after transthoracic oesophagectomy the lungs release large quantities of the eicosanoid, 
thromboxane A2 (TXA2) into the systemic circulation; an event which coincided with an 
increase in extravascular lung water, lung resistance and a fall in lung compliance [128]. Pre-
treatment with a thromboxane synthase inhibitor was observed to significantly inhibit 
postoperative lung injury [128]. Schilling and co-workers later reported finding significantly 
increased TXB2 (a metabolite of TXA2) concentrations in blood taken from the post-
pulmonary, but not pre-pulmonary, circulation of patients who had developed ARDS after 
oesophagectomy [124]. An equivalent rise in post-pulmonary TXB2 was not observed in 
control subjects and oesophagectomy patients who did not develop ARDS. These findings 
may provide further evidence that TXA2, originating from the lungs, is associated with the 
development of ARDS following oesophagectomy. Shilling and co-workers performed a 
subsequent clinical trial in which patients undergoing oesophagectomy were pre-treated with 
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ketoconazole, a thromboxane synthase inhibitor [129]. When compared to a group of 
historical controls the authors identified that prophylactic treatment with ketoconazole, 
significantly reduced the incidence of postoperative ALI [129]. Interestingly, the same group 
found no difference in venous or arterial levels of leukotriene B4 (LTB4), a prominent 
marker of inflammation, in patients who developed ARDS following oesophagectomy [124]. 
Other inflammatory mediators which have been found to be elevated in the BALF of patients 
following oesophagectomy include, NE [127] granulocyte colony stimulating factor (G-CSF) 
[130], secretory leukocyte protease inhibitor (SLPI) [131] and nitrogen free radicals [132]. 
Elevated levels of NE, G-CSF and SLPI in the BALF of oesophagectomy patients were 
associated with the development of postoperative respiratory complications [127, 130-131]. 
1.3.2.3 Pulmonary endothelial permeability 
ARDS/ALI is a syndrome of inflammation and increased permeability [120]. Consequently 
several groups have attempted to investigate the effect of oesophagectomy on pulmonary 
vascular permeability [114, 133-134]. Rocker and co-workers presented evidence that 
transthoracic oesophagectomy is associated with a significant increase in puhnonary vascular 
permeability [133]. They observed that whilst vascular permeability was greatest on the 
thoracotomy (collapsed lung) side, contralateral elevation of vascular permeability was also 
seen. If correct these findings strongly suggest that oesophagectomy necessitating single lung 
collapse and one lung ventilation is associated with bilateral lung injury. 
1.3.3 Mechanisms lung injury during oeosphagectomy 
Evidence discussed herein indicates that oesophagectomy provides a prelude to the induction 
of a potent metabolic inflammatory response, signs of which are readily detectable both 
systemically and locally within the lungs. Inflammatory lung damage is the most common 
complication to disrupt the postoperative recovery of patients undergoing oesophagectomy. 
Potential sources of lung injury occurring as a result of oesophagectomy include direct lung 
trauma, the use of prolonged periods of OLV, pulmonary and intestinal ischemia reperfusion 
injury and postoperative intrathoracic anastomotic leak. In particular, OLV is suggested to be 
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one of most significant factors underlying the development of postoperative lung injury 
following transthoracic oesophagectomy [18]. This assumption is supported by several 
reports which identify that the incidence of pulmonary complications is significantly higher 
after transthoracic compared to transhiatal oesophagectomy [37, 123, 135]. Other studies 
have however shown that the rate of postoperative pulmonary complications remains high 
even after transhiatal oesophagectomy, with several authors reporting rates comparable to 
transthoracic oesophagectomy [136-139]. Mechanisms responsible for the development of 
lung injury after oesophagectomy are therefore most likely to be multifactorial, a supposition 
strengthened by the fact that currently there remains no unifying theory to explain this 
complication. 
1.3.3.1 Lung injury associated with one lung ventilation 
It is hypothesised that the use of OLV during oesophagectomy and other transthoracic 
procedures is largely responsible for the development of lung injury following these 
surgeries. Much of the evidence which supports this assumption comes, not from the 
oesophagectomy field, but from those who have investigated lung injury following 
pulmonary surgery. In one series Licker and co-workers identified that the duration of 
surgery and OLV was associated with the development of ALI in patients who had 
undergone pulmonary resection for lung cancer [140]. In a separate publication, Tandon et 
al, likewise identified that the duration of OLV was an independent risk factor for the 
development of pulmonary complications following oesophagectomy [121]. Possible 
mechanisms underlying the development of lung injury after thoracotomy and associated 
OLV are discussed in detail by Baudouin [18], requiring that only a brief overview is 
provided here. In his review Baudouin presents four possible sources of lung injury relating 
to the use of OLV [Figure 1.2]. 
(i) Ischaemia reperfusion injury: pulmonary ischaemia reperfusion injury is known to 
occur as a result of lung collapse and re-expansion during OLV. Furthermore, animal models 
have confirmed that relatively short periods of lung ischaemia, followed by reperfusion, are 
associated with the development of ALI [141]. In humans, elevated markers of oxidative 
stress (a central feature of ischaemia reperfusion injury), such as malondialdehyde, are 
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observed in patients who have undergone OLV, supporting the involvement of ischaemia 
reperfusion in the development of limg injury after oesophagectomy [142]. An alternative, 
indirect, method by which ischaemia reperfusion may mediate lung injury after 
oesophagectomy is related to the observation that intestinal perftision, particularly at the 
proximal end of the reconstructed gastric tube, is significantly reduced during the operation 
[143]. Although the importance of this pathway has so far not been investigated with respect 
to oesophagectomy related lung injury, it is well documented that ALI and ARDS may 
follow experimental intestinal ischaemia reperfiision injury in animals [144]. 
(ii) High fraction of inspired oxygen: often during OLV the dependent lung is ventilated 
with a high fraction of inspired oxygen, ft is proposed that high inspiratory oxygen may 
promote the formation of reactive oxygen species that can, in turn, induce lung damage. 
(iii) Ventilator Induced Lung Injury, it is accepted that ventilation of the lungs at an 
elevated tidal volume is a critical factor in the induction of ventilator induce lung injury. This 
was verified by the ARDSNet trial which demonstrated a significant survival benefit 
associated with lower tidal volume ventilation [145]. Consequently, the use of near normal 
tidal volumes during OLV may have a potentially adverse effect on the single ventilated 
lung. 
(iv) Pulmonary capillary stress failure: due to hypoxic pulmonary vasoconstriction in the 
collapsed lung during OLV the ventilated lung is perfused with a greater proportion of the 
puhnonary blood flow. As a result pulmonary arterial pressures are increased potentially 
causing capillary stress failure [146]. 
Figure 1.2 Sources of lung injury during oesophagectomy 
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1.4 Methods of global metabolic profiling 
1.4.1 Gas-phase breath analysis 
The analysis of trace gases within exhaled breath, for the purpose of non-invasive disease 
diagnosis, is a rapidly emerging field of medical research, which builds on previous major 
breakthroughs in mechanistic, diagnostic and monitoring aspects of pulmonary and systemic 
metabohsm. Although often not regarded as contributing significantly to modem medical 
practice, the analysis of exhaled breath has been used routinely for respiratory and 
anaesthetic gas monitoring in the perioperative and critical care setting for many years [147]. 
Moreover, the milestone discovery that exhaled nitric oxide is a clinically useful biomarker 
of airway inflammation has the potential to change nearly all aspects of asthma diagnosis and 
therapeutic monitoring and has confirmed the place of candidate trace gas analysis in 
respiratory medicine [148]. Crucially, concurrent technological developments, allowing more 
accurate and on-line detection of trace gases at levels equivalent to which they are found 
within exhaled breath, typically parts-per-million (ppm) and parts-per-billion (ppb), have 
supported the field. These achievements have, in turn, helped to refocus international efforts 
in exploring the hypothesis that trace gases within the breath, either in isolation or in 
combination, may reflect altered pulmonary metabohsm that is associated with disease 
processes [149]. 
Much recent activity has been directed at determining the unique pattern of exhaled trace 
gases in patients with lung cancer [150-152] and pneumonia [153-155], Analysis of exhaled 
trace gases is not, however, restricted only to gaseous signatures of lung pathology, but may 
also reflect unique systemic metabolic changes associated with physiological processes, such 
as glucose and lipid metabolism [156-158]. This understanding has been applied to 
monitoring individual volatile metabolites, within the breath of patients suffering from a 
variety of different diseases including: acute myocardial infarction, heart failure, organ 
rejection, surgical stress, diabetes and ALI [159-164]. Each of these conditions is 
characterised by complex tissue and systemic metabolic alterations, which may in turn be 
associated with the accumulation of volatile metabolites within tissues and blood. These 
volatiles may then be delivered, via the blood, to the lungs where they are released either by 
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the alveoli or airway mucosa into the gas-phase, providing unique volatile signatures of 
systemic events. Beyond individual volatile breath metabolites, recent progress in the 
development of metabolic profiling tools (fluid- and solid-phase metabonomics) has allowed 
new insight into the global metabolic alterations associated with systemic and organ specific 
disease [165]. The emergence of techniques using exhaled breath (gas-phase metabonomics), 
offers a non-invasive method to support these multivariate approaches of diagnostics and 
monitoring. 
1.4.1.1 Origins of prominent metabolites detectable within exhaled breath 
Since the initial report of Pauling and co-workers in the early 1970's [166], hundreds of trace 
gases have been identifed in human breath [149]. Although some of these compounds are 
anticipated to be of exogenous origin, and hence are of limited diagnostic potential, a 
proportion are expected to be derived, at least in part, from within the body. In order 
therefore to anticipate the physiological meaning and diagnostic potential of these 
compounds, an understanding of their source of origin within the body is essential. A 
summary of the evidence for the origins of prominent breath metabolites, that are the subject 
of targeted analysis in studies presented within this thesis, is provided below. 
1.4.1.1.1 Acetone 
Acetone (2-propanone) is a volatile metabolite, found in relative abundance within exhaled 
breath [167]. Although the characteristic odour of acetone in the breath was first documented 
centuries ago, its biological significance has only been recognised relatively recently. 
Initially considered an unimportant intermediate of metabolism, research performed in the 
middle part of the twentieth century demonstrated an important role for acetone in a number 
of prominent metabolic pathways [168]. Endogenous production of acetone occurs by one of 
two processes, decarboxylation of acetoacetate and dehydrogenation of isopropanol, with the 
former mechanism predominating in mammals [Figure 1.3] [168]. A proportion of the 
acetone produced systemically, is transported in the blood and is excreted by the lungs [169]. 
Owen et al have previously reported that at low plasma concentrations, approximately 20% 
of acetone produced within the body is released in the breath, increasing to up to 80% at 
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higher plasma levels [170]. There are also reports of a linear relationship between breath and 
plasma acetone, at least up to plasma concentrations of lOmM [168, 170]. 
Raised acetone within the breath has been linked to a number of important 
(patho)physiological processes, the most common being starvation. Previous studies have 
demonstrated a rise in breath acetone following overnight fast and a subsequent decline after 
the ingestion of both carbohydrate and protein meals [158, 171]. Depletion of hepatic 
glycogen stores initiates lipolysis and mobilisation of fatty acids from adipose tissue. Under 
such circumstances elevated levels of acetyl-CoA leads to the generation of ketone bodies; 
acetoacetate, P-hydroxybutyrate and acetone by the liver [172-173]. As well as starvation 
[173], levels of acetone are elevated in the blood and breath of patients with diabetes mellitus 
[164, 168, 174]. Diabetes, resulting from either an inability to produce insulin or insulin 
resistance, is characterised by raised blood sugar, lipolysis and ketogenesis. Finally, breath 
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acetone is also found to be raised in patients with congestive heart failure, presumably due to 
changes in basal metabolic rate and incipient mahiutrition that is often associated with this 
disease [175]. 
1.4.1.1.2 Ethanol 
Exhaled ethanol is most commonly described in a medico-legal context, relating to the 
assessment of alcohol intoxication. Apart from alcoholic beverages, some foods, especially 
ripe fruits, constitute potentially significant exogenous sources of ethanol, that once absorbed 
into the blood may subsequently be released in the breath [158, 176]. Although not 
technically endogenous in origin, microbial fermentation of carbohydrates within the oral 
cavity and gastrointestinal tract is an important source of ethanol within sober individuals 
[177-178], Isolated measurement of ethanol within the oral cavity has identified that the 
mouth is the primary source of this metabolite in exhaled breath [179]. This finding was 
substantiated by an earlier report which showed that mouth washing with aqueous sucrose 
solution led to an increase in breath ethanol [180]. Studies in mice have shown an age 
dependent link between obesity and breath ethanol, leading the authors to hypothesise that 
overproduction of intestinal ethanol is, at least in part, responsible for the development of 
obesity-related fatty liver [178]. Another study reported an increase in blood ethanol 
following jejunal-ileal bypass in dogs and obese patients [181]. Disruption of gut flora, 
secondary to either disease or surgical intervention, may therefore influence the level of 
ethanol within the blood and breath. Whilst potentially constituting only a small proportion 
of the ethanol that is detectable within exhaled breath, there is evidence that ethanol is 
produced within human cells as an intermediate step in the metabolic pathway for the 
ehmination of excess energy-releasing substrates from mitochondria [177]. It is possible that 
disease states may impact on this pathway leading to small, but potentially detectable 
changes in ethanol levels within the breath. 
1.4.1.1.3 Propanol 
Propanol is an alcohol that is present within the human body mainly as isopropanol [167]. 
Propanol, a precursor of acetone [Figure 1.3], is reported to be raised within the blood of 
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patients during episodes of diabetic ketoacidosis [182-185], Recently propanol has also been 
proposed as a potential biomarker of lung cancer [152]. 
1.4.1.1.4 Hydrogen cyanide 
Hydrogen cyanide is present at relatively low levels within the breath of humans [179]. Early 
studies confirmed that hydrogen cyanide in the breath originates from the oropharynx and is 
the result of oxidation of thiocyanate by salivary peroxidase [186]. This was recently 
confirmed by Wang et al, who analysed the relative differences in hydrogen cyanide within 
mouth- and nose-exhaled breath and in the oral cavity [179]. 
Headspace analysis of the gas above agar plates inoculated with the sputum of cystic fibrosis 
patients infected with Pseudomonas aeruginosa, have shown these bacteria are producers of 
hydrogen cyanide [187]. A subsequent clinical trial by the same authors found raised 
hydrogen cyanide in the exhaled breath of children with cystic fibrosis, many of whom were 
colonised with Pseudomonas aeruginosa [188]. In Pseudomonads, hydrogen cyanide is 
produced by the oxidation of glycine by the membrane-bound flavoenzyme hydrogen 
cyanide synthase, and occurs maximally during transition from the exponential to stationary 
growth phase [189]. 
1.4.1.1.5 Isoprene 
Isoprene (2-methyl-1,3-butadiene) is the most abundant hydrocarbon within exhaled breath, 
and is recognised to be almost entirely of systemic origin [179]. Whilst the precise details of 
isoprene's origin within the body are incompletely defined, it is thought to be formed mainly 
along the mevalonic pathway of cholesterol biosynthesis [Figure 1.4] [156, 190-194], A 
mechanistic link between breath isoprene and cholesterol synthesis was upheld by several 
authors who found that cholesterol-lowering therapy led to a parallel decrease in breath 
isoprene [156, 190], Breath isoprene concentrations are observed to follow a circadian 
rhythm [190, 194] and are known to be age dependent, with significantly lower levels 
recorded in children [195-197], The findings of several studies also indicate that isoprene 
within exhaled breath is influenced by changing cardiac output [156-157, 161]. 
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Exposure of healthy subjects to ozone has been reported to induce a delayed increase in 
breath isoprene, that was suggested to be a physiological response to oxidative lung damage 
[157]. Other studies have linked increased isoprene in the breath to surgical stress [161], 
psychological stress [198], haemodialysis [199-201] and neutrophil activation after 
myocardial infarction [159]. Finally, isoprene elimination in the breath has been shown to be 
reduced in patients with ARDS [202-203]. 
1.4.1.1.6 Acetic acid 
Acetic acid is an essential metabolic intermediate important for the generation of acetyl-CoA. 
The findings of a recent study demonstrated higher levels of acetic acid in mouth- compared 
to nose-exhaled breath, suggesting that the oral cavity is the primary source of acetic acid 
within the breath [204]. In alkaline environments, such as the blood-alveolar interface, acetic 
acid exists predominantly as non-volatile acetate ions [204]. Following lung injury, where 
there is a fall in airway pH [205], it is possible that the systemic contribution of acetic acid to 
exhaled breath may increase. This hypothesis however remains untested. 
1.4.1.1.7 Ammonia 
Ammonia is a common breath metabolite originating from either the deamination of amino 
acids or the hydrolysis of urea by bacteria within the gastrointestinal tract [Figure 1.5] [164, 
206-208], An observed rise in the level of breath ammonia, in healthy fasted subjects, after 
ingestion of a protein rich meal is taken to be conformation of the protein origin of this 
metabolite [158]. Whilst the liver converts the majority of endogenously produced ammonia 
to urea, a proportion of that which remains is excreted either in the urine, through the skin or 
in exhaled breath. Accordingly, abnormal levels of blood and breath ammonia have been 
hnked to diseases affecting both the liver and kidneys. Plasma ammonia levels are reported 
to be elevated in patients with acute liver failure [209-211] and a strong correlation was 
observed between plasma ammonia and the severity of hepatic encephalopathy [210]. 
Increased breath ammonia has also been shown to be characteristic of a ureamic state in 
patients with end-stage renal failure [212]. Furthermore, ammonia levels in the breath have 
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been observed to decline during haemodialysis and correlate with a simultaneous fall in 
blood urea and creatinine [212-213], 
Recent experiments that analysed ammonia within mouth- and nose-exhaled breath and in the 
oral cavity identified that this metabolite was largely generated in the mouth, with minimal 
systemic contribution (~100ppb) [206]. Oral bacteria and enzymatic activity on the substrates 
arginine and urea, that are present in saliva, are possible sources of orally produced 
ammonia. An observed rise in breath ammonia following mouthwash with an aqueous 
solution of urea supports this hypothesis [180]. 
1.4.1.2 Analytical methods used for breath analysis 
There are currently several different methods for the analysis of trace gases. Frequently 
researchers have chosen non-specific chemical sensing matrices for diagnostic purposes 
[214-215], Although these are promising and potentially sensitive point of care devices, they 
are unable to identify specific biomarkers. Most studies which aim to identify and quantify 
specific components of exhaled breath have utilised gas cliromatography-mass spectrometry, 
GC-MS [216], Altliough both sensitive and reliable, shortcomings of this technique concern 
the need for off-line sample collection, pre-concentration, processing and expense. The 
development of other mass spectrometry techniques including proton transfer reaction-mass 
spectrometry (PTR-MS) and selected ion flow tube-mass spectrometry (SIFT-MS) has 
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alleviated many of these difficulties and allowed the on-line and real time analysis of exhaled 
breath. There are however several key differences separating the SIFT- and PTR-MS 
systems. Firstly, unlike PTR-MS which relies on a single precursor ion (H3O+), SIFT-MS is 
able to utilise three independent precursor ions (H3O+, N0+, O2+), which serves to improve 
its ability to positively identify individual trace gases based on their characteristic ion 
molecular reactions with each precursor. Secondly, at present the SIFT-MS system, when 
used in its multiple ion monitoring mode, is capable of on-line quantification of trace gases in 
units of absolute concentration, whereas the PTR-MS instrument must first be calibrated 
against known standards to achieve equivalent quantification. Finally, at the current time, 
PTR-MS is regarded as the more sensitive of the two techniques [216], although reports of 
SIFT-MS analysis within the parts-per-trillion range are emerging [217]. Utilisation of these 
methods has already generated novel discoveries in the fields of cancer, infectious disease 
and metabolism [149, 218-219], 
1.4.1.2.1 Selected ion flow tube mass spectrometry 
Originally conceived in the 1970's [220] SIFT-MS serves as an important method by which 
ion-neutral reactions at thermal interaction energies can be accurately and reliably studied 
[221]. Early development of the SIFT-MS technique was focused mainly on the investigation 
of molecular genesis within the cold interstellar clouds of the Milky Way, which had been 
observed by radio astronomers [222]. The use of SIFT-MS for this purpose was principally 
borne out of the shortcomings of both the flowing afterglow [223] and ion cyclotron 
resonance [224] techniques. It was however not long before this new analytical technique 
was used to investigate the terrestrial atmosphere and the analysis of complex gas mixtures 
including exhaled breath. Consequently, over the last two decades there have been a large 
number of publications outlining the potential use of the SIFT-MS technique for applications 
within environmental, biological and clinical sciences [218]. 
Principles of SIFT-MS 
Within the SIFT-MS instrument positive precursor ions are created by a microwave 
discharge ion source that is located upstream from a quadrupole mass filter [Figure 1.6]. The 
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purpose of the quadrupole mass filter is to select out precursor ions that possess the desired 
mass-to-charge ratio (m/z) from the multitude of ions produced within the discharge source 
[218]. The SIFT-MS technique utilises three specific positive precursor ions, HaO^, NO^and 
O] . Once the quadrupole mass filter has selected one of these specific precursors, the ions 
pass through a venturi type orifice (typical diameter l-2mm) into a fast flowing stream of an 
inert carrier gas (in the majority of cases pure helium of pressure -lOOPa and temperature 
~300K) that is directed along the length of a flow tube [218]. The precursor ions within the 
carrier gas continue along the length of the flow tube as a cold ion swarm. A calibrated 
capillary, heated to prevent the condensation of water vapour and trace gases, injects sampled 
gas from an external source into the carrier gas/precursor ion swarm. In the time that remains 
for the cold ion swarm to pass along the remaining length of the flow tube, the precursor ions 
and trace gases within the sample react to create characteristic product ions [218]. 
Downstream, the product ions are separated according to their specific m/z values by a 
differentially-pumped quadrupole mass spectrometer and. their individual abundance is 
quantified by a channeltron multiplier counting system [218]. By this method the SIFT-MS 
instrument can detect and quantify multiple trace gases simultaneously. This is however 
dependent on the condition that the kinetics of the ion-molecular reactions are accurately 
known for the flow tube parameters. 
SIFT-MS precursor ions 
The SIFT-MS instrument utilises one of three mass selected precursor ions; H3O+, NO^ or 
O2 , to ionise trace gases within a sample. These precursors represent a small group of ions 
that have the highly desirable characteristic of reacting readily with trace gases, whilst 
remaining relatively unreactive with the major components of the bulk matrix of atmospheric 
and exhaled air i.e. N2, O2, CO2, H2O and Ar [218,225]. The basis for this prerequisite is that 
if the precursor ions were to react with these major elements of air and breath, their levels 
would be rapidly exhausted [225]. The ability of SIFT-MS to use more than one precursor 
ion also permits the accurate identification of compounds, especially in cases where isobaric 
(same weight) product ions are formed following a reaction with one of the precursor ions. 
42 
Modes of SIFT-MS operation 
(i) Full-Scan mode 
The SIFT-MS instrument can be used in the full scan (FS) mode to obtain a complete mass 
spectrum of an ionised gas sample. To record a FS, the quadrupole mass analyser sweeps a 
defined range of m/z ratios for a chosen time period. Experiments in the FS mode yield the 
count rates of individual product ions at each of the m/z values, calculated from the number 
of counts recorded and the total sampling time for each specific m/z value. Count rates can 
be presented as either a complete mass spectrum or raw data file. Interpretation of the data is 
achieved by relating the relative intensities of peaks within a spectrum to specific trace gases 
known to give product ions at the same m/z value. 
(ii) Multiple Ion Monitoring mode 
The multiple ion monitoring (MIM) mode permits the on-line and real time quantification of 
a select number of trace gases within a sample passing into the SIFT-MS instrument. To 
achieve this the SIFT-MS instrument rapidly alternates the quadrupole mass analyser 
between the m/z values of all of the primary ions as well as selected product ions, known to 
be derived firom the trace gas(es) under investigation. This real time mode is facilitated by the 
fast response time of the SIFT-MS instrument, -10ms [216], which is, in turn, the result of 
the short dwell times that the instrument spends on each m/z value and the fast flow rate of 
both sample and carrier gases. Presented in figure 1.7 is an example of data obtained from a 
MIM mode scan of acetone, analysed by SIFT-MS in three repeat exhalations using the HgO^ 
precursor ion. 
Accuracy and detection limit of SIFT-MS 
The detection limit of SIFT-MS is dependent on the count rate of the product ions formed 
within the flow tube, which is in turn dependent on the precursor ion count rate. The 
precursor ion count rate of the Profile-3 SIFT-MS instrument (Instrument Science Ltd, 
Crewe, UK) under optimum conditions is in excess of 10^ s"' which permits a detection limit 
of Ippb s"' of sample analysis time [216]. Standard atmospheres of organic vapours, present 
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gas 
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Entry port 
Heated sample 
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precursor 
ions 
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Figure 1.6 Schematic representation of the SIFT-MS apparatus 
(A) Selected precursor ions react with trace gases in a sample (B) to form characteristic product ions (C) which are isolated and quantified within a downstream 
mass spectrometer and ion detector. 
44 
10' 5^ % 5 . 9 6 % 5 . 9 0 % 
Water 
Vapour 
3 ± 9 8 p 
time IS 
89 ± 67 ppb 551 ± 63 p 
Figure 1.7 SIFT-MS multiple ion monitoring (MIM) mode scan 
MIM mode scan showing tlie quantitative analysis of acetone in tliree 
repeat exiialations using tlie HsO"^  precursor ion. Concentration is 
determined using tlie signal ratios of precursor and product ions 
together witli the known reaction time and flow rates of sample and 
carrier gases. Alveolar portions of each exlialation are indicated. 
at a wide range of partial pressures in dry air, have been used to validate the accuracy of the 
SIFT-MS technique [226-227]. From these experiments it was ascertained that the accuracy 
of SIFT-MS, for measurement of organic compounds, was greater than 10% over a range of 
partial pressures (lOppb to 20ppm). Atmospheric air and exhaled breath however have a high 
water vapour content, typically 1-2% and 6% relative humidity respectively [218]. Previous 
authors therefore deemed it necessary to determine the effects of high relative humidity on 
tlie analysis of trace gases in atmospheric air and exhaled breath. As anticipated, the presence 
of water vapour had a significant effect on the quantification of volatile trace gases by SIFT-
MS. However, it was also shown that when the overall kinetics of the reactions of water 
vapour with the precursor ions and trace gases were understood, and accurately accounted for 
in the analysis, the problem of water vapour in the sample was mitigated [228-229]. The 
ability to accurately determine the relative humidity of a sample does in fact provide an 
important internal control that is invaluable for the analysis of exlialed breath [228] and also 
permits the accurate quantification of trace gases within the headspace above liquids [230]. 
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1.4.2 Fluid-phase metabonomics 
Whilst in the past bioanalytical techniques such as genomics and proteomics have been used 
to study the effects of endogenous and exogenous stimuli on biological systems, these 
methods are costly, labour intensive and ignore the changing metabolic status of the whole 
organism [231]. As highly time-resolved intermediates and end products of cellular 
processes, metabolites reflect the global integrated responses of organs or entire biological 
systems to normal and abnormal stimuli [232]. In light of this metabonomics has become an 
established platform for the quantitative analysis of the "dynamic multiparametric responses 
of living systems to pathophysiological stimuli [231]." Methods commonly used to detect 
and quantify changes in the metabolic profiles of both biofluid and tissue samples include 
proton nuclear magnetic resonance spectroscopy (^H NMR) and liquid chromatography mass 
spectrometry (LC/MS) [165, 233-236]. Both techniques permit the simultaneous 
identification of a wide range of metabolites in a single measurement [165, 233]. 
Furthermore, the structure and concentrations of metabolites can be inferred from proper 
interpretation of the resulting spectra. The fact that metabonomics approaches are generally 
specific yet non-selective does however confer some disadvantages. In particular, factors 
relating to gender, age, environment, lifestyle and diet have a major impact on an 
individual's metabolic phenotype, thus making it potentially harder to determine the 
influence of disease. This situation is made worse in patients with multiple comorbidities and 
polypharmacy. 
The vast quantities of data that result from metabonomics experiments require careful 
interpretation in order to evaluate the impact of disease and therapeutic intervention. In the 
first instance the spectra of samples acquired firom one organism or patient group can be 
directly compared with those of a relevant control. Where appropriate, univariate statistical 
methods can be used to explore apparent differences. Whilst not always necessary, the 
identity and absolute concentrations of individual metabolites can also be elucidated by this 
approach. Pattern recognition methods, also known as chemometrics and multivariate 
analysis, are considered an important part of interpreting the highly complex data sets that 
result from metabonomics studies [165]. Such methods use information about the intensities 
of peaks within a spectrum to construct multidimensional plots of metabolic activity [165], 
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which can be reduced to two- or three-dimensions, allowing easier visualisation of potential 
clustering of metabolic phenotypes. Common pattern recognition methods used in 
metabonomics include principal-component analysis (PCA) and partial least squares analysis 
(PLS). 
1.4.2.1 NMR-based metabonomics 
High resolution NMR is particularly suited to the analysis of metabolites within biofluids 
and tissues, for those reasons already discussed, as well as the fact that samples require 
minimal preparation and are not destroyed during the course of the analysis. The non-
destructive nature of NMR also permits the accurate detection of metabolites within non-
disrupted tissues and cells. Whilst NMR is generally not as sensitive as MS, much of the 
variability that is associated with MS is not observed. 
The theory of NMR is based on the principle that certain atomic nuclei posses inherent 
quantum mechanical magnetic properties, which explain their interactions with an externally 
apphed magnetic field, Bq. Such properties are attributed to the fact that these nuclei posses 
both charge and the characteristic of spin. With respect to NMR experiments, the hydrogen 
nucleus (^H) is the simplest and most commonly used. The nucleus consists of a single 
proton and has spin quantum number When not under the influence of an external 
magnetic field nuclei are orientated randomly. Upon insertion into a magnetic field an 
individual nuclei can assume one of two different orientations, in line with, or in 
opposition to, the magnetic field. At room temperature there will be a slight excess of nuclei 
ahgned with the magnetic field, in what is a lower energy state compared to those nuclei 
ahgned in opposition to the magnetic field. As a consequence there is a net magnetisation in 
Une with the applied magnetic field (often referred to as the Z axis). The proton of the ' h 
nucleus can absorb electromagnetic energy provided that this energy is of the precise 
radiofrequency which amounts to the quantised energy gap separating the high and low 
energy states of the proton. Absorption of this energy permits the reorientation of a small 
proportion of ' h nuclei to the higher energy state, equalising the number of protons in each 
state. Under these circumstances net magnetisation no longer resides along the Z axis, but is 
transferred (90°) into the XY plane. During a subsequent period of 'relaxation' net 
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magnetisation is gradually lost from the XY plane and returns to the equilibrium position 
along the Z axis. The NMR signal is proportional to the population difference between to two 
energy states. As these differences are very small NMR must be appropriately sensitive to 
detect them. 
Within molecules (metabolites) nuclei are bonded with, or in close proximity to, other 
atomic nuclei including 'H, carbon, oxygen and nitrogen. The interactions between these 
nuclei is what determines the locations of individual nuclei signals and the characteristic 
'splitting' patterns of their peaks within the resultant spectra. 
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1.5 Summary of current knowledge and indications for future investigations 
Oesophagectomy is an invasive surgical procedure, commonly associated with high rates of 
postoperative morbidity and mortality. In spite of those risks, oesophagectomy remains the 
mainstay of treatment for patients with localised oesophageal cancer. Considerable debate 
however remains as to the most appropriate surgical technique for oesophageal resection. 
Although two competing approaches, transthoracic and transhiatal oesophagectomy have 
emerged, the global outcomes of these procedures are yet to be clearly reported. 
Those authors who have previously investigated the metabolic inflammatory response to 
oesophagectomy and related lung injury have relied ahnost entirely on characterisation of 
fluid-phase cytokines and acute phase proteins, an approach which has yielded variable and 
sometime contradictory results. Furthermore by accepting this conventional approach, the 
field has overlooked the potentially powerful method of gas- and fluid-phase metabolic 
profiling. 
Major surgery is known to involve a spectrum of important metabolic changes, the full extent 
and exact nature of which remain unknown. It is expected that footprints of these changes 
will be evident in both the gas- and fluid-phases. There is thus an opportunity for a novel 
systems based approach towards the investigation of surgical stress and lung injury after 
oesophagectomy. Furthermore, current diagnostic approaches for the assessment of surgical 
stress and postoperative complications lack a molecular basis, especially methods applicable 
at the bedside. One novel approach in this direction is molecular analysis of exhaled breath. 
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1.6 Overall objectives of this thesis 
The overall objectives of this thesis were threefold: 
1. To determine both international and local outcomes following oesophagectomy. 
Secondary objectives integral to achieving this first objective were as follows: 
(i) To conduct a systematic review and meta-analysis of outcomes following 
transthoracic and transhiatal oesophagectomy. 
(ii) To review local outcomes of oesophagectomy in order to asses whether the 
patient population intended for future clinical studies was representative of global 
series. 
2. To develop a reliable method for the collection and analysis of breath samples 
within the clinical setting, through the investigation of sources of instrument 
specific, methodological and physiological variability. 
Secondary objectives integral to achieving this second objective were as follows: 
(i) To determine the stability of breath samples stored within sample bags. 
(ii) To investigate the repeatability of the analysis of prominent exhaled metabolites 
in healthy subjects using SIFT-MS. 
(iii) To examine the influence of respiratory manoeuvres on the detection of 
metabolites within exhaled breath. 
(iv) To determine variation in the levels of inspiratory trace gases within different 
clinical environments. 
(v) An additional methodological objective was to develop an evidence-based set of 
criteria for the diagnosis of pneumonia in patients following oesophagectomy. 
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3. To investigate metabolic changes in response to oesophagectomy and postoperative 
pneumonia, with a specific focus on the use of non-invasive breath analysis. 
Secondary objectives integral to achieving this third objective were as follows: 
(i) To determine the normal concentration of common metabolites within the exhaled 
breath of patients with gastroesophageal cancer. 
(ii) To determine the normal concentration of common metabolites within the exhaled 
breath of patients with commimity acquired pneumonia. 
(iii) To determine the impact of oesophagectomy on the concentration of exhaled 
metabohtes. 
(iv) To employ a 'H NMR-based metabonomics approach to distinguish serum and 
urine metabolic markers of surgical stress following oesophagectomy. 
51 
Section II 
Outcomes of oesophagectomy 
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2. TRANSTHORACIC VERSUS TRANSHIATAL OESOPHAGECTOMY FOR THE 
TREATMENT OF OESOPHAGOGASTIC CANCER: A META-ANALYSIS 
2.1 Objectives 
The objective of this systematic review and meta-analysis was (i) to compare the outcomes of 
transthoracic and transhiatal oesophagectomy in terms of postoperative morbidity and 
mortality and 5-year survival and (ii) to assess the methodological and reported surgical 
quahty of included studies. 
2.2 Introduction 
Oesophagectomy is the main treatment for potentially curable oesophageal cancer, but 
considerable debate exists as to the most appropriate surgical technique. Whilst the 
transthoracic approach achieves superior visualisation of the operative field and allows more 
thorough dissection of the tumour and adjacent lymphatics, [14, 21] it has often been linked 
to higher rates of postoperative morbidity and mortality. In comparison a transhiatal 
approach limits the extent of surgical trauma, but critics argue that the basic surgical 
principals of exposure and haemostasis are not adhered to and that the oncological quality of 
the resection is compromised by insufficient mediastinal clearance. As the transthoracic 
approach allows a more radical oncological resection it has the potential to result in a 
survival advantage. 
Although randomised controlled trials, retrospective cohort studies and two systematic 
reviews [16-17] have sought to determine which technique is best, none have yet provided 
conclusive evidence. This meta-analysis is the first to incorporate evidence from studies 
pubUshed after 2000, including two randomised controlled trials. The quality of study design 
and surgical resection are also examined. Markers of surgical quality that are associated with 
survival include: surgeon case load, [42-48] hospital volume, [42, 44, 49-71] lymph node 
yield, [27-28, 30-31, 237-247] technical complications [248-249] and early mortality. 
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2.3 Methods 
2.3.1 Search strategy 
A literature search (title and abstract) of the EMBASE (1947-2010), MEDLINE (1950-2010) 
PsycINFO (1806-2010) databases through the OVID platform, and Cochrane Library (1800-
2010) was conducted for studies comparing transthoracic and transhiatal oesophagectomy for 
oesophagogastric cancer. Searches were limited to studies published in the English language 
until 31®' January 2010. Full details of the search strategy are outlined in table 2.1. 
Table 2.1 Electronic search strategy 
Search No. EMBASE, MEDLINE, PsycINFO (OVID) Cochrane Library 
#1 transhiatal.ti,ab. (1412) transhiatal.ti.ab,kw. (38) 
#2 limit #1 to english language (1219) thoracotomy.ti,ab,kw. (898) 
#3 thoracotomy.ti,ab. (28778) #1 or #2(928) 
#4 limit #3 to english language (22157) transthoracic.ti,ab,kw. (439) 
#5 #2 or #4 (23149) two-stage.ti,ab,kw. (13822) 
#6 transthoracic.ti,ab. (19999) three-stage.ti,ab,kw. (9135) 
#7 limit #6 to english language (16356) #4 or #5 or #6 (16844) 
#8 two-stage.ti,ab. (25431) #3 and #7 (126) 
#9 limit #8 to english language (23055) oesophagectomy.ti,ab,kw, (58) 
#10 three-stage.ti,ab. (3860) #8 or #9 (178+) 
#11 limit #10 to english language (3477) 
#12 #7 or #9 or #11 (42619) 
#13 #5 and #12 (881) 
#14 remove duplicates from #13 (525) 
ti, title, ab, abstract, kw, key words, tincluding 120 clinical trials published in the English 
language. 
Two reviewers (P Boshier and O Anderson) screened the titles and abstracts of studies 
identified through the electronic searches and the full texts of potentially relevant articles 
were obtained. The reference lists of acquired studies were handsearched to identify further 
potentially relevant studies. Inclusion criteria were: comparative studies (including cases 
series) examining potentially curative transthoracic and transhiatal oesophagectomy for the 
treatment of oesophagogastric cancer. Exclusion criteria are detailed in table 2.2. Studies that 
reported the same patient population were excluded, except for the most recent or complete 
publication. Two reviewers (PB and OA) independently extracted data from the studies 
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including; primary author, year of publication, country of origin, characteristics of study 
population (age, gender, neoadjuvant therapy and tumour histology, site and stage), design of 
study, number of patients who underwent surgery by each technique and outcomes reported. 
Table 2.2 Exclusion criteria 
Criteria No. excluded 
1 Review article 2 
2 Opinion paper 1 
3 Case report 1 
4 Delayed reconstruction 1 
5 Single approach utilised 1 
6 Unable to separate benign and malignant disease 10 
7 Results could not be analysed with respect to surgical approach 15 
8 Paper reporting outcomes of either the same or overlapping patient cohortst 16 
Total number excluded 47 
tThe exception being when both the early and late outcomes of the same patient cohort were 
published separately 
2.3.2 DeHnitions 
Oesophagogastric cancer; malignancy affecting any part of the thoracic or cervical 
oesophagus or gastric cardia. Transhiatal oesophagectomy; open resection of the oesophagus 
performed through the oesophageal hiatus and thoracic inlet, without thoracotomy [23-24], 
Vagal nerve sparing and endoesophageal pull through procedures were not considered in this 
meta-analysis. Transthoracic oesophagectomy; open resection of the oesophagus employing 
thoracotomy, including all single-, two- and three- stage procedures utilising either a right or 
left thoracotomy or thoracoabdominal incision. 
2.3.3 Outcome measures 
Study outcomes included; lymph node clearance; operative time; operative blood loss; length 
of hospital stay; postoperative mortality; respiratory and cardiac morbidity; anastomotic leak; 
vocal cord palsy; postoperative haemorrhage; wound infection; anastomotic stricture and 5-
year survival. 
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2.3.4 Methodological quality 
Methodological quality was assessed using criteria adapted from Yakoub et al [250]. Studies 
were awarded stars based on criteria related to study design, comparability of patient groups, 
reporting of outcome data and the quality of follow up. The range of possible scores was 0-
16 stars. Sensitivity analysis of studies with 11 or more stars was performed. (Details and 
results of methodological quality assessment are available as supplementary material in 
Appendix I). 
2.3.5 Surgical quality 
Minimum surgical quality standards set included: >10 procedures performed per year for 
surgeons participating in the trial [45, 47-48], >10 procedures performed per year for the 
hospitals involved in the trial [42, 51, 55, 57-69] and >20 lymph nodes resected on average 
[27-28, 30, 244-246]. Complications, although important, are poorly reported in the 
literature, consequently they were split into anastomotic leak and other technical 
complications including: vocal cord paralysis, splenectomy, haemorrhage and chyle leak, 
which were considered together as a group [251]. Jamieson et al. examined evidence 
originating from Western and Eastern centres and found that the rate of anastomotic leak was 
<10% and <5% on average respectively [34]. A threshold of <10% was set for anastomotic 
leak, <10% for the other technical complications [34] and <10% early mortality rate (<30 day 
or in-hospital) [34, 36, 69-70, 72, 252-257]. 
Higher surgical quality standards set included: >30 procedures annual case load or >100 
procedures performed by the surgeon in total [44], annual hospital volume >30 procedures 
[69-71], >30 lymph nodes resected on average [27-28, 30, 246-247], <5% was set for 
anastomotic leak and <5% for other technical complications [34] and <5% early mortality 
rate (<30 day or in-hospital) [16, 69, 258-263]. 
A paper fiilfilling a minimum surgical quality standard scored one star and fulfilment of a 
higher surgical quality standard scored two stars. The range of possible scores was 0-12 stars. 
In order for a paper to be classified as satisfactory, a minimum of one star was required in 
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every category. (Details and results of surgical quality assessment are available as 
supplementary material in Appendix I) 
2.3.6 Statistical analysis 
Meta-analysis was performed in accordance with the recommendations of the Cochrane 
Collaboration and the Quality of Reporting of Meta-analysis guidelines [264-265], Analysis 
was conducted using the statistical software Review Manager Version 5.0 (The Cochrane 
Collaboration, Software Update, Oxford). For categorical variables, statistical analysis was 
performed by calculation of the odds ratio, which corresponds to the odds of an adverse event 
occurring in the treatment group (transthoracic oesophagectomy), compared to the reference 
group (transhiatal oesophagectomy). An odds ratio of more than one indicates that the 
probability of an outcome is more likely to occur in the treatment group, and is considered 
statistically significant when P<0.05 and when the 95% confidence interval does not include 
the value one. The Mantel Haenszel method was used to combine the odds ratios for 
outcomes of interest. In line with recommendations for meta-analysis of surgical research, a 
random effects model was used [250] as it is more robust in terms of anticipated 
heterogeneity in patient and hospital related risk factors. The random effects weighted mean 
difference (WMD) was used as the summary statistic for continuous variables. 
Statistical heterogeneity in each meta-analysis was assessed using the T^ (tau-squared), Chi^, 
and f statistics [265-266]. Heterogeneity was regarded as significant if T^ was greater than 
zero and if either the P-value of Chi^ analysis was less than 0.10 or f was greater the 30%. 
Reanalysing the date using both fixed and random effects models fiirther assessed 
heterogeneity. Funnel plots were also examined to evaluate publication bias [267]. Subgroup 
analyses included: (i) prospective randomised controlled trials (RCTs) and (ii) studies 
pubhshed after and including the year 2000. Sensitivity analyses included: (i) studies scoring 
>11 stars for methodological quality and (ii) studies meeting the minimum reported surgical 
quality threshold. 
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2.4 Results 
2.4.1 Selected studies 
Fifty-two studies matched the selection criteria and were eligible for meta-analysis [72, 83, 
123, 137-139, 239, 246, 268-312]. Search results are presented in figure 2.1. Reviewers' 
agreement for data extraction was 100%. When the early and late results of the same study 
were presented as separate publications, outcomes were treated as a single study for the 
purpose of meta-analysis [72, 291]. One study that was reported as a RCT was considered as 
a prospective cohort study due to an inadequate method of randomisation [280]. As a result, 
selected studies included five RCTs, [72, 268, 281, 285, 291, 293] seven non randomised 
prospective studies [83, 137, 246, 280, 289-290, 297] and 40 retrospective studies, with a 
total of 5905 patients, of which 3389 (57.4%) underwent transthoracic oesophagectomy and 
2516 (42.6%) underwent transhiatal oesophagectomy. A summary of included studies and 
patient demographics are presented in table 2.3. The results of the overall meta-analysis are 
presented in table 2.4. (Full details of included and excluded studies are available as 
supplementary material in Appendix I) 
2.4.2 Patient and tumour characteristics 
Seventy-eight percent of patients undergoing oesophagectomy were male. Both gender and 
age were not significantly different between groups. There was no significant relationship 
between surgical approach and tumour histology or neoadjuvant therapy. Overall analysis 
revealed that tumours of the middle oesophagus were more commonly resected via a 
transthoracic approach, (46.3% vs. 31.7%, OR 1.75, CI 1.30-2.35, P<0.001) although 
heterogeneity was significant (P=0.01, 1^=48%). Whilst transhiatal resection was chosen 
significantly more often for early stage O/I tumours (OR 0.64, CI 0.50-0.81, f<0.001) the 
transthoracic approach was more often utilized for advanced stage IV tumours (OR 1.42, CI 
1.12-1.80, P=0.003) [Figures 2.2]. Analysis revealed no heterogeneity for stages O/I and IV. 
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Records identified through electronic database 
searching (search performed on 31/01/2010) 
OVID (EMABSE, MEDLINE, PsyclNFO): n = 525 
Cochrane Library: n =178 
Total = 703 
Records screened 
n = 703 
1 F 
Full-text articles assessed 
for eligibility 
n = 89 
Full-text articles included 
after electronic search 
n = 41 * 
Records excluded after 
review of titles and 
abstracts 
n = 614 
Full-text articles 
excluded, with reasons 
n = 47 
Additional records 
identified through 
handsearching of 
reference lists 
n = 11 
Studies included in 
quantitative synthesis 
(meta-analysis) 
n = 5 2 * 
*HuIscher JBF 2002 and Omloo JMT 2007 which, respectively, present the early and 
late results of the same randomised controlled trial, are considered as a single study. 
Figure 2.1 Systematic search and selection strategy 
Table 2.3 Summary of included studies 
First author Year Country Study period Study type 
No. of 
patients 
Patient gender 
(M/F) 
Patient age 
(mean ± SD) Quality scoret Ref. 
TTE THE TTE THE TTE THE Metliod Surgical 
Areja D 2006 Pakistan 1999 2001 RCT 15 15 
- - -
9 3 [268] 
Berdejo L 1995 Spain 1987 1994 Retrospective 20 21 18/2 18/3 
-
8 5 [269] 
Bolton J 1994 USA 1981 1993 Retrospective 34 48 - - - 8 2 [270] 
Bonavina L 1995 Italy 1980 1993 Retrospective 168 85 - - - 8 4 [271] 
Bousamra M 2002 USA 1990 1999 Retrospective 47 43' - - - 5 2 [272] 
Boyle MJ 1999 USA 1991 1996 Retrospective 27 38 
- - -
11 2 [273] 
Braghetto 1 2006 Chile 1990 2003 Retrospective 60 59" - - - 7 3 [274] 
Caracci B 1983 USA 1975 1982 Retrospective 13 22 - - 62.0 ± 6.6 54.6 ± 6.3 8 0 [275] 
CariatI A 2002 Italy 1978 2000 Retrospective 49 14 40/9 11/3 
-
9 1 [276] 
Chan WH 2000 Singapore 1989 1996 Retrospective 33 34 25/8 29/5 
-
9 1 [277] 
Chang A 2008 USA 1992 2002 Retrospective 643 225 499/144 162/63 
-
10 0 [278] 
Chou S-H 2005 Taiwan 1997 2002 Retrospective 50 23 46/4 21/2 52.6 ± 10.6 57.4 ± 12.4 9 4 [279] 
Chou S-H 2009 Taiwan 2003 2006 Prospective 47 40 44/3 38/2 54.8 + 10.3 59.1 + 11.1 9 2 [280] 
Chu K-M 1997 Hong Kong 1990 1994 RCT 19 20 17/2 18/2 63.9 ± 4.8 60.7 ± 8.0 15 3 [281] 
FokM 1989 Hong Kong 1982 1986 Retrospective 172 38 152/20 31/7 - 6 5 [282] 
Gluch L 1999 Australia 1985 1996 Retrospective 33 65 25/8 39/26 62.5 ± 11.0 65.8 ± 10.0 11 3 [139] 
Gockel 1 2005 Germany 1985 2004 Retrospective 47 103 - - - 10 3 [283] 
Goldfaden D 1986 USA 1965 1984 Retrospective 43 29 
- - -
11 2 [284] 
Goldmine M 1993 France 1988 1991 RCT 35 32 33/2 31/1 57.4 ± 8.4 57.4 ± 7.9 13 4 [285] 
Graham AJ 1998 Canada 1985 1997 Retrospective 32 119' - - - 8 6 [286] 
Gupta NM 2000 India 1982 1990 Retrospective 27 39 - - - 13 0 [287] 
Hanklns JR 1989 USA 1977 1987 Retrospective 52 26 42/10 18/8 55.7 + 8.4 56.1 + 6.4 9 3 [288] 
Homesh NA 2006 Yeman 1998 2004 Prospective 41 43 19/22 25/18 59.0 ± 12.37 61.2 ± 8.34 10 2 [289] 
Horstmann O 1995 Germany 1886 1989 Prospective 41 46 39/2 41/5 
-
10 1 [290] 
Hulscher JBF 2002 Holland 1994 2000 RCT 114 106 97/17 92/14 
-
16 5 [72, 291] 
IkeguchI M 2000 Japan 1989 1998 Retrospective 14 19 - - - 10 1 [292] 
Jacobi CA 1997 Germany 1992 1995 RCT 16 16 - - - 14 2 [293] 
Jauch KW 1992 Germany 1982 1989 Retrospective 37 49 30/7 43/6 
- -
13 1 [138] 
Johansson J 2004 USA 1988 1998 Retrospective 27 22" 26/1 18/4 
- -
10 4 [239] 
Junginger T 2006 Germany 1985 2004 Retrospective 159 70 
- - - -
10 3 [294] 
Kudo T 1990 Germany 1986 1988 Retrospective 35 37= 
- - - -
5 6 [295] 
Make la J 1991 Finland 1960 1989 Retrospective 46 43 
- -
64.0 ± 9.0 62.0 ± 12.0 10 3 [296] 
Marton S 2005 Hungary 2000 2002 Prospective 31 52 27/4 46/6 
- -
8 3 [297] 
Millikan KW 1995 USA 1978 1993 Retrospective 71 67' 
- - - -
7 5 [123] 
Mohsen H 1993 Hungary 1987 1992 Retrospective 41 22® 
- - - -
5 1 [298] 
Moon MR 1992 USA 1974 1990 Retrospective 24 63" 22/2 56/7 
- -
11 0 [299] 
Morgan MA 2007 UK 1998 2005 Prospective 119 32 92/27 27/5 
- -
13 5 [137] 
Muller JM 1989 Germany 1978 • 1988 Retrospective 41 95 
- - - -
9 1 [300] 
Naunheim KS 1992 USA 1985 1992 Retrospective 27 11 
- -
74.2 ±3.5 74.2 ± 3.8 6 0 [301] 
OhDS 2006 USA 1987 2005 Retrospective 27 3l' 
- - - -
9 5 [302] 
Pac M 1993 Turkey 1983 1991 Retrospective 120 118 74/46 66/52 53.5 ±7.9 51.7 ± 8.4 10 7 [303] 
Pommier RF 1998 USA 1987 • 1996 Retrospective 40 38 
- - - -
6 3 [304] 
Putman JB 1994 USA 1986 1992 Retrospective 179 42 
- - - -
8 5 [305] 
Saha Al 2009 UK 2000 2006 Retrospective 24 4' 21/3 3/1 
- -
11 3 [306] 
Sato N 1993 Japan 1993 Prospective 14 5 14/0 5/0 59.1 ±9.2 72.0 ± 6.8 8 4 [83] 
Shahian DM 1986 USA 1978 1984 Retrospective 65 30 45/20 19/11 63.1 ±9.5 62.4 ±8.1 12 2 [307] 
Stark SP 1996 USA 1988 1994 Retrospective 16 32 16/0 30/2 56.0 ± 10.0 63.0 ± 12.0 13 4 [308] 
Steiger Z 1981 USA 1977 1981 Retrospective 20 21 
- -
- -
7 6 [309] 
Suttie SA 2007 UK 1994 2003 Retrospective 71 31 54/17 23/8 
- -
11 5 [310] 
Svanes K 1995 Norway 1984 1992 Retrospective 32 51 
- - - -
5 3 [311] 
Tilanus HW 1993 Holland 1980 1990 Retrospective 152 141 107/45 102/39 
- -
7 2 [312] 
Yekebas EF 2006 Germany 1992 2002 Prospective 79 41 63/16 27/14 - - 9 1 [246] 
TIE, transthoracic oesophagectomy. THE, transhiatal oesophagectomy. +Full details of methodological and surgical quality scoring systems are provided online as supplementary information. "An additional 25 
patients that were reported in this study were excluded from meta-analysis (21 benign disease, 4 emergency oesophagectomy). ''An additional 47 patients that were reported in this study were excluded from 
meta-analysis (laparoscopic transhiatal oesophagectomy). 'An additional 2 patients that were reported in this study were excluded from meta-analysis (transabdominal oesophagectomy). Three patients who 
died shortly following oesophagectomy were excluded from the analysis by the authors (surgical approach was not defined). ° An additional 28 patients that were reported in this study were excluded from meta-
analysis (2-stage procedure with delayed reconstruction). 'An additional 19 patients that were reported in this study were excluded from meta-analysis (transabdominal oesophagectomy). 'An additional 2 
patients that were reported in this study were excluded from meta-analysis (endoesophageal pull through). ''Outcomes of a single patient who underwent transhiatal dissection and substernal bypass through a 
median sternotomy were not reported by the authors.' An additional 20 patients that were reported in this study were excluded from meta-analysis (vagal sparing oesophagectomy).' An additional 16 patients 
that were reported in this study were excluded from meta-analysis (laparoscopic transhiatal oesophagectomy). 
Table 2.4 Overall results of meta-analysis 
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No. of 
studies 
No. of 
patients OR/WIV1D 95%CI P-value 
H6x' 
P-value 
HG 
I' 
Adenocarcinoma 21 2358 0.76 0.47, 1.21 0.24 <0.001 77 
Squamous cell carcinoma 20 2138 1.38 0.86, 2.21 0.18 <0.001 76 
Tumour site 
Upper 1/3 and cervical oesophagus 19 2136 0.62 0.34, 1.13 0.12 <0.001 65 
Middle 1/3 20 2327 1.75 1.30, 2.35 <0.001 0.01 48 
Lower 1/3, GOJ and cardia 22 2506 0.72 0.52,1.00 0.05 <0.001 63 
Tumour stage 
O/l 28 3428 0.64 0.50, 0.81 <0.001 0.66 0 
II 32 3823 0.96 0.78,1.19 0.71 0.09 26 
III 30 4013 1.20 0.99, 1.45 0.06 0.04 34 
IV 22 3271 1.42 1.12, 1.80 0.003 0.51 0 
Neoadjuvant therapy 9 708 0.87 0.41, 1.85 0.72 0.002 68 
Lymph nodes excised 4 461 7.67 1.12, 14.21 0.02 <0.001 94 
Operative and hospital details 
Operative time (mins) 12 1113 84.57 39.69,129,45 <0.001 <0.001 96 
Operative blood loss (ml) 8 762 47.55 -125.97, 221.08 0.59 <0.001 85 
Mean length of ICU stay (days) 3 360 -0.41 -3.47, 2.65 0.79 0.01 78 
Mean length of hospital stay (days) 12 1137 3.86 1.11, 6.61 0.006 <0.001 75 
Postoperative complications 
Mortality 48 5627 1.48 1.20,1.83 <0.001 0.77 0 
All respiratory complications 42 4141 1.32 1.05, 1.66 0.02 <0.001 48 
All cardiac complications 27 2772 1.03 0.77,1.37 0.86 0.98 0 
Anastomotic leak 39 3847 0.69 0.53, 0.89 0.005 0.07 26 
Chyle leak 12 1727 1.56 0.75, 3.24 0.23 0.23 21 
Vocal cord paralysis 29 2989 0.57 0.38, 0.84 0.005 0.09 27 
Haemorrhage 20 2191 0.65 0.41, 1.03 0.07 0.93 0 
Wound infection 20 2293 1.89 1.35, 2.64 <0.001 0.85 0 
Pneumothorax 10 991 0.43 0.14,1.34 0.15 0.09 41 
Pleural effusion 8 737 0.83 0.52,1.33 0.43 0.32 14 
Anastomotic stricture 16 2490 0.58 0.43, 0.79 <0.001 0.21 21 
Pneumonia 24 2380 1.37 1.05,1.79 0.02 0.28 13 
ARDS/AU 9 874 1.29 0.74, 2.27 0.37 0.54 0 
Atelectasis 6 600 2.06 0.87, 4.88 0.1 0.29 20 
Pulmonary embolism 12 1129 1.12 0.50, 2.50 0.79 0.95 0 
Myocardial infarction 13 1311 0.47 0.22,1.02 0.06 0.99 0 
Arrhythmia 6 500 0.92 0.48,1.74 0.79 0.82 0 
Renal insufficiency 5 569 0.84 0.28, 2.50 0.76 0.91 0 
5-year survival 26 3643 1.03 0.80,1.32 0.84 0.02 41 
OR, odds ratio; WMD, weighted mean difference; CI, confidence interval; HG, heterogeneity; x , Chi squared 
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Transthoracic Transhiatal Odds Ratio 
study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 
1.9.1 Stage O/I 
Bolton 1994 0 34 1 48 0.4% 0.46 [0.02, 11.61] 
Bousamra 2002 4 47 12 43 2.356 0.24 [0.07, 0.82] 
Boyle 1999 4 27 9 38 2.1% 0.56 [0.15, 2.05] 
Cariati 2002 2 49 2 14 1.0% 0.26 [0.03, 2.00] 
Chan 2000 1 33 2 34 0.7% 0.50 [0.04, 5.79] 
Chang 2008 36 643 18 225 5.5% 0.68 [0.38, 1.23] 
Chu 1997 2 19 4 20 1.2% 0.47 [0.08, 2.93] 
Gluch 1999 4 33 9 65 2.2% 0.86 [0.24, 3.03] 
Coldfaden 1986 0 43 1 29 0.4% 0.22 [0.01, 5.55] 
Goldmine 1993 12 35 19 32 3.1% 0.36 [0.13, 0.96] 
Graham 1998 6 32 23 119 3.1% 0.96 [0.36, 2.61] 
Gupta 2000 5 27 6 39 2.1% 1.25 [0.34, 4.60] 
Hankins 1989 0 52 5 26 0.5% 0.04 [0.00, 0.70] 
Horstmann 1995 4 41 5 46 1.9% 0.89 [0.22, 3.55] 
Hulscher 2002 17 114 12 106 4.1% 1.37 [0.62, 3.03] 
Jacobi 1997 2 16 1 16 0.7% 2.14 [0.17, 26.33] 
Jauch 1992 S 37 6 49 2.2% 1.12 [0.31, 4.00] 
Millikan 1995 0 71 2 67 0.5% 0.18 [0.01, 3.89] 
Moon 1992 2 24 6 63 1.4% 0.86 [0.16, 4.61] 
Muller 1989 3 41 9 95 1.9% 0.75 [0.19, 2.94] 
Oh 2006 21 24 31 31 0.5% 0.10 [0.00, 1.99] 
Pac 1993 1 120 2 118 0.7% 0.49 [0.04, 5.45] 
Pommier 1998 4 40 10 38 2.2% 0.31 [0.09, 1.10] 
Putman 1994 27 179 8 42 3.6% 0.75 [0.32, 1.81] 
Saha 2009 22 24 4 4 0.4% 1.00 [0.04, 24.55] 
Sato 1993 4 14 4 5 0.7% 0.10 [0.01, 1.19] 
Shahian 1986 13 65 8 30 3.0% 0.69 [0.25, 1.89] 
Suttie 2007 5 71 6 31 2.1% 0.32 [0.09, 1.13] 
Subtotal (95% CI) 1955 1473 50.2% 0.64 [0.50, 0.81] 
Total events 206 225 
Heterogeneity: Tau' = 0.00; Chi' = 23.44, df = 27 (P = 0.66); 1' = 0% 
Test for overall effect: Z = 3.59 (P = 0.0003) 
1.9.2 Stage IV 
Bolton 1994 1 34 3 48 0.8% 0.45 [0.05, 4.57] 
Bousamra 2002 3 47 3 43 1.4% 0.91 [0.17,4.76] 
Boyle 1999 0 27 2 38 0.5% 0.27 [0.01, 5.76] 
Chan 2000 6 33 4 34 1.9% 1.67 [0.42, 6.54] 
Chang 2008 30 643 4 225 2.8% 2.70 [0.94, 7.76] 
Gockel 2005 17 47 27 103 4.4% 1.60 [0.76, 3.34] 
Goldfaden 1986 4 43 2 29 1.3% 1.38 [0.24, 8.10] 
Goldmine 1993 6 35 4 32 1.9% 1.45 [0.37, 5.69] 
Graham 1998 8 32 7 119 2.6% 5.33 [1.76, 16.12] 
Hankins 1989 16 52 6 26 2.7% 1.48 [0.50, 4.39] 
Homesh 2006 2 41 2 43 1.0% 1.05 [0.14, 7.83] 
Hulscher 2002 17 114 7 106 3.4% 2.48 [0.98, 6.24] 
Jacobi 1997 1 16 2 16 0.7% 0.47 [0.04, 5.73] 
Jauch 1992 5 37 5 49 2.0% 1.38 [0.37, 5.15] 
Junginger 2006 38 159 15 70 4.8% 1.15 [0.58, 2.27] 
Millikan 1995 12 71 7 67 3.1% 1.74 [0.64, 4.73] 
Moon 1992 10 24 29 63 3.3% 0.84 [0.32, 2.17] 
Morgan 2007 9 119 0 32 0.5% 5.59 [0.32, 98.62] 
Muller 1989 10 41 16 95 3.5% 1.59 [0.65, 3.89] 
Pac 1993 48 120 43 118 6.0% 1.16 [0.69, 1.96] 
Pommier 1998 1 40 7 38 0.9% 0.11 [0.01, 0.97] 
Suttie 2007 1 71 0 31 0.4% 1.34 [0.05, 33.82] 
Subtotal (95% CI) 1846 1425 49.8% 1.42 [1.12, 1.80] 
Total events 245 195 
Heterogeneity: Tau' = 0.00: Chi' = 20.23, df = 21 (P = 0.51); f = 0% 
Odds Ratio 
M-H, Random, 9SX CI 
3801 2898 100.0% Total (95% CI) 
Total events 451 420 
Heterogeneity: Tau' = 0.13; Chi' = 65.05, df = 49 (P = 0.06): I' = 25% 
Test for overall effect: Z = 0,67 (P = 0.50) 
0.93 [0.75, 1.151 
i.002 0.1 
Favours Transthoracic 
10 5 
Favours Transhiatal 
Figure 2.2 Tumour stages O/I and IV 
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2.4.3 Extent of resection 
Lymph node yield was adequately reported in 4 studies [72, 246, 279, 308]. hi the 
transthoracic group a mean of eight more lymph nodes were retrieved compared with the 
transhiatal group (P=0.02, CI 1-14), although heterogeneity was significant (f<0.001, 
1^=94%) [Figure 2.3]. 
study or Subgroup 
Transthoracic 
Mean SD Total 
Transhiatal 
Mean SD Total Weight 
Mean Difference 
IV, Random, 95% CI 
Mean Difference 
IV, Random, 95% CI 
Chou 2005 9.3 2.7 50 5.3 1.9 23 27.2% 4.00 [2.92, 5.08] 
Hulscher 2002 31 14 114 15 9 106 25.8% 15.00 [11.91, 18.09) 
Stark 1996 10.8 8.1 16 10.7 10.1 32 23.2% 0.10 [-5.19, 5.39] 
Yekebas 2006 25.9 14.4 79 14.6 12.1 41 23.8% 11.30 [6.42, 16.18) 
Total (95% CI) 259 202 100.0% 7.67 [1.12, 14.21) 
Heterogeneity: Tau' = 40.70: Chi' = 52.98, df = 3 (P < 0.00001): I' = 94% 
Test for overall effect: Z = 2.30 (P = 0.02) -io ^ 5 Favours Transthoracic Favours Transhiatal 
Figure 2.3 Lymph nodes excised 
2.4.4 Length of operation and hospital stay 
Transthoracic procedures took a mean of 85 minutes longer than the transhiatal approach. 
(P<0.001, CI 40-129). There was no significant difference in blood loss. The postoperative 
length of hospital stay of patients who underwent transhiatal oesophagectomy was on 
average four days less than transthoracic oesophagectomy patients (P<0.01, CI 1-7) [Figure 
2.4]. Heterogeneity was significant for length of operation, blood loss and hospital stay 
( f <0.001, f>75%). 
Transthoracic Transhiatal Mean Difference 
study or Subgroup Mean SD Total Mean SD Total Weight IV, Random, 95% CI 
Cariati 2002 31.39 9.3 49 24 6.45 14 9.8% 7.39 [3.12, 11.66) 
Chou 2005 20.7 17.4 50 18.6 13.7 23 6.7% 2.10 [-5.29, 9.49] 
Chou 2009 33.7 25.4 47 216 13.7 40 5.8% 12.10 [3.69, 20.51) 
Chu1997 27 4.8 19 18 9.8 20 9.2% 9.00 [4.19, 13.81] 
Cluch 1999 26 16 33 23 11 65 7,9% 3.00 [-3.08, 9.08) 
Gupta 2000 15.44 7.19 27 8.15 1.8 39 11.4% 7.29 [4.52, 10.06] 
Hankins 1989 26.7 15.7 52 25.4 17.7 26 6.1% 1.30 [-6.73, 9.33) 
Jauch 1992 24.7 13.6 37 34.6 20 49 6,9% -9.90 [-17.01. -2.79) 
Naunheim 1992 23 15.1 27 19.2 9 11 6,3% 3.80 [-3.99, 11.59) 
Pac 1993 19 7.3 120 11.5 5.4 118 12.3% 7.50 (5.87, 9.13) 
Putman 1994 20 21 134 19 12 42 8.9% 1.00 [-4.08, 6.08] 
Shahian 1986 17.4 11.7 65 20.5 13.4 30 8.4% -3.10 [-8.68, 2.48) 
Total (95% CI) 660 477 100.0% 3.86 [1.11, 6.61] 
Heterogeneity: Tau' = 15.34: Chi' = 44.80, df = 11 IP < 0.00001); I' = : 75% 
Test for overall effect: Z = 2.75 (P = 0.006) 
Mean Difference 
IV, Random, 95% CI 
-io -lo 10 20 
Favours Transthoracic Favours Transhiatal 
Figure 2.4 Hospital stay 
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2.4.5 Postoperative complications 
Meta-analysis of all studies found there to be no significant difference in the incidence of 
postoperative cardiac complications (both overall and individual), chyle leak, haemorrhage, 
pneumothorax, pleural effusion, acute respiratory distress syndrome and acute lung injiiry, 
atelectasis, pulmonary embolism and renal insufficiency between operative groups. 
2.4.5.1 Early mortality 
Early mortality, reported as either <30 day or in hospital mortality, was significantly greater 
for transthoracic (341/3222, 10.6%) compared to transhiatal (172/2405, 7.2%) 
oesophagectomy (OR 1.48, CI 1.20-1.83, f<0.001) [Figure 2.5]. Studies did not show 
significant heterogeneity. 
2.4.5.2 Overall respiratory complications 
The incidence of overall respiratory complications was significantly higher in the 
transthoracic group (775/2173, 35.7%) compared to the transhiatal group (552/1968, 28.0%) 
(OR 1.32, CI 1.05-1.66, P=0.02) [Figure 2.6], although heterogeneity was significant 
(P<0.001, f=48%). 
2.4.5.3 Pneumonia 
Rates of pneumonia were significantly higher in the transthoracic group (285/1331, 21.4%) 
compared to the transhiatal group (182/1049, 17.3%) (OR 1.37, CI 1.05-1.79, P=0.02) 
[Figure 2.7]. Heterogeneity between studies was not significant. 
2.4.5.4 Anastomotic leak 
Rates of anastomotic leak were significantly lower following transthoracic (219/2070, 
10.6%) compared to transhiatal (301/1777, 16.9%) oesophagectomy (OR 0.69, CI 0.53=0.89, 
p=0.005) [Figure 2.8]. Heterogeneity was significant (P=0.07,1^=26%). 
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Transthoracic Transhiatal Odds Ratio 
study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 
Areja 2006 4 15 3 IS 1.556 1.45 [0.26, 8.01] 
Berdejo 1995 4 20 1 21 0.856 5.00 [0.51, 49.27] 
Bolton 1994 5 34 0 48 0.5% 18.08 [0.96, 339.02] 
Bonavina 1995 18 168 5 85 4.2% 1.92 [0.69, 5.36] 
Boyle 1999 5 27 3 38 1.9% 2.65 [0.58, 12.21] 
Braghetto 2006 7 60 6 59 3.3% 1.17 [0.37. 3.70] 
Caracci 1983 1 13 3 22 0.8% 0.53 [0.05, 5.68] 
Cariati 2002 11 49 2 14 1.6% 1.74 [0.34, 8.96] 
Chan 2000 3 33 2 34 1.3% 1.60 [0.25, 10.25] 
Chang 2008 84 643 15 225 13.5% 2.10 [1.19, 3.73) 
Chou 2005 2 SO 2 23 1.1% 0.44 [0.06, 3.32] 
Chou 2009 1 47 1 40 0.6% 0.85 [0.05, 14.00] 
Chu1997 0 19 3 20 0.5% 0.13 [0.01, 2.66] 
Fok 1989 28 172 7 38 5.3% 0.86 [0.35, 2.15] 
Cluch 1999 2 33 3 65 1.3% 1.33 [0.21, 8.40] 
Gockel 2005 7 47 3 103 2.2% 5.83 [1.44, 23.69] 
Goldfaden 1986 6 43 2 29 1.6% 2.19 [0.41, 11.69] 
Goldmine 1993 3 35 2 32 1.3% 1.41 [0.22, 9.01] 
Graham 1998 3 32 3 119 1.6% 4.00 [0.77, 20.85] 
Gupta 2000 7 27 4 39 2.4% 3.06 [0.80, 11.76] 
Nankins 1989 3 52 2 26 1.3% 0.73 [0.11, 4.69] 
Homesh 2006 3 41 4 43 1.8% 0.77 [0.16, 3.67] 
Horstmann 1995 8 41 12 46 4.3% 0.69 [0.25, 1.89] 
Hulscher 2002 5 114 2 106 1.6% 2.39 [0.45, 12.57) 
Ikeguchi 2000 3 14 3 19 1.4% 1.45 [0.25, 8.58] 
Jacob! 1997 1 16 3 16 0.8% 0.29 [0.03, 3.13] 
Jauch 1992 5 37 8 49 3.0% 0.80 [0.24, 2.68] 
Junginger 2006 12 159 3 70 2.6% 1.82 [0.50, 6.67) 
Kudo 1990 1 35 1 37 0.6% 1.06 [0.06, 17.61] 
Makela 1991 5 46 4 43 2.3% 1.19 [0.30, 4.75] 
Marton 2005 4 31 6 52 2.4% 1.14 [0.29, 4.39] 
Millikan 1995 9 71 3 67 2.4% 3.10 [0.80, 11.98] 
Mohsen 1993 9 41 1 22 1.0% 5.91 [0.70, 50.10] 
Moon 1992 3 24 8 63 2.2% 0.98 [0.24, 4.06] 
Morgan 2007 5 119 2 32 1.5% 0.66 [0.12, 3.56] 
Muller 1989 8 41 7 95 3.7% 3.05 [1.02, 9.07] 
Naunheim 1992 5 27 2 11 1.3% 1.02 [0.17, 6.27) 
Oh 2006 0 27 2 31 0.5% 0.21 [0.01, 4.67] 
Pac 1993 13 120 8 118 5.2% 1.67 [0.67, 4.19] 
Pommier 1998 1 40 2 38 0.7% 0.46 [0.04, 5.31] 
Putman 1994 13 179 2 42 1.9% 1.57 [0.34, 7.22] 
Saha 2009 2 24 0 4 0.4% 1.00 [0.04, 24.55) 
Shahian 1986 4 65 4 30 2.1% 0.43 [0.10, 1.841 
Stark 1996 0 16 1 32 0.4% 0.64 [0.02, 16.50] 
Steiger 1981 0 20 2 21 0.5% 0.19 [0.01, 4.22] 
Suttie 2007 2 71 1 31 0.7% 0.87 [0.08, 9.96] 
Svanes 1995 3 32 2 51 1.3% 2.53 [0.40, 16.07) 
Tilanus 1993 13 152 7 141 4.9% 1.79 [0.69, 4.62] 
Total (95% CI) 3222 2405 100.0% 1.48 [1.20,1.83) 
Odds Ratio 
M-H, Random, 95% CI 
Total events 341 172 
Heterogeneity: Tau' = 0.00; Chi' = 39.55, df = 47 (P = 0.77); I' 
Test for overall effea: Z = 3.66 (P = 0.0003) 
: 0% 3.bi ~o!t 1*0" lio 
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Figure 2.5 Early mortality 
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Transthoracic Transhiatal Odds Ratio 
study or Subgroup Events Total Events Total Weight M -H, Random, 95% CI 
Areja 2006 10 15 13 IS 1.2X 0.31 [0.05, 1.93] 
Berdejo 1995 2 20 0 21 0.5% 5.81 [0.26, 128.90) 
Bousamra 2002 7 47 5 43 2.1% 1.33 [0.39, 4.5S] 
Boyle 1999 16 27 11 38 2.6% 3.57 [1.26, 10.10] 
Braghetto 2006 18 60 18 59 3.4% 0.98 [0.45, 2.13] 
Caracci 1983 6 13 12 22 1.8% 0.71 [0.18, 2.83] 
Cariati 2002 19 49 6 14 2.2% 0.84 [0.25, 2.82] 
Chan 2000 17 33 17 34 2.8% 1.06 [0.41, 2.77] 
Chou 2005 5 50 3 23 1.6% 0.74 [0.16, 3.40] 
Chou 2009 6 47 4 40 1.9% 1.32 [0.34, 5.04] 
Chu 1997 8 19 12 20 2.0% 0.48 [0.14, 1.74] 
Fok 1989 151 172 28 38 3.1% 2.57 [1.09, 6.03] 
Gluch 1999 16 33 34 65 3.2% 0.86 [0.37, 1.98] 
Gockel200S 1 47 1 103 0.6% 2.22 [0.14, 36.23] 
Coldfaden 1986 16 43 3 29 1.9% 5.14 [1.34, 19.72] 
Goldmine 1993 12 35 18 32 2.7% 0.41 [0.15, 1.09] 
Graham 1998 14 32 33 119 3.3% 2.03 [0.91, 4.54] 
Gupta 2000 15 27 8 39 2.5% 4.84 [1.63, 14.36] 
Hankins 1989 25 52 15 26 2.8% 0.68 [0.26, 1.75] 
Homesh 2005 2 41 2 43 1.0% 1.05 [0.14, 7.83] 
Horstmann 1995 21 41 25 46 3.2% 0.88 [0.38, 2.05] 
Hulscher 2002 65 114 29 106 4.1% 3.52 [2.00, 6.20] 
Ikeguchi 2000 3 14 2 19 1.1% 2.32 [0.33, 16.18] 
Jacob! 1997 15 16 12 16 0.8% 5.00 [0.49, 50.83] 
Jauch 1992 18 37 24 49 3.1% 0.99 [0.42, 2.32] 
Makela 1991 14 46 6 43 2.5% 2.70 [0.93, 7.84] 
Marton 2005 4 31 6 52 1.9% 1.14 [0.29, 4.39] 
IMillikan 1995 29 71 11 67 3.3% 3.52 [1.58, 7.83] 
Mohsen 1993 11 35 3 22 1.8% 2.90 [0.71, 11.91] 
Moon 1992 6 24 8 63 2.2% 2.29 [0.70, 7.49] 
Morgan 2007 36 119 12 32 3.3% 0.72 [0.32, 1.63] 
Muller 1989 21 41 40 95 3.5% 1.44 [0.69, 3.01] 
Oh 2006 5 27 4 31 1.7% 1.53 [0.37, 6.41] 
Pac 1993 30 120 35 118 4.1% 0.79 [0.45, 1.40] 
Pommler 1998 9 40 10 38 2.6% 0.81 [0.29, 2.29] 
Putman 1994 16 179 4 42 2.3% 0.93 [0.29, 2.95] 
Shahian 1986 15 65 10 30 2.8% 0.60 [0.23, 1.56] 
Stark 1996 1 16 14 32 0.9% 0.09 [0.01, 0.73] 
Steiger 1981 4 20 4 21 1.6% 1.06 [0.23, 4.98] 
Suttie 2007 25 71 7 31 2.8% 1.86 [0.70, 4.93] 
Svanes 1995 10 32 19 51 2.9% 0.77 [0.30, 1.96] 
Tllanus 1993 51 152 24 141 4.2% 2.46 [1.42, 4.28] 
Total (95% CI) 2173 1968 100.0% 1.32 (1.05, 1.66] 
Total events 775 552 
Heterogeneity: Tau' = 0.24; Chi' = 78.97, df = 41 (P = 0.0003): r = 48% 
Test for overall effect: Z = 2.39 (P = 0.02) 
Odds Ratio 
M-H, Random, 95% CI 
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Figure 2.6 Overall respiratory complications 
2.4.5.5 A nastom otic stricture 
Rates of anastomotic stricture were significantly lower following transthoracic (301/1380, 
21.8%) compared to transhiatal. (279/1110, 25.1%) oesophagectomy (OR 0.58, CI 0.43-0.79, 
P<0.001). Studies did not show significant heterogeneity. 
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Transthoracic Transhiatal Odds Ratio 
study or Subgroup Events Total Events Total Weight M l-H, Random, 95% CI 
Areja 2006 8 15 6 15 3.156 1.71 [0.40, 7.29] 
Braghetto 2006 12 60 10 59 6.7» 1.23 [0.48, 3.10] 
Caracci 1983 6 13 12 22 3.4X 0.71 [0.18, 2.83] 
Chan 2000 15 33 14 34 6.3% 1.19 [0.45, 3.13] 
Chou 2005 5 50 3 23 2.9% 0.74 [0.16, 3.40] 
Chou 2009 6 47 4 40 3.6% 1.32 (0.34, 5.04] 
Chu 1997 0 19 2 20 0.7% 0.19 [0.01, 4.22] 
Fok 1989 63 172 15 38 9.9% 0.89 [0.43, 1.82] 
Goldfaden 1986 6 43 0 29 0.8% : 10.23 [0.55, 188.97] 
Goldmine 1993 6 35 6 32 4.1% 0.90 [0.26, 3.13] 
Graham 1998 6 32 11 119 5.2% 2.27 [0.77, 6.69] 
Gupta 2000 13 27 7 39 5.0% 4.24 [1.39, 12.92] 
Homesh 2005 1 41 1 43 0.9% 1.05 [0.06, 17.36] 
Ikeguchi 2000 3 14 2 19 1.8% 2.32 [0.33, 16.18] 
Jacobi 1997 S 16 3 16 2.5% 1.97 [0.38, 10.17] 
Makela 1991 10 46 1 43 1.6% 11.67 [1.42, 95.58] 
Milllkan 1995 12 71 10 67 6.9% 1.16 [0.46, 2.89] 
Mohsen 1993 6 35 2 22 2.3% 2.07 [0.38, 11.31] 
Morgan 2007 30 119 10 32 7.7% 0.74 [0.32, 1.74] 
Muller 1989 20 41 38 95 9.6% 1.43 [0.68, 2.99] 
Pac 1993 12 120 1 118 1.6% : 13.00 [1.66, 101.66] 
Putman 1994 7 179 0 42 0.9% 3.70 [0.21, 65.99] 
Suttie 2007 25 71 7 31 6.3% 1.86 [0.70, 4.93] 
Svanes 1995 8 32 17 51 6.1% 0.67 [0.25, 1.79] 
Total (95% CI) 1331 1049 100.0% 1.37 (1.05, 1.79] 
Total events 285 182 
Heterogeneity; Tau' = 0.06: Chi' = 26.37, df = 23 (P = 0.28); 1' = 13% 
Test for overall effect: Z = 2.28 (P = 0.02) 
odds Ratio 
M-H, Random, 95X CI 
Figure 2.7 Pneumonia 
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2.4.5.6 Vocal cord paralysis 
The occurrence of vocal cord paralysis was observed significantly less often following 
transthoracic oesophagectomy (87/1541, 5.6%) compared to transhiatal oesophagectomy 
(158/1448, 10.9%) (OR 0.57, CI .38-0.84, P=0.005). Heterogeneity was significant (P=0.02, 
l M l % ) . 
2.4.5.7 Wound infection 
The transthoracic approach was associated with a higher rate of wound infection (127/1255, 
10.1%) than transhiatal procedures (66/1038, 6.4%) (OR 1.89, CI 1.35-2.64, p<0.001). There 
was no evidence of heterogeneity. 
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Transthoracic Transhiatal Odds Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 
Areja 2006 2 15 0 15 0.6% 5.74 (0.25, 130.37] 
Bousamra 2002 5 47 9 43 3.3% 0.45 (0.14, 1.47] 
Boyle 1999 1 27 5 38 1.2% 0.25 (0.03,2.31] 
Braghetto 2006 13 60 13 59 4.8% 0.98(0.41.2.34] 
Caracci 1983 0 13 6 22 0.7% 0.09 (0.00, 1.82] 
Carlati 2002 6 49 2 14 1.8X 0.84(0.15,4.69] 
Chan 2000 7 33 5 34 3.0% 1.56 (0.44, 5.53] 
Chou 2005 5 50 3 23 2.2% 0.74(0.16, 3.40] 
Chou 2009 10 47 2 40 2.1% 5.14 [1.05, 25.04] 
Fok 1989 7 172 1 38 1.3% 1.57(0.19, 13.15] 
Gluch 1999 3 33 3 65 2.0% 2.07 (0.39, 10.85] 
Goldfaden 1986 4 43 2 29 L8% 1.38 (0.24, 8.10] 
Goldmine 1993 3 35 2 32 1.6% 1.41 (0.22, 9.01] 
Graham 1998 4 32 19 119 3.4% 0.75 (0.24, 2.39] 
Gupta 2000 5 27 9 39 3.1% 0.76 [0.22,2.58] 
Hankins 1989 3 52 5 26 2,39S 0.26 [0.06, 1.18] 
Homesh 2006 5 41 9 43 3.3% 0.52 (0.16, 1.72] 
Horstmann 1995 10 41 23 46 4.5% 0.32 [0.13,0.81] 
Hulscher 2002 18 114 15 106 5.7% 1.14 (0.54,2.39] 
Ikeguchi 2000 3 14 4 19 1.9% 1.02 (0.19, 5.53] 
Jacobi 1997 2 16 2 16 1.3% 1.00 (0.12, 8.13] 
Jauch 1992 4 37 19 49 3.3% 0.19 (0.06, 0.63] 
Makela 1991 9 46 3 43 2.6% 3.24 [0.82, 12.90] 
Millikan 1995 3 71 5 67 2,4% 0.55 [0.13,2.38] 
Mohsen 1993 7 35 5 22 2.9% 0.85 (0.23, 3.11] 
Moon 1992 3 24 16 63 2.7% 0.42 [0.11, 1.60] 
Morgan 2007 11 119 2 32 2.2% 1.53 (0.32, 7.27] 
Muller 1989 13 41 30 95 5.3% 1.01 [0.46,2.21] 
Oh 2006 2 27 3 31 1.6% 0.75 [0.12,4.84] 
Pac 1993 6 120 5 118 3.2% 1.19(0.35,4.01] 
Pommier 1998 3 40 5 38 2.3% 0.54 [0.12, 2.41] 
Putman 1994 14 179 5 42 3.7% 0.63 (0.21, 1.85] 
Sato 1993 1 14 1 5 0.7% 0.31(0.02,6.12] 
Shahlan 1986 3 65 10 30 2.6% 0.10 [0.02, 0.39] 
Stark 1996 1 16 5 32 1.2% 0.36 (0.04, 3.37] 
Steiger 1981 0 20 4 21 0.7% 0.09 (0.00, 1.89] 
Suttie 2007 5 71 5 31 2.8% 0.39 [0.11, 1.47] 
Svanes 1995 2 32 3 51 1.6% 1.07 (0.17, 6.76] 
Tilanus 1993 16 152 36 141 6.4% 0.34 (0.18, 0.65] 
Total (95% CI) 2070 1777 100.0% 0.69 (0.53, 0.89] 
Total events 219 301 
Heterogeneity: Tau' = 0.16; Chf = 51.52, df= 38 (P = 0.07); I ' = 26% 
Test for overall effect: Z = 2.84 (P = 0.005) 
Odds Ratio 
M-H, Random, 95% CI 
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Figure 2.8 Anastomotic leak 
2.4.6 Five-year survival 
Complete 5-year follow-up of all patients was achieved in a single study [72, 291]. Overall 
analysis of 5-year survival showed no significant difference between the transthoracic 
(577/2170, 26.6%) and transhiatal (380/1473, 25.8%) groups (OR 0.84, CI 0.80-1.32, 
p=0.84) and was subject to significant heterogeneity (P=0.02,1^=41%) [Figure 2.9]. 
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Transthoracic Transhiatal Odds Ratio 
Study or Subgroup Events Total Events Total Weight M-H, Random, 95% CI 
Bonavina 1995 111 168 44 85 7.596 1.81 [1.07, 3.09) 
Bousamra 2002 10 47 14 43 4.3S6 0.56 [0.22, 1.44) 
Boyle 1999 2 27 11 38 2.OX 0.20 [0.04, 0.97) 
Cariati 2002 6 49 1 14 1.29S 1.81 [0.20, 16.47] 
Chang 2008 130 643 56 225 9.1% 0.76 [0.53, 1.09) 
Gockel2005 6 47 33 103 4.356 0.31 [0.12, 0.80) 
Goldfaden 1986 7 43 4 29 2.7% 1.22 [0.32, 4.60) 
Graham 1998 6 32 20 119 4.096 1.14 [0.42, 3.13) 
Gupta 2000 3 27 3 39 1.996 1.50 [0.28, 8.06) 
Hulscher 2002 41 114 36 106 7.396 1.09 [0.63, 1.90) 
Ikeguchi 2000 9 14 11 19 2.496 1.31 [0.32, 5.43] 
Jauch 1992 8 37 10 49 3.896 1.08 [0.38, 3.06] 
Johansson 2004 8 27 2 22 1.9% 4.21 [0.79, 22.41] 
Junginger 2006 43 159 10 70 5.696 2.22 [1.04, 4.73] 
IMakela 1991 6 46 5 43 2.996 1.14 [0.32, 4.05] 
Moon 1992 4 24 8 63 2.896 1.38 [0.37, 5.07] 
Morgan 2007 40 119 17 32 5.396 0.45 [0.20, 0.99] 
Naunheim 1992 5 27 0 11 0.796 5.62 [0.29, 110.80] 
Oh 2005 23 24 25 31 1.296 5.52 [0.62, 49.39) 
Pac 1993 12 120 15 118 5.2% 0.76 [0.34, 1.71] 
Pommier 1998 11 40 11 38 4.196 0.93 [0.35, 2.50) 
Putman 1994 25 134 7 42 4.596 1.15 [0.46, 2.88] 
Shahian 1986 8 65 7 30 3.596 0.46 [0.15, 1.42] 
Stark 1996 6 16 4 32 2.496 4.20 [0.98, 18.03) 
Suttie 2007 12 42 12 31 4.1% 0.63 [0.24, 1.70] 
Yekebas 2006 35 79 14 41 5.496 1.53 [0.70, 3.36] 
Total (95% CI) 2170 1473 100.0% 1.03 [0.80, 1.32] 
Total events 577 380 
Heterogeneity; Tau' = 0.15; Chi' = 42.17, df = 25 (P = 0.02): 1' = 41% 
Test for overall effect: Z = 0.20 (P = 0.84) 
Odds Ratio 
M-H, Random, 95X CI 
Figure 2.9 Five-year survival 
4 -
0.01 0.1 "Iio" 4 -100 
Favours Transthoracic Favours Transhiatal 
2.4.7 Subgroup and sensitivity analyses 
The results of subgroup and sensitivity analysis are available as supplementary material in 
Appendix 1. Five-year survival was not significantly different in subgroup or sensitivity 
analyses and was consistently associated with significant heterogeneity. 
2.4.7.1 Randomised controlled trials 
Compared to the findings of overall analysis, tumour location, early mortality, overall 
respiratory complications, anastomotic leak, vocal cord paralysis, wound infection and 
anastomotic stricture were no longer significantly different. Lymph node count, operative 
time and mean length of hospital stay showed the same significant results as in the overall 
analysis. Whilst subgroup analysis of RCTs confirmed the previous finding that transthoracic 
70 
oesophagectomy was more often performed for more advanced tumours, this was only 
significant for stage HI disease (47.3% vs. 36.8%, OR 1.54, CI 1-2.38, P=0.05). Significant 
findings specific to RCT subgroup analysis were: chyle leak was more common after 
transthoracic oesophagectomy (9.6% vs. 1.9%, OR 5.55, CI 1.20-25.67, P=0.03) and pleural 
effusion was significantly more common following transhiatal oesophagectomy (15.3% vs. 
30.1%, OR 0.43, CI 0.20-0.94, P=0.03). None of these comparisons were subject to 
significant heterogeneity; although four were based on data from a single study. 
2.4.7.2 Studies published after and including the year 2000 
Twenty-one studies published after and including the year 2000 were analysed as a subgroup. 
Compared to the findings of overall analysis, overall respiratory complications, anastomotic 
leak, vocal cord paralysis and pneumonia were no longer significantly different. Tumour site, 
tumour stage, lymph node count, operative time, mean hospital stay, early mortality, wound 
infection and anastomotic stricture showed the same significant results as in the overall 
analysis. Heterogeneity was no longer significant for the comparison of tumours of the 
middle third of the oesophagus. The finding that atelectasis was observed significantly more 
often after transthoracic oesophagectomy (16.7% vs. 0%, OR 11.32, CI 1.32-96.97, P=0.03) 
showed no evidence of heterogeneity and was specific to studies published in the last 10 
years. 
2.4.7.3 Sensitivity analysis 
Fifteen studies which received >11 stars for methodological quality were included in 
sensitivity analysis. Compared to the findings of overall analysis, lymph node count, 
operative time, mean length of hospital stay, early mortality, overall respiratory 
complications, vocal cord paralysis, anastomotic stricture and pneumonia were no longer 
significantly different. Wound infection and anastomotic leak showed the same significant 
results as in the overall analysis. Sensitivity analysis confirmed the previous finding that 
transthoracic oesophagectomy was more often performed for more advanced tumours, 
however this was only significant for stage III disease (52.9% vs. 41.3%, OR 1.36, CI 1.05-
1.75, i^0.02). Although no difference was shown between operative approach and tumours 
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of the middle and lower oesophagus, patients with tumours of the upper and cervical 
oesophagus underwent transhiatal oesophagectomy significantly more often (1.4% vs. 8.8%, 
OR 0.29, CI 0.10-0.84, P=0.02). This relationship was not associated with significant 
heterogeneity. Heterogeneity in all other significant comparisons was the same as in the 
overall analysis. 
No study satisfied all six minimum surgical quality standards. The average surgical quality 
star rating of all 52 included studies was three. Only three studies gave an indication of the 
experience or case load of the surgeon(s) involved. In contrast, 47 studies reported hospital 
volume. Eleven studies reported information regarding lymph node yield. Four studies 
reported this information in a format suitable for meta-analysis. Fifteen studies reported the 
Ro resection rate. Forty-two studies reported the technical complication rate, 44 studies 
reported the anastomotic leak rate and 17 studies reported the anastomotic stricture rate. 
Fifty-one studies reported the early mortality rate. 
2.5 Discussion 
The results of this meta-analysis show that transhiatal oesophagectomy is associated with 
significantly reduced operative time, length of hospital stay, postoperative respiratory 
complications and early mortality. In comparison transthoracic oesophagectomy is associated 
with significantly fewer anastomotic leaks, anastomotic strictures and vocal cord palsies. 
Other outcomes, including 5-year survival, are shown not to differ significantly. These 
findings are comparable with the results of two previous systematic reviews published in 
1999 and 2001 [16-17]. 
Although survival is shown to be equivalent, transhiatal oesophagectomy was chosen 
significantly more frequently for early stage tumours and transthoracic oesophagectomy for 
advanced tumours. As few studies provide an adequate description of the methods used to 
allocate patients, selection bias cannot be ruled out. Significantly more lymph nodes were 
retrieved from patients in the transthoracic group; therefore the difference in cancer stage 
may be due to stage migration [72, 243]. Rating the reported quality of surgical resections 
shows that no study met all minimum surgical quality criteria. Of the 52 studies included in 
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this meta-analysis, four provided adequate information on lymph node retrieval. Only one of 
these studies reported a lymph node yield that exceeded current recommended standards 
[26]. Approaching the oesophagus through the chest and performing an oncological clearance 
that is less than the recommended standard mitigates against the potential survival advantage 
of the transthoracic approach. There is evidence that an increased extent of 
lymphadenectomy is associated with improved survival following oesophagectomy [25-32], 
The strengths of this study are its comprehensive systematic search of the English-language 
hterature and the inclusion of 52 comparative trials including, five RCTs, two of which have 
not been included in previous reviews. Subgroup analysis of studies published within the last 
10 years ensures that this meta-analysis is relevant to current practice whilst subgroup 
analysis of RCTs addresses potential selection bias. This is also the first time methodological 
and reported surgical quality has been used to assess these trials in a meta-analysis. 
The weakness of this review is the inclusion of trials of low methodological and surgical 
quahty and the presence of significant heterogeneity in the results. The Oxford Centre for 
Evidence-Based Medicine guidelines show that although systematic reviews of RCTs are 
considered to be the highest level of evidence, this relies on the absence of significant 
methodological, clinical and statistical heterogeneity. If a systematic review/meta-analysis 
has significant heterogeneity then the maximum grade of recommendation that can be made 
is the lowest level (D) [313]. Isolation of the results of RCTs and other studies of high 
methodological quality was achieved through subgroup analysis. Whilst the results of 
subgroup analyses do not contradict the overall analysis, they remain subject to significant 
heterogeneity 
Limitations of the surgical quality criteria are that they are arbitrary cut offs. The minimum 
criteria are based on averages reported in the literature and considered to be adequate results, 
whilst the higher quality criteria are based on rates reported in specialised centres and 
considered to be excellent results [314]. Rq resection rate was not included as a marker of 
surgical quality, because there is no clear threshold. However, Ro resection has been shown 
to correlate with survival [243, 315-320] with few reports to the contrary [321]. 
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This review provides a comprehensive analysis of studies comparing transthoracic and 
transhiatal oesophagectomy, highlighting deficiencies in the literature. It has demonstrated 
that evidence contained within comparative studies carmot be used to provide firm 
conclusions regarding the outcomes of these surgeries. Non-comparative studies that are 
often performed by specialised surgeons are unsuitable for meta-analysis, but may 
demonstrate the maximum efficacy of these procedures [74]. 
2.6 Conclusion 
la conclusion, this meta-analysis of studies comparing transthoracic with transhiatal 
oesophagectomy for cancer demonstrates no difference in 5-year survival, however 
lymphadenectomy and reported surgical quality was sub-optimal in both groups and the 
transthoracic group had significantly more advanced cancer. Findings should therefore be 
viewed with caution. Only through adequate surgical quality and standards of reporting may 
the true benefit of these surgeries be determined. 
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3. EARLY OUTCOMES OF OESOPHAGOGASTRIC CANCER RESECTIONS: A 
CASE SERIES OF A SINGLE SURGEON'S EXPERIENCE 
3.1 Objectives 
The primary objective of this study was to review the case series of a single consultant 
surgeon specialising in upper gastrointestinal cancer surgery, in order to determine whether 
the patient population intended for future clinical studies was representative of other 
pubhshed series. A secondary objective was to determine, through single- and multi-variate 
statistical analysis, factors predisposing the development of postoperative pneumonia. 
3.2 Introduction 
A systematic review of the English-language literature comparing transthoracic and 
transhiatal oesophagectomy has helped to define the global experience of these surgeries 
(refer to Chapter 2). Where data is drawn from a large number of surgeons and hospitals 
there is expected to be a wide range in quality of surgical treatment [322]. This is especially 
true of technically difficult operations such as oesophagectomy. Whilst meta-analysis of 
randomised controlled trials and comparative studies confirmed the high rates of morbidity 
and mortality that are often associated with oesophagectomy, overall conclusions were 
weakened by low surgical quality, poor reporting and differences in institutional practices. 
Together these factors are likely to explain the wide variation in outcomes that are reported 
by different studies. It is generally accepted that postoperative outcomes after 
oesophagectomy are superior in centres where there is higher case volume [51, 55-57, 59, 
63], prompting calls for centralisation of this surgery to specialised centres. As well as 
surgeon-specific skills [63], the improved results of high volume centres are likely to reflect 
standardisation of perioperative clinical pathways, providing an infrastructure for patient 
management [75]. 
Due to inter-institutional variability, local outcomes after oesophagectomy were reviewed to 
determine the specific characteristics of the patient population intended for future 
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perioperative clinical studies. Case series review also allowed for the analysis of factors 
predictive of postoperative respiratory complications. 
All oesophagectomies were via a radical transthoracic approach incorporating either two- or 
three-field lymphadenectomy and were performed by a single consultant surgeon specialising 
in upper gastrointestinal cancer. It is the view of surgeons at St Mary's Hospital that 
transhiatal oesophagectomy is a procedure that does not have oncological value and hence 
has no place in the management of oesophageal cancer. This view is mirrored by Japanese 
surgeons who also do not perform transhiatal oesophagectomy. Patients who underwent 
transabdominal radical D2 gastrectomy by the same surgeon were reviewed for comparative 
purposes [323]. Radical D2 gastrectomy provides an appropriate control group because the 
abdominal lymphadenectomy that is performed during this procedure is similar to that used 
in patients undergoing oesophagectomy. Although not requiring a thoracic stage, D2 
gastrectomy is associated with considerable perioperative morbidity and mortality [324]. 
3.3 Methods 
3.3.1 Patients 
Between July 7^ 2003 and February 19^ ^ 2009 a consecutive series of 159 patients underwent 
either oesophagectomy or gastrectomy for oesophagogastic cancer, under the care of a single 
consultant surgeon (G Hanna). Nine patients were excluded &om the analysis: eight (5%) 
who were found to be unresectable at the time of surgery and one patient for whom no 
medical records could be obtained. The remaining 150 patients were divided into two groups 
according to the operative approach used: transthoracic oesophagectomy or transabdominal 
gastrectomy. 
Clinical data including, patient demographic details, clinical history, comorbidity, tumour 
characteristics, neo-adjuvant therapy, details of the operative procedure and postoperative 
recovery were acquired upon retrospective review of medical and operative records. For each 
patient a total 289 discrete variables were recorded within a specifically designed database 
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(Microsoft Office Access 2007, Microsoft Corp., Redmond, WA, USA) (A fiill list of 
recorded variables are available as supplementary material in Appendix II). 
Pre-operative workup included medical history and examination, oncological staging and 
functional evaluation. Oncological staging typically consisted of oesophagogastroscopy 
(100%), thoracic and abdominal CT (100%), laparoscopy (73%), PET or PET-CT (51%) and 
endoscopic ultrasound (47%). Second line investigations performed at the time of 
preoperative assessment included routine blood analysis, and in selected patients, lung 
ftmction tests, cardiac ultrasound and cardiopulmonary exercise testing. Postoperative 
pathological tumour-node-metastasis (TNM) stage was assigned in accordance with the 
Union Internationale Contre le Cancer 1997 system [325]. 
3.3.2 Preoperative risk prediction 
Assessment of preoperative patient comorbidity was performed using the Charlson 
Comorbidity Index, a weighted index of 19 conditions to which are assigned scores of 1,2, 3 
or 6 depending on the risk of death associated with that condition [Table 3.1] [326]. An 
individual's risk of mortality is determined by summation of individual scores. 
O-POSSUM mortality scoring was retrospectively applied to the study population as a 
benchmark of operative risk. This scoring system, developed specifically for use in 
oesophagogastic surgery is based on the methods used by both POSSUM (Physiological and 
Operative Severity Score for the enumeration of Mortality and morbidity) and P-POSSUM 
[327]. Variables required for these scoring systems are given in table 3.2. Computation of O-
POSSUM score was performed by introducing preoperative physiological and surgical 
variables for each patient into an online calculator (supplied on the website: http://www.risk 
prediction.org.uk). All patients were assigned an American Society of Anesthesiologists 
(ASA) physical status classification by consultant anaesthetist one day prior to surgery that 
was independent of the surgeons' clinical assessment. 
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Table 3.1 Charlson Comorbidity Index: weighted index of comorbidityt 
Assigned weights for 
diseases Conditions 
1 Myocardial infarction 
Congestive heart disease 
Peripheral vascular disease 
Cerebrovascular disease 
Dementia 
Chronic pulmonary disease 
Connective tissue disease 
Ulcer disease 
Mild liver disease 
Diabetes 
2 Hemiplegia 
Moderate or sever renal disease 
Diabetes with end organ damage 
Any tumour 
Leukaemia 
Lymphoma 
3 Moderate or severe liver disease 
6 Metastatic solid tumour 
AIDS 
tTaken from: Charlson ME, et al. A new method of classifying prognostic 
comorbidity in longitudinal studies: development and validation. J Chronic 
Dis. 1987;40(5):373-83 
Table 3.2 Input variables of POSSUM, P-POSSUM and O POSSUM 
scoring systems 
Physiology score Operative severity score 
Age (years) Operative severity 
Cardiac signs/chest radiograph Multiple proceduret 
Respiratory history/chest radiograph Total blood loss (ml)t 
Systolic blood pressure (mmHg) Peritoneal soilingt 
Pulse (beats/minute) Presence of malignancy 
Glasgow Coma Scale Mode of surgery 
Haemoglobin (g/lOOmI) 
White cell count (xlo"/ l ) 
Urea (mmol/l) 
Sodium (mmol/l) 
Potassium (mmol/l) 
Electrocardiogram 
tVariable not used in the O-POSSUM scoring system 
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3.3.3 Operative technique 
3.3.3.1 Transthoracic oesophagectomy 
In 87 patients resection of tumours of the oesophagus, gastroesphageal junction and/or 
proximal stomach were performed through one of three transthoracic approaches. The most 
commonly performed transthoracic procedure was the two-stage (Ivor Lewis) 
oesophagectomy in 57 (65%) cases. This approach requires an initial laparotomy for 
mobilisation of the stomach followed by right-sided thoracotomy and resection of the 
oesophagus and proximal stomach [Figure 1.2]. Abdominal and thoracic stages were 
performed sequentially. During the second, thoracic, stage patients were transferred to a left 
lateral position with right lung collapse by endo-bronchial intubation. Gastrointestinal 
continuity was restored using a newly fashioned stomach tube based on the right gastric and 
gastroepiploic arteries, with anastomosis made between the residual oesophagus and gastric 
fundus. In 18 patients (21%) who underwent three-stage oesophagectomy, initial 
mobilisation of the oesophagus was performed either via an open thoracotomy (n=14) or 
thoracoscopically (n=4). In all 18 patients mobilisation of the stomach during second stage 
was via a laparotomy, with oesophagogastic anastomosis formed in the neck at the third 
stage. The remaining 12 (14%) patients underwent total gastrectomy and lower 
oesophagectomy via left thoracolaparotomy. 
3.3.3.2 Transabdominal gastrectomy 
Sixty-three patients underwent laparotomy for either total (64%) or distal subtotal 
gastrectomy (36%). Selection of either total or subtotal gastrectomy was based on the size, 
type and location of the primary tumour. 
3.3.3.3 Lymphadenectomy 
Formal lymphadenectomy was performed as part of all transthoracic and transabdominal 
procedures. For both two- and three-stage oesophagectomies, two-field lymphadenectomy 
was performed, involving en-bloc resection of nodal tissues and adjacent structures in both 
the abdomen and thorax. In three patients who underwent three-stage oesophagectomy lymph 
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node dissection was continued in the neck. With the exception of a single patient who 
received D1 lymph node dissection, D2 lymphadenectomy was performed in all patients 
undergoing either total or subtotal gastrectomy. 
3.3.3.4 Anastomosis 
In all cases, regardless of surgical approach, a single layered hand-tied anastomosis with 
interrupted sutures was made. 
3.3.4 Definitions of postoperative complications 
Definitions of surgical complications are as follows: anastomotic leak, either clinical or 
radiological evidence of a leak; chyle leak, drainage of >1000ml of chylous fluid over the 
course of 24hrs; haemorrhage, significant (>1000ml) blood loss from a defined source; 
recurrent laryngeal nerve palsy, clinical suspicion of nerve palsy confirmed by specialist 
assessment; wound infection, requiring antibiotic therapy; any abscess, pleural effusion or 
pneumothorax requiring percutaneous drainage. The diagnosis of postoperative pneumonia 
was based on clinical evidence of chest infection, for which antibiotic therapy was started. 
Operative death was considered as any death within 90 days of surgery or during the same 
hospital admission as the operative procedure. 
3.3.5 Study of selection, operative and reporting bias 
Selection bias was assessed through calculation of predicted (O-POSSUM) mortality. 
Comparison of lymph node yield, a marker of the extent of surgery, with patient body mass 
index and predicted mortality was used to assess operative bias. Finally, the database and a 
random sample of medical records were externally audited by Professor M. Sasako 
(November 2009) in order to exclude reporting bias. 
3.3.6 Statistical analysis 
Statistical analysis was performed using SPSS version 17.0 (SPSS Inc., Chicago, USA). Chi-
squared or Fisher's exact tests were used to compare categorical data; Student's t-test or the 
80 
Mann-Whitney U test were used to compare continuous data. Simple linear regression was 
used to determine the correlation of lymph node yield with body mass index and O-POSSUM 
score. All reported P values are two-sided, with statistical significance assumed at <0.05. 
Univariate and multivariate logistic regression was used to identify potential risk factors for 
the development of postoperative pneumonia. Predictors with P<0.05 in univariate analysis 
were entered in the multivariate model. All variables were entered in the first step of the 
model using the 'enter' method. 
3.4 Results 
3.4.1 Patient characteristics 
Patient groups were matched for gender, age, body mass index and tumour stage [Table 3.3]. 
There was a tendency towards a greater proportion of males in the transthoracic group 
(P=0.055). Likewise patients in the transthoracic group tended to be younger in comparison 
to patients undergoing transabdominal resection (P^O.OSl). Although age was not found to 
be significantly different, it was determined that a higher proportion of patients undergoing 
transabdominal resection were aged 70 years or over (26% vs. 48%, P=0.035). Transthoracic 
resections were performed almost exclusively for patients with tumours of the oesophagus or 
gastroesophageal junction, whilst transabdominal resections were used predominantly for 
tumours of the stomach. Groups were comparable for all categories of TNM tumour stage. 
All patients who underwent minimally invasive thoracoscopic three-stage oesophagectomy 
were confirmed as having pathological staging pTl, NO, MO. In accordance with local policy, 
a greater proportion of patients undergoing transthoracic resection received preoperative 
neoadjuvant therapy which typically consisted of three cycles of chemotherapy (71% vs. 
25%,P<0.001). 
Comorbidity and risk prediction scores are presented separately for each group in table 3.4. 
Patient smoking habits were similar for both groups, as were the number of patients without 
additional significant comorbidity. With the exception of diabetes, which was more prevalent 
in patients undergoing transthoracic resection (14% vs. 3%, P=0.043), the incidence of all 
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other major comorbidities were equivalent, as were Charlson Comorbidity scores, ASA 
grades, physiology scores and O-POSSUM predicted mortality. 
Table 3.3 Characteristics of patient groups 
Transthoracic 
(n=87) 
Transabdominal 
(n=63) P* 
Gender ratio [M:F] 70:17 42:21 0.055 
Age (years) [mean ± SD] 61.7 ±11.5 65.4 ±11.7 0.051^ 
[Range] [30-84] [40-85] 
Age >70years 23 (26) 27 (48) 0.035 
BMI [mean ± SD] 25.4 ± 4.0 25.1 ±5.3 0.605^ 
[Range] [15.0-41.1] [16.9-35.4] 
Tumour location 
Oesophagus upper 1/3 1(1) 0(0) 1.000* 
Oesophagus middle 1/3 3(3) 0(0) 0.264* 
Oesophagus lower 1/3 24 (28) 0(0) <0.001* 
GOJ 48 (55) 5(8) <0.001 
Proximal stomach 8(9) 5(8) 0.787 
Middle stomach 3(3) 39 (62) <0.001* 
Distal stomach 0(0) 14 (22) <0.001* 
Histology 
Adenocarcinoma 75 (86) 60 (95) <0.097* 
Squamous cell carcinoma 11 (13) 0(0) <0.003* 
Other 1(1) ' 3(5)" <0.310* 
pTNM stage 
0/1 17 (20) 12 (19) 0.940 
II 25 (29) 22 (35) 0.420 
III 35 (40) 23 (36) 0.644 
IV 6(7) 1(2) 0.239* 
Unknown 4(5) 5(8) 0.493* 
Neoadjuvant therapy 62 (71) 16 (25) <0.001 
Values in parentheses are percentages unless otherwise indicated. SD, standard deviation. BMI, body mass 
index. pTNM, pathological tumour node metastasis. ^High grade dysplasia. "Leiomyosarcoma, MALT 
lymphoma, unspecified malignancy. *x^ test unless otherwise indicated: ^Fisher's exact test, ^Student's t-
test. 
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Table 3.4 Comorbidity and risk prediction scores 
Transthoracic 
(n=87) 
Transabdominal 
(n=63) P* 
Smoking history; 
Current or ex-smoker 
Pack years 
No additional disease 
[median, range] 
54 (62) 
30 [1-175] 
27 (31.0) 
36 (57) 
22 [2-55] 
24 (38.1) 
0.543 
0.334* 
0.368 
Comorbidity 
Hypertension 
Ischaemic heart disease 
Cerebral vascular disease 
Peripheral arterial disease 
Diabetes 
Chronic respiratory d i s e a s e t 
Chronic renal impairment 
30 (35) 
10(12) 
3(3) 
1(1) 
12 (14) 
12 (14) 
2(2) 
25 (40) 
10 (16) 
3(5) 
2(3) 
2(3) 
8(13) 
2(3) 
0.514 
0.436 
0.696* 
0.572* 
0.043* 
0.846 
1.000* 
Charlson comorbidity score [mean ± SD] 
[Range] 
2.9 + 1.2 
[2-7] 
2,6 ±1 .0 
[2-7] 
0.125" 
ASA grade 
2 
3 
4 
61 (70) 
26 (30) 
0(0) 
49 (78) 
13 (20) 
1(2) 
0.295 
0.613 
0.420* 
POSSUM physiologic score 
<20 
>20 
[mean ± SD] 
[Range] 
18 ± 4 
[12-31] 
62 (71) 
25 (29) 
18 ±5 
[12-30] 
40 (63) 
23 (37) 
0.338" 
0.314 
O-POSSUM score (%) 
<5 
5-10 
11-20 
>21 
[mean ± SD] 
[Range] 
10.6 + 6.9 
[1.0-34.1] 
14 (16) 
33 (38) 
31(36) 
9(10) 
10.2 + 9.6 
[0.7-53.9] 
19 (30) 
22 (35) 
16 (25) 
6 ( 1 0 ) 
0.770' 
0.040 
0.706 
0.182 
0.869 
Values in parentheses are percentages unless otherwise indicated. SD, standard deviation. ASA, American 
Society of Anesthesiologists physical status classification. O-POSSUM, Physiological and Operative Severity 
Score for the enumeration of Mortality and morbidity developed specifically for use in oesophagogastric 
surgery. ^Including chronic obstructive pulmonary disease and asthma. test unless otherwise indicated: 
*Fisher's exact test, ^Student's t-test, *Mann-Whitney U test. 
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3.4.2 Operative details 
Mean operative time was significantly longer in patients undergoing transthoracic compared 
to transabdominal resection (582 vs. 383 mins, f<0.001) [Table 3.5]. The duration of OLV 
(185 mins) accounted for almost one-third of the total operative time of transthoracic 
procedures. Intraoperative transfusion was required in 15 (17%) and 12 (19%), transthoracic 
and transabdominal resections respectively, with a median of two units given. In most cases 
the primary indication for transfusion was low preoperative haemoglobin. Although not 
formally assessed the estimated blood loss for the majority of procedures, regardless of 
approach, was less than 500ml. The volume of intraoperative blood loss was deemed to 
exceed 1000ml in three transthoracic cases and a single transabdominal case, each patient 
requiring a minimum of three units of blood intraoperatively. Lymph node yield was 
significantly higher in patients undergoing transthoracic procedures (53 vs. 40, P<0.001). 
3.4.3 Postoperative outcomes 
3.4.3.1 Surgical complications 
There were no postoperative deaths in either group. The number of patients who were 
without postoperative complications, that required additional intervention, was similar in 
both treatment groups, although there was a tendency towards improved outcomes after 
transabdominal procedures (38% vs. 52%, P=0.078). The incidence of individual 
postoperative complications occurring in each of the two treatment groups are presented in 
table 3.6. Anastomotic leak occurred in two patients in both the transthoracic and 
transabdominal groups (2% vs. 3%, P=1.000). Surgical re-intervention was required to repair 
one of the two intrathoracic leaks. In one patient who underwent total gastrectomy via a 
transabdominal approach, a minor anastomotic leak was detected at the time of routine 
contrast swallow, performed on the fifth postoperative day. This patient demonstrated no 
chnical evidence of a leak and was consequently managed conservatively, with a delay of 
oral intake. In the remaining patients, leaks were managed conservatively by establishing 
adequate drainage, antibiotic therapy and an alternative nutritional source. Two patients in 
the transthoracic group had postoperative chyle leak, one of whom required reoperation to 
hgate the thoracic duct. Postoperative haemorrhage occurred in two patients who underwent 
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Table 3.5 Operative details 
Transthoracic 
(n=87) 
Transabdominal 
(n=63) P* 
Operative approach 
2-stage oesophagectomy (Ivor Lewis) 
3-stage oesophagectomy (open) 
3-stage oesophagectomy (thoracoscopic) 
Total gastrectomy (thoracolaparotomy) 
Total gastrectomy (abdominal only) 
Partial gastrectomy 
57 (65) 
14(16) 
4(5) 
12 (14) 
0(0) 
0(0) 
0(0) 
0(0) 
0(0) 
0(0) 
40 (64) 
23 (36) 
Length of operation (min) 
Length of OLV (min) 
Blood loss >1000ml 
Intraoperative transfusion 
Excised lymph nodes 
Positive lymph nodes 
[mean ± SD] 
[Range] 
[mean ± SD] 
[Range] 
[median, range] 
[mean ± SD] 
[Range] 
[median, range] 
582 ± 86 
[360-765] 
185 ± 49 
[80-365] 
3(3) 
15 (17) 
2[1-6] 
53 + 21 
[5-103] 
2 [0-36] 
383 ± 90 
[240-600] 
<0.001* 
1(2) 
12 (19) 
2 [2-5] 
40117 
[5-87] 
0 [0-41] 
1.000" 
0.776 
<0.001 
0.143" 
§ 
Values in parentheses are percentages unless otherwise indicated. OLV, one lung ventilation. *x test 
unless otherwise indicated: *Fisher's exact test, ^Student's t-test, "Mann-Whitney U test. 
transabdominal resection, in both cases reoperation was required to ensure haemostasis. In 
the first patient haemorrhage occurred on the second postoperative day and was isolated to an 
omental vessel. The second patient, a renal transplant recipient, suffered a delayed splenic 
bleed on the eleventh postoperative day that was assumed to be associated with concurrent 
immunosuppression. Five patients developed postoperative abdominal abscesses, all of 
whom underwent transabdominal resection (8%, P=0.012). In two patients abscess formation 
was the result of duodenal stiunp leak. Recurrent laryngeal nerve palsy occurred in four 
patients who underwent transthoracic resection and was in most cases temporary. Although 
more common in transabdominal patients, rates of wound infection were not significantly 
different in both groups (10% vs. 18%, P=0.206). 
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Table 3.6 Postoperative outcomes 
Transthoracic Transabdominal 
D* 
(n=87) (n=63) r 
Without complications 33 (38) 33 (52) 0.078 
IVIortality 0(0) 0(0) 
-
Overall technical complications* 8 p ) 9(14) 0.332 
Surgical complications 
Anastomotic leak 2(2) 2(3) 1.000* 
Chyle leak 2(2) 0(0) 0.510* 
Haemorrhage 0(0) 2(3) 0.175* 
Abdominal abscess 0(0) 5(8) 0.012* 
RLN palsyt 4(5) 
- -
Wound infection 9(10) 11(18) 0.206 
Respiratory complications 
Pleural effusion 20 (23) 2(3) 0.001* 
Pneumothorax 4(5) 1(2) 0.399* 
Pulmonary embolism 0(0) 1(2) 0.420* 
Pneumonia 29 (33) 12 (19) 0.053 
ARDS/ALI 3(3) 1(2) 0.639* 
Cardiac complications 
Arrhythmia 17 (21)* 7(11) 0.115 
MI/ACS 4(5) 3(8) 1.000* 
Acute renal failure 1(1) 3(5)1 0.310* 
Unplanned return to theatre 8(9) 6(10) 0.946 
ICU stay (days) [Median, range] 3 [0-71] 0 [0-46] <0.001* 
HDU stay (days) [Median, range] 4 [0-25] 6 [0-28] 0.010* 
Hospital stay (days) [Median, range] 13 [5-124] 12 [6-97] 0.094* 
Values in parentheses are percentages unless otherwise indicated. SD, standard deviation. RLN, recurrent 
laryngeal nerve palsy. ARDS/ALI, acute respiratory distress syndrome/acute lung injury. MI/ACS, myocardial 
infarction/acute coronary syndrome. ICU, intensive care unit. HDD, high dependency unit, ^includes: 
anastomotic leak, chyle leak, haemorrhage, abdominal abscess and RLN palsy. ^In most cases, RLN palsy 
was temporary. ®Six patients with a documented history or atrial fibrillation prior to surgery are excluded 
from the analysis. ^Two of these cases were acute-on-chronic renal failure. *x^ test unless otherwise 
indicated: ^Fisher's exact test, *Mann-Whitney U test. 
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3.4.3.2 Respiratory complications 
Pleural effusion, requiring percutaneous drainage, complicated the recovery of 23% of 
patients who underwent transthoracic resection, compared to 3% of patients in the 
transabdominal group (f=0.001). Pneumothorax and pulmonary embolism were either rarely 
observed or absent in both groups. Pneumonia was the most commonly reported 
complication in both groups. Although not statistically significant, proportionally more 
patients who underwent transthoracic resection developed postoperative pneumonia 
compared to those patients who underwent transabdominal resection (33% vs. 19%, 
7^=0.053). The development of postoperative pneumonia, and in several patients ARDS/ALI, 
was frequently preceded by other major surgical complications. 
3.4.3.3 Cardiac complications 
Arrhythmias often occurred in the presence of other major surgical and medical 
complications. In accordance with this observation, rates of postoperative arrhythmias were 
greater, although not significantly, in the transthoracic group (21% vs. 11%, P=0.115). In six 
patients who had a document preoperative history of arrhythmia, postoperative arrhythmias 
were not considered as a complication. Myocardial infarction/acute coronary syndrome 
occurred in 5% and 8% of patients who underwent transthoracic and transabdominal 
resection respectively {P=\.000). 
3.4.3.4 Length of hospital stay 
Median postoperative hospital stay was equivalent for both transthoracic and transabdominal 
groups, 13 and 12 days respectively (/^0.094). Variation in the median duration of intensive 
care and high dependency unit stay reflected differences in the postoperative management 
pathways of both sets of patients. 
3.4.4 Prediction of postoperative pneumonia 
Univariate logistic regression analysis of all pre- and peri-operative variables identified age, 
operative approach, length of operation, day of extubation and intraoperative urine output 
87 
<100ml/hr as independent predictors of postoperative pneumonia [Table 3.7]. Operative 
approach was excluded from further analysis both because of its known association with 
operative length and due to its weaker influence on prediction. Exclusion of this variable also 
meant that the ratio of events (cases of pneumonia) per variable was greater than 10, as is 
recommend by Peduzzi et al. [328]. Multivariate logistic regression analysis of the remaining 
four variables identified age as the only variable to remain a significant predictor of 
pneumonia (OR 1.062, CI 1.018, 1.109, f=0.006). To determine a model in which all 
predictors were significant, reanalysis was performed using all combinations of variables. 
Reanalysis identified age and length of operation as the variables upon which the final model 
was built [Table 3.7]. The receiver operating characteristic (ROC) curve for the model, with 
area under the curve 0.716, is presented in figure 3.1. 
To validate the model, a 'test' data set comprising of 37 patients who underwent either 
transthoracic or transabdominal resection for oesophagogastric cancer at St Mary's Hospital 
between March and December 2009 was used. (Details of the test population including, 
predicted and observed pneumonia rates are given as supplementary material in Appendix 
n). Risk of pneumonia was calculated using the logistic function 
P = 1 + ePo+PiXi+PiXz 
Where p is the probability of pneumonia, Pq (-7.672) is a constant (the intercept), (0.06) 
and ^2 (0.005) are the coefficients of the predictor variables, age and length of operation 
respectively, x\ is patient age in years and %% is the length of operation in minutes. The power 
of the model to discriminate between positive and negative cases was assessed by ROC curve 
analysis, with an area under the curve of 0.48, indicating that the prediction of pneumonia 
was no better than chance [Figure 3.2]. Further attempts were made to validate the model 
using data assimilated from published literature [268, 275, 279-281, 287-288, 303]. When 
observed and predicted pneumonia rates were compared, the model was found to 
significantly under predict the incidence of pneumonia (f=0.001) [Table 3.8]. 
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Table 3.7 Logistic regression analysis of potential predictors of postoperative pneumonia 
Univariate analysis Multivariate analysis 
Odds ratio (95% CI) P Odds ratio (95% CI) P 
Age (yr) 
Operative approach 
Length of operation (min) 
Extubation (postoperative day) 
Intraoperative urine output (<100ml/hr) 
1.048 (1.011, 1.086) 
2.364 (1,074, 5.200) 
1.005 (1.001, 1.008) 
2.305 (1.276, 4.164) 
2.176 (1.021, 4.636) 
0.010 
0.033 
0.004 
0.006 
0.044 
1.062 (1.019, 1.106) 
Not in model 
1.005 (1.002,1.009) 
Not in model 
Not in model 
0.004 
0.001 
CI, confidence interval 
04 oa &E 
1 • Specificity 
Diagonal segments are produced by lies. 
oa Oj 0* 
1 - specificity 
Diagonal segmeNs are produced by ties. 
Figure 3.1 ROC cur\ e, multiple logistic regression Figure 3.2 ROC cur^ e for pneumonia prediction in 
model for pneumonia classification the test population 
Table 3.8 Validation of multivariate logistic regression model using published date 
Author Year 
Operative 
approach 
Number of 
patients 
Mean age 
(yrs) 
Mean 
operative 
time (mins) 
Predicted risl< 
of pneumonia (%) 
Observed rate 
of pneumonia 
(%)+ 
Ref. 
Areja D 2006 TT 15 50 315 0.04 0.53 [268] 
TH 15 55 225 0.04 0.40 
Caracci B 1983 TT 13 62 378 0.11 0.46 [275] 
TH 22 55 330 0.06 0.55 
Chou S-H 2005 TT 50 53 373 0.07 0.10 [279] 
TH 23 57 266 0.05 0.13 
Chou S-H 2009 TT 47 55 385 0.08 0.13 [280] 
TH 40 59 264 0.06 0.10 
Chu K-M 1997 TT 19 64 210 0.06 0.00 [281] 
TH 20 61 174 0.04 0.10 
Gupta NM 2000 TT 27 44 326 0.03 0.48 [287] 
TH 39 41 137 0.01 0.18 
Hankins JR 1989 TT 52 56 492 0.13 00.38 [288] 
TH 26 56 352 0.07 0.54 
Pac M 1993 TT 120 54 348 0.06 0.10 [303] 
TH 118 52 186 0.03 0.01 
tComparison of observed and predicted rates of pneumonia determined that the model significantly under predicted the incidence of pneumonia (Mann-
Whitney U test, P=0.001). 
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3.4.5 Study of selection, operative and reporting bias 
The mean O-POSSUM predicted mortality for the transthoracic and transabdominal groups 
were 10.6% and 10.2% respectively [Table 3.4]. For over half of the patients undergoing 
transthoracic and transabdominal resection the predicted mortality from these procedures was 
less than 10%. For 10% of patients in both groups predicted mortality was >21%. There was 
no correlation between lymph node yield, body mass index and O-POSSUM score, therefore 
excluding operative bias [Figure 3.3]. External auditing of the database and a random 
selection of hospital notes found no evidence of reporting bias. 
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Figure 3.3 Assessment of operative bias 
Transthoracic oesophagectoiny lyinph node yield against (Al) body mass index (BMI) and (A2) O-POSSUM 
predicted mortality score. Transabdominal gastrectomy against (Bl) BMI and (B2) O-POSSUM score. 
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3.5 Discussion 
A meta-analysis presented in the previous chapter found no conclusive evidence to support 
the adoption of either transhiatal or transthoracic oesophagectomy, although the former was 
generally associated with lower rates of perioperative morbidity and mortality. The review 
did however find evidence of large variation in results published by different surgeons and 
institutions, which was attributed to poor reporting of outcomes and inadequate surgical 
quality. 
Because of these uncertainties a review of local outcomes after oesophagectomy was 
conducted. The characteristics of included patients were comparable with other case series 
originating fi^om Western centres. Operative time was significantly longer for transthoracic 
procedures, due to consecutive abdominal and thoracic phases, with an intermediate period 
required for repositioning and re-draping the patient [308]. The mean operative time for 
transthoracic procedures was 1.5 hours longer than typically reported by other series (refer to 
Chapter 2). hi the current study operative time was considered as the time from the start of 
general anaesthesia to the point of skin closure. As a result, a large proportion of the 
additional time was attributed to central and arterial line placement and patient transfer to the 
operating theatre, both of which routinely occurred after anaesthetic induction. Meticulous 
lymphadenectomy and hand sewn anastomotic technique also contributed to the extended 
duration of transthoracic procedures. The increased operative length did not have a negative 
impact on intraoperative blood loss, which although not accurately measured, was estimated 
to be between 100ml and 500ml in the majority of cases. In many other Western centres 
blood loss during transthoracic oesophagectomy typically exceeds 1000ml [288, 301, 305]. 
Intraoperative transfiision was required in less than 20% of cases and was more often a 
response to low preoperative haemoglobin as opposed to intraoperative blood loss. 
Lymph node metastasis is the single most important prognostic determinant of locoregional 
and systemic disease recurrence after oesophagectomy [15, 26]. For this reason radical 
resection involving either two- or three-field lymphadenectomy, improves long term survival 
after oesophagectomy [26, 329-331], In the current study mean lymph node yield for 
transthoracic resections was 53 and was appreciably higher than reported by other authors 
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[72,246, 279, 308]. Furthermore, radical lymphadenectomy was performed without mortality 
and with acceptable morbidity. 
Early mortality in this case series was 0%. Whilst similar early mortahty is often reported by 
small case series [281, 302, 308-309], it is uncommon for larger studies to achieve equivalent 
results. Early mortality following transthoracic oesophagectomy, reported in 48 studies, was 
10.6% (refer to Chapter 2). A recent case series reporting the outcomes of 340 patients who 
underwent oesophagectomy, presented an in-hospital and 90-day mortality of one (0.3%) 
[75]. Surgery did not however have radical intent and the maximum number of lymph nodes 
resected was <30 (personal communication between G Hanna and author). In the current 
study O-POSSUM failed to accurately predict operative mortality after either transthoracic or 
transabdominal procedures. This finding is in agreement with previous reports which 
demonstrate O-POSSUM over predicts mortality and fails to identify those patients at risk of 
postoperative death following oesophagectomy [332-334], The O-POSSUM score was 
developed using data collected from several UK hospitals and included patients with both 
oesophageal and gastric disease, undergoing a range of surgical procedures [327]. Twenty 
percent of these patients had benign disease or a diagnosis that was unrecorded and 7.5% 
underwent emergency surgery [327]. In contrast, the current study reports only the outcomes 
of patients who underwent elective surgery for ©esophagogastric cancer. O-POSSUM is not 
therefore an accurate method of risk prediction in oesophagogastric cancer surgery, 
especially when patients are operated on in specialist centres. It may however provide a 
standardised means of assessing selection bias in different studies. 
Although not statistically significant, a greater proportion of patients who underwent 
transthoracic resection experienced postoperative complications. Rates of technical and 
surgical complications were low, typically less than 5%. Comparison of local outcomes with 
series originating for Japan [335] and other International centres (refer to Chapter 2) is 
presented in table 3.9. Intrathoracic anastomotic leak remains the most feared complication 
following transthoracic oesophagectomy, on account of its association with significant 
morbidity and mortality [336]. Previous meta-analysis has demonstrated wide variation in the 
rates of anastomotic leak reported by different centres that may both reflect the varied 
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Table 3.9 Comparison of outcomes following transthoracic oesophagectomy 
St Mary's Akiyama Meta-analysis of 
Hospital Japan [335] world literature 
(n=87) (n=704) (n=3389) 
Mortality [%] 0 5 11 
Major technical complication 
Anastomotic leak [%] 2 6 11 
Chyle leak [%] 2 - 4 
Haemorrhage [%] 0 - 3 
RLN palsy [%] 4 13 6 
Pneumonia [%] 33 13 21 
Hospital stay [mean no. of days] 13 - 24 
Lymph node yield [mean] 53 - 19 
definitions of this complication as well as surgeon's proficiency. Technical mastery of 
anastomotic teclinique, avoiding devascularisation of the neo-oesophagus and undue tension 
at tlae site of the join, is considered essential to a successful outcome. In the present study 
two patients in each group experienced anastomotic leak. With the exception of one minor 
leak, anastomotic leak was associated with further significant morbidity including chest 
infection, pleural effusion and arrhythmias. 
The relationship between oesophagectomy and postoperative chest complications is well 
established [18, 337]. However, as the majority of authors fail to accurately define diagnostic 
criteria for even the most common respiratory complications, the results of individual studies 
are seldom comparable. Consequently, rates of pneumonia after transthoracic 
oesophagectomy are observed to vary within the range of 0% to 53%. In the current study 
pneumonia was the most common complication in both surgical groups, but occurred more 
often after transthoracic resections. Rates of severe lung injury, defined as either ARDS or 
ALI [120], were relatively low and far less than reported in some series [37, 121]. hi an effort 
to help minimise the incidence of postoperative pulmonary complications all patients 
included in the current study were subject to aggressive pain management and early 
mobilisation. 
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Due to the high incidence of pneumonia reported in this case series, uni- and multi-variate 
logistic regression were used to determine factors predicting this outcome. Previous studies 
have shown the following variables to be risk factors for pulmonary morbidity after 
oesophagectomy: age, body mass index, history of active smoking, spirometry, operative 
duration, operative blood loss, performance status, proximal tumour location, failure to 
administer corticosteroids and failure to provide respiratory physiotherapy [121, 255, 338-
340]. Li the current study the majority of pre- and intra-operative variables were found not to 
be associated with the development of pneumonia. Only age, operative approach, length of 
operation, day of extubation and intraoperative urine output <100ml/hr were significant 
predictors of postoperative pneumonia. Multivariate logistic regression analysis subsequently 
led to the construction of a predictive model based on what were the most important 
determinants of postoperative pneumonia in the training data set; age and length of operation. 
Attempts to validate the model, using test data sets, proved unsuccessful. Failure of the 
model to predict new cases of pneumonia may in part reflect the small sample size of the 
training and test data sets, as well as heterogeneity between patient cohorts. In addition, 
predictive models do not acknowledge the importance of postoperative patient care which is 
considered a major factor influencing the development of postoperative pneumonia. 
An important aim of this study was to assess the possible influence of selection, operative 
and reporting bias on observed outcomes. Selections bias was assessed using O-POSSUM 
mortality scoring that has been specifically developed for use in oesophagogastric surgery. 
Predicted mortality was comparable to published rates of mortality following 
oesophagectomy in the UK and other Western populations [34, 327]. Lymph node yield is 
considered a marker of the quality of surgical resection [27-28, 30-31, 237-247]. Comparison 
of lymph node yield with both patient body mass index and O-POSSUM score showed no 
evidence of operative bias, confirming that the quality of radical resection was equivalent in 
all patients. External auditing of the database and a random selection of patient notes by an 
independent expert showed no evidence of reporting bias. 
Limitations of this study include its reliance on retrospective data collection and relatively 
small sample size. Notwithstanding, on average 200 data entries were recorded for each 
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patient, indicating the completeness of data collection. Whilst in England approximately 
2000 oesophagectomies are performed each year [18], annual resection rates, even in high 
volume centres, remain low. Expanding reviews, such as this one to include other centres, 
may be one method of increasing overall sample size. As already discussed, wide variation 
between surgeons and institutional practices could prove detrimental to the overall 
conclusions drawn from such studies. As a direct result of this study a prospectively 
maintained database has been established at St Mary's Hospital to record key demographic, 
treatment and outcome data for all patients undergoing oesophagogastric surgery for cancer. 
3.6 Conclusion 
This study confirms that when due diligence is paid to surgical technique and perioperative 
patient care, radical oesophagectomy and gastrectomy can be performed safely and without 
mortality. Respiratory complications however remain the most common source of 
postoperative morbidity. Importantly, this ensures a suitable population for future clinical 
studies. Failure of multivariate logistic regression analysis, based on routinely collected 
perioperative variables, to correctly predict new cases of postoperative pneumonia, suggests 
a role for other approaches in the future. This could include gas- and fluid-phase metabolic 
profiling. 
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Section III 
Methodology 
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4. METHODOLOGY 
4.1 Outline of experiments 
Whilst breath analysis offers an attractive approach to the non-invasive detection and 
monitoring of disease, there remains uncertainty as to the influence of different factors on the 
accurate and reliable measurement of volatile metabolites within the breath. The overall 
objective of this section was to develop a reliable method for the analysis of breath samples 
within the clinical setting. Specific areas that are investigated include; (i) the stability of 
breath samples stored off-line within Nalophan® sample bags, (ii) instrument specific 
variability and intra- and inter-individual variability, (iii) the influence of respiratory 
manoeuvres and (iv) the levels of trace gases within inspiratory room air. 
The findings of a meta-analysis presented in the preceding section demonstrated wide 
variation in the reported rates of pneumonia after oesophagectomy. This variation was 
largely attributed to inconsistency in reporting of this complication by different series. 
Therefore, in order to ensure the accurate diagnosis of pneumonia in patients undergoing 
oesophagectomy, evidence-based criteria for the diagnosis of this complication were 
developed. 
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4.2 Experiment 1: Investigation of the suitability of Nalophan® bags for the off-line 
storage of breath samples 
4.2.1 Objective 
The objective of this study was to determine the stability of prominent exhaled metabolites 
within Nalophan® sample bags. 
4.2.2 Introduction 
A significant factor that has promoted the development of on-line and real time techniques 
for the analysis of exhaled breath has been the inherent difficulties associated with off-line 
trace gas analysis, which requires prior sample collection and storage. However, despite their 
clear advantages, the latest on-line techniques for trace gas analysis are at present restricted 
by their limited availability, which is partly a reflection of their high cost. Furthermore, many 
of the current instruments capable of on-line trace gas analysis are also constrained by their 
relatively large size, and hence limited portability. For these reasons, at the current time, off-
line breath analysis remains an integral component of breath research regardless of the 
analytical approach employed. 
There remains concern over the potentially adverse effect of breath gas storage, prior to 
sample analysis, particularly related to the overall stability of breath samples within storage 
vessels. In the current study the suitability of Nalophan® as a material for the construction of 
breath collection bags was assessed. 
4.2.3 Methods 
4.2.3.1 Sample collection and analysis 
The short term stability of volatile breath metabolites within Nalophan® sample bags was 
assessed. Ten healthy subjects were asked to provide a single mixed (whole) off-line breath 
sample by exhaling directly into double thickness (2 x 25|im) Nalophan® (Kalle UK Ltd., 
Witham, UK) bags [Figure 4.1]. Samples were analysed by SIFT-MS immediately following 
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Figure 4.1 Diagrammatic representation of double thickness Nalophan® sample bags 
(a) Two Nalophan® sheets, cut from a seamless tube, were placed one inside each other and were 
sealed at both ends by an impulse heat sealer. At one of the ends an opening of sufficient size was 
left in order to allow the placement of a 1ml syringe which acted as a mouthpiece, (b) Cable ties 
were used to fmnly clamp shut the opening where the syringe entered the sample bag. Removal 
of the plunger of the syringe allowed bags to be filled with breath. After collection of breath 
samples, bags were sealed by replacing the plunger into the barrel of the syringe. 
collection and again after one and five hours. A delay of one hour represents a conservative 
estimate of the average time interval between sample collection and SIFT-MS analysis within 
the clinical setting. In comparison, five hours was chosen as the maximum duration samples 
would be stored, whilst permitting analysis on the same day as collection. 
To reduce condensation, all samples were placed within an incubator held at 37°C, five 
minutes prior to and for the duration of sample analysis. Breath metabolites analysed using 
tlae MIM mode of the SIFT-MS instrument were as follows: acetone, ethanol, propanol, 
hydrogen cyanide, isoprene, acetic acid and ammonia. The quantification of these 
metabolites by SIFT-MS has been described previously [179, 341]. Metabolite 
concentrations within samples were determined over a 60 second MIM mode scan. 
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4.2.3.2 Statistical analysis 
Statistical analysis was performed using the SPSS 17.0 software package (SPSS Inc., 
Chicago, USA). Breath metabolite concentrations (not-normally distributed) are presented as 
median values with their associated interquartile range (IQR). Statistical differences between 
breath metabolite concentrations measured after different durations of storage within 
Nalophan® sample bags were assessed using the Friedman repeated measures analysis, whilst 
pair-wise comparisons between different time points were made using the Sign test. The level 
of statistical significance was assigned to f-values <0.05. 
4.2.4 Results 
The concentrations of selected breath metabolites after variable periods of storage within 
Nalophan® sample bags are presented in table 4.1. All breath metabolites remained stable in 
Nalophan® bags for a minimum of one hour, with the exception of ammonia which increased. 
Wlien the experiment was repeated using the same methodology, but measuring only 
ammonia, levels of this metabolite remained stable during the first hour of storage. After five 
hours storage water vapour and acetic acid levels had fallen significantly whilst the 
concentration of ethanol and ammonia increased. 
Table 4.1 Short term stability of volatile breath metabolites within Nalophan sample bags 
Precursor 
Ion 
Product 
lon(s) 
0 hours 
(ppb)t 
1 hour 
(ppb) 
5 hours 
(ppb) 
p t 
Water [%] [H3OI 37,55,73 5.81 [5.39-6.64] 5.86 [5.37-6.31] 1.41 [1.27-1.50] 0.001 
Acetone [HbOI 59,77 265 [243-524] 294 [253-527] 277 [248-376] 0.905 
Ethanol [HaOl 83 172 [123-224] 181 [135-228] 235 [181-335] 0.006 
Propanol [HbOI 43 18 [14-23] 19 [16-23] 17 [14-18] 0.285 
Hydrogen cyanide [HsOl 28 15 [11-18] 13 [9-16] 12 [9-16] 0.704 
Isoprene [NOT 66,68 97 [67-186] 106 [95-185] 107 [57-143] 0.387 
Acetic acid [NOT 90 68 [54-76] 61 [44-72] 17 [14-24] 0.001 
Ammonia [ 0 2 l 17,35 489 [416-538] 1797 [632-2889] 804 [425-930] 0.007 
t All concentrations are given In parts-per-bllllon, with the exception of water which is a percentage. + Freidman test. 
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4.2.5 Discussion 
Nalophan®, although mentioned as an appropriate material from which gas sample bags can 
be made, has yet to be thoroughly investigated with regard to its suitability for the collection 
and storage of breath samples. Previously, sample bags constructed from Nalophan® have 
been used for the collection and storage of odorous gases, however only one study gave 
reference to sample stability [342]. A recent publication by Beghi et al., did however 
characterise the difftision of water vapour through the walls of Nalophan® sample bags [343]. 
The same study also determined that the loss of water from the samples did not influence the 
concentration of 11 volatile compounds stored within the bags [343]. 
Consistent with the findings of previous studies [343], water levels of breath samples stored 
within Nalophan bags fell significantly after five hours. Whilst the loss of water is attributed 
to a diffusion based process across the bag walls, changes in the levels of other trace gases 
are less well understood. The finding that ethanol levels increased after prolonged storage 
may be a reflection of the high levels of this trace gas within ambient room air (refer to 
Experiment 4 of this chapter). Of the volatile metabolites investigated, ammonia was the only 
one whose levels were altered significantly after one hour of storage. Repeating the 
experiment, analysing only ammonia, eliminated this response. It is expected that the act of 
sample analysis, which causes a loss of sample volume, may be partly responsible for the 
observed increase in ammonia. In addition, because of ammonia's known interactions with 
the walls of the sample bag as well as its high water solubility, it may be particularly 
vulnerable to variations in surface-area-to-volume ratio and water vapour content during off-
line sampling. Importantly, the concentration of breath acetone, propanol, hydrogen cyanide 
and isoprene were found to remain stable in Nalophan® sample bags for up to five hours. 
4.2.6 Conclusion 
In order to avoid the potential adverse affects of off-line sampling in studies discussed within 
this thesis, all breath samples were analysed as soon after collection as possible, which in 
most cases was within one hour. Notwithstanding, the interpretation of data collected by off-
line breath sampling should be undertaken with due caution. 
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4.3 Experiment 2: Repeatability of the measurement of exhaled volatile metabolites 
using selected ion flow tube-mass spectrometry 
4.3.1 Objective 
The objective of this study was to determine the repeatability of the measurement of 
prominent exhaled metabolites in human subjects using SIFT-MS. 
4.3.2 Introduction 
Whilst the analysis of volatile metabolites within exhaled breath is a promising field of 
medical research, there remains an important requirement to determine the degree of 
instrument specific variability in measuring different exhaled metabolites. Likewise the 
influence of methodological variability must also be considered. Such information is 
essential as it will help support both appropriate selection of sampling methodology and 
interpretation of whether an observed difference in repeated measurements is likely to 
represent a true change in clinical status. 
4.3.3 Methods 
4.3.3.1 Breath sampling methodology 
Breath samples were analysed using the MIM, mode of the SIFT-MS instrument, a full 
description of which is provided elsewhere [218]. Breath samples were collected by asking 
subjects to inhale deeply, close to total lung capacity, and to then promptly provide a 
complete exhalation into the sampling device. Calculation of metabolite concentration within 
on-line breath samples was performed by integration over the duration of the expiratory 
plateau [Figure 1.7]. Alternatively calculation of metabolite concentrations in off-line (bag) 
samples was performed by determining their levels over a 60 second MIM mode scan. Off-
line samples were left for a period of one hour before analysis, reflecting the typical duration 
between sampling and analysis observed within the clinical setting. Breath samples are 
known to be stable during this period (refer to the results of Experiment 1 of this chapter) 
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[344]. For a minimum of five minutes prior to, and for the duration of sample analysis, breath 
samples were enclosed within an incubator held at 37°C. 
Breath metabolites investigated in the present study were as follows: acetone, ethanol, 
propanol, ammonia, hydrogen cyanide, isoprene and acetic acid. 
Analysis of repeatability was performed on /og-transformed data through computation of 
Lin's concordance correlation coefficient [345] and the mean intra-individual coefficient of 
variability, determined as the average ratio of the standard deviation and the mean of paired 
data sets. Use of /og-transformed data is in accordance with previous studies which show the 
concentrations of common breath metabolites follow more closely a /og-normal distribution 
[346]. 
4.3.3.2 Experiment I: instrument specific variability 
Healthy subjects (n=10) were asked to provide single mixed (whole) breath samples by 
exhaling directly into single-use sample bags (~2 litres) constructed from double thickness 
Nalophan®. Metabolites within collected samples were analysed, and immediately (<10 
seconds) re-analysed to assess instrument specific variability. Changes in sample metabolite 
composition between repeat analyses were considered to be negligible. 
4.3.3.3 Experiment II: on-line control of expiratory pressure and flow 
Healthy subjects (n=10) were requested to exhale into the entry port of the SIFT-MS 
instrument. Volatile metabolites were analysed within three repeat breaths. This process was 
repeated using a standardised protocol, for which the entry port of the SIFT-MS instrument 
was integrated with an independent LR2500 multiple-gas analyser (Logan Research Ltd. 
Rochester, UK), the latter allowing expiratory flow rate and mouth pressure to be set at 
50ml/s and >5 cmHzO respectively [Figure 4.2]. 
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4.3.3.4 Experiment III: off-line sampling from different respiratory tract compartments 
The repeatability of two off-line breath sampling methodologies was assessed. Mixed off-line 
breath samples (n=2) were collected in short succession from 10 healthy volunteers. Alveolar 
breath samples (n=2) were collected from 10 healthy volunteers using a CO2 triggered 
'alveolar' breath sampler (developed at Innsbruck Medical University, Innsbruck, Austria), 
within which Nalophan® sample bags were placed. At the preselected activation threshold, 
4% co2, an average of three exhalations were required to collect a sample of ~2 litres 
[Figure 4.3]. 
4.3.4 Results 
4.3.4.1 Subjects 
Sixteen healthy, non-smoking subjects (4 female and 12 male; 19 ±1 yrs) were enrolled to 
take part in one or more of the proposed studies. Testing by one-way ANOVA showed no 
significant difference in the mean age, height, weight, BMI or time since last oral intake 
between subjects participating in different experiments. 
4.3.4.2 Experiment 1: instrument specific variability 
The repeatability of SIFT-MS was examined through the immediate re-analysis of mixed 
breath samples. Excellent repeatability, as indicated by a Lin's concordance coefficient, Rc, 
>0.9 [345] was observed for the major breath metabolites acetone, isoprene and ammonia 
[Table 4.2]. For all metabolites examined, observed mean coefficients of variability, Cv, 
were <20%. Plotting Cv as a function of total product ion count rate and concentration 
[Figure 4.4] established signal intensity as a key determinant of measurement accuracy. In 
addition the predicted measurement error, determined by the instrument software from the 
total number of counts recorded [347], matched approximately the observed difference (bias) 
between repeated analyses' of the same sample. It was also noted that the repeat analysis of a 
sample tended to yield higher metabolite concentrations, as indicated by a negative bias. As 
only a small number of samples were investigated the significance of this finding remains 
uncertain. It may however be the case that there is an initial loss of sample onto the clean 
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Figure 4.2 Diagrammatic representation of SIFT-MS manifold for on-line analysis 
Subjects exlialed into the manifold via a cardboard mouthpiece. Exlialed breath was initially sampled 
via a calibrated heated sample capillary into tlie SIFT-MS instrument. Beyond the SIFT-MS entry 
port exhaled breath was directed into the manifold of the LR2500 multiple-gas analyser which 
sampled the breatli stream for NO and CO2 gas analysis. Subsequent sample lines monitored mouth 
pressure and expiratory flow. A custom-made addition to tlie manifold contained tliree precision-
machined flow restrictors in parallel: clamps applied to compressible plastic tubing within the three 
expiratory limbs enabled effective and rapid interchange between expiratory flow rates. 
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Figure 4.3 Diagrammatic representation of CO2 triggered breath sampling device 
Alveolar breath samples were collected using a purpose built CO? triggered breath sampling device. Once positioned within the device, samples bags were 
filled by instructing the subject to breathe tidally into an attached mouthpiece. Built in pressure and CO2 sensors within the mouthpiece holder, delivered data 
to the main body of the sampler, wherein the mean duration and alveolar plateau phase of each exhalation was determined. The sampler device was preset to 
recognise and activate upon measuring a CO2 concentration of >4% within each exhaled breath. The mechanism by which breath was collected into 
Nalophan® bags within the sampling device, required the simultaneous activation of an electronic valve and a battery powered pump, the latter creating a 
sub-atmospheric pressure within the vacuum box. Exhaled breath was conducted from the mouthpiece of the device to the sample bag along heated Teflon® 
transfer lines. To adequately fill each sample bag the subject was required to exhaled into the sampling device approximately three times in total. 
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surfaces of the instrument. Further investigation of instrument specific variability using 
accurately known gas standards is therefore recommended. As intra-day and inter-day 
repeatability of the instrument were not investigated, further work is also required in this 
regard. 
Table 4.2 Instrument specific variability 
Median Predicted error" Bias" Precision" Rc' Cv' 
ppb Ion count" (ippb) (ppb) (ppb) 
Acetone 525 478 21 -16 52 0.99 0.01 
Ethanol 186 12 56 -53 124 0.52 0.07 
Propanol 23 16 4 3 8 0.70 0.06 
Hydrogen cyanide 9 11 3 -2 5 0.39 0.19 
Isoprene 184 51 31 -8 30 0.94 0.02 
Acetic acid 107 14 29 -25 98 0.37 0.07 
Ammonia 1192 310 85 -44 311 0.98 0.01 
Total number of product ion counts registered during a 60 second M I M mode scan. Average predicted measurement error 
determined f rom the total number of counts (generated by SIFT-MS software, see Ref. 347). ^ Bias, mean difference between 
repeated measures. Precision, standard deviat ion of the differences between repeated measures. * Rc, Lin's concordance 
correlat ion coeff icient. ^ Cv, mean coeff icient o f variabil i ty 
4.3.4.3 Experiment II: on-line control of expiratory pressure ami flow 
To investigate the influence of standardisation of expiratory pressure and flow, a custom 
manifold was developed to allow control of these parameters. Median values and 
repeatability statistics are presented in table 4.3. Results suggest that standardisation can 
improve repeatability of the analysis of acetone, propanol, hydrogen cyanide and isoprene. 
Although these findings may reflect a reduction in the influence of methodological sources of 
variability, the precise mechanisms whereby such effects are mediated remain uncertain. 
The site of release of breath metabolites within the airways and its relation to the chosen 
sampling methodology may contribute to observed variability. Several recent publications, 
comparing metabolite levels in mouth- and nose-exhaled breath and within the oral cavity, 
support this hypothesis [179]. The findings of tlie current investigation suggest that for breath 
metabolites of presumed systemic origin, acetone and isoprene [179], measured on-line by 
non-standardised methods, Cv tends to be lower in comparison to orally released compounds, 
with the notable exception of ammonia. These results are however best explained by 
differences in the concentrations of these metabolites within the breath rather tlian their site 
of release (refer to the findings of Experiment I of this study). 
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Figure 4.4 Scatter plots of the mean coefficient of variability, Cv (%) 
Scatter plots of Cv as function of (A) total recorded product ion count and (B) ppb level, registered for the 
different breatli metabolites listed in Table 4.2. 
Ethanol, propanol, hydrogen cyanide and acetic acid were found in higher concentrations 
witliin breath collected using a standardised sampling methodology (Mann-Wliitney U test; 
p<0.03). These metabolites are released in significant quantities from the oral cavity [179, 
204]. Findings might therefore suggest that the adoption of a standardised protocol, in 
particular the use of a restricted expiratory flow rate, leads to enrichment of the levels of 
orally generated breath metabolites. One possible explanation for this is that at lower 
expiratory flow rates the duration over which volatile metabolites are pennitted to diffuse 
between the oral mucosa and gas phase is prolonged. 
Table 4.3 Repeatability of non-standardised [NS] and standardised [S] breath analysis 
IVIedian Precision' Re" Cv' 
(ppb) (ppb) 
NS S NS S NS S NS S 
Acetone 598 507 73 78 0.43 0.90 0.02 0.02 
Ethanol 58 208 136 165 0.22 0.12 0.89 0.55 
Propanol 15 28 12 17 0.07 0.66 0.53 0.12 
Hydrogen cyanide 13 34 12 16 0.44 0.89 0.45 0,09 
Isoprene 281 251 118 150 0.73 0.90 0.25 0.09 
Acetic acid 77 145 64 80 -0.17 0.08 0.90 0.40 
Ammonia 1007 1433 184 160 0.88 0.90 0.03 0.02 
^ Precision, standard deviation of the dif ference between repeated measures, calculated as: 2 /3* {breath 1 - breath 3). Rc, Lin's 
concordance correlat ion coeff icient. ^ Cv, mean intra-lndividual coeff icient o f variabil i ty 
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In contrast with the results for Cv, the standard deviation of intra-subject differences in repeat 
breath samples, presented in table 4.3 as precision, tended to be greater for standardised 
compared to non-standardised breath samples. Further analysis revealed that differences were 
related to greater inter-subject variability in standardised experiments. Explanation of these 
results is likely to concern the influence of additional physiological and environmental 
factors that require further investigation. 
4.3.4.4 Experiment III: off-line sampling from different respiratory tract compartments 
The repeatability of off-line mixed and alveolar breath sampling was assessed. Median 
values and repeatability statistics are presented in table 4.4. Off-line measurement of acetone 
showed excellent repeatability in both mixed and alveolar samples. With the exception of 
Table 4.4 Repeatability of analysis of mixed [M] and alveolar [A] breath samples 
IVIedian Precision' RC^  Cv' 
(PPb) (PPb) 
iVI A IVI A IVI A M A 
Acetone 548 542 81 102 0.96 0.94 0.01 0.01 
Ethanol 203 108 63 62 0.41 0.59 0.05 0.06 
Propanol 22 17 15 5 0.60 0.71 0.08 0.05 
Hydrogen cyanide 10 10 10 5 0.18 0.68 0.23 0.17 
Isoprene 213 274 63 86 0.67 0,79 0.17 0.17 
Acetic acid 139 116 53 55 0.69 0.21 0.05 0.06 
Ammonia 1216 1301 827 791 0.27 0.67 0.04 0.04 
^ Precision, standard deviation of the differences between repeated measurements. " Rc, Lin's concordance correlat ion coefficient. ^ Cv, 
mean intra-individual coeff icient of variabil i ty 
acetic acid, alveolar breath sampling tended to improve repeatability of the analysis, while 
differences between Cv values for the two sampling approaches were less marked. The 
finding, in selected cases, of superior precision as compared to results presented in table 4.2 
is attributed to the diminished influence of inter-subject variability. 
The concentration of ethanol was observed to be higher within mixed compared to alveolar 
breath (p=0.01) suggesting its release is predominantly from those regions of the respiratory 
tract that are not involved in gas exchange, including the oral cavity and larger airways. 
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Whilst the opposite relationship was seen for isoprene, this failed to reach statistical 
significance (p>0.05). It is therefore gratifying that current findings appear to be in 
agreement with the reports of previous authors who demonstrate ethanol and isoprene to be 
primarily of oral and systemic origin respectively [179, 348]. 
4.3.5 Discussion 
In spite of the findings presented herein there remains limited consensus as to the 
requirement for standardised practices within the field of exhaled breath analysis. It is 
unlikely that the adoption of guidelines similar to those proposed by the American Thoracic 
and European Respiratory Societies for the measurement of exhaled NO [349] will be 
justified for the majority of exhaled metabolites. Should standardisation of the measurement 
of selected breath metabolites be thought necessary in the future, a greater understanding of 
their source of origin within the respiratory tract, as well as knowledge of a defined 
association with both healthy and disease states is required. Further work is now needed to 
determine the influence of these factors as well as to more clearly define the effects of 
different sampling methodologies on the detection of exhaled metabolites. Allied with these 
investigations, continued refinement of the SIFT-MS technique, in particular improved 
sensitivity, will help support the analysis of volatile metabolites in the low ppb range and 
beyond. 
A limitation of this study is that observations were made firom only a relatively small number 
of healthy subjects. Whether findings are applicable to metabolites analysed within the breath 
of patients with disease states remains unknown. Further work is needed in order to 
understand the relationship between pathologic status and measurement repeatability. 
4.3.6 Conclusion 
This study presents new evidence of the short term repeatability of SIFT-MS analysis of 
prominent breath metabolites detected over a wide concentration range. For those metabolites 
investigated this technique is both reliable and repeatable. Whilst sampling methodology 
does appear to have a role in influencing the level of observed repeatability and variability, 
I l l 
metabolite concentration and physiological variability remain the principal determinants of 
these parameters. Patterns of intra- and inter-individual variability in healthy subjects that are 
presented are intended to support interpretation of changes brought about by pathological 
states, in turn, helping to establish mass spectrometry based methods within the clinical 
setting. Future work is now needed to determine the influence of other sampling 
methodologies as well as disease status on the day-to-day variation in exhaled metabolite 
levels. 
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4.4 Experiment 3: Influence of respiratory manoeuvres on the on-line detection of 
exhaled trace gases by SIFT-MS 
4.4.1 Objective 
The objective of this study was to examine the effect of a range of respiratory manoeuvres on 
the detection of volatile metabolites within the breath of human subjects. 
4.4.2 Introduction 
One of the greatest lessons on clinical applicability of breath analysis has been the 
recognition of the strong expiratory flow dependency of exhaled NO and the demonstration 
that multiple respiratory manoeuvres influencing minute volume, respiratory drive and 
breatholding greatly affect exhaled NO concentration [350-351], These findings have led to 
the publication of international recommendations for standardised measurement of exhaled 
NO [349], which have, in turn, supported its development as a diagnostic method. There is 
however, limited experimental evidence defining the effects and potential significance of 
confounding factors which may influence the quantification of many of the other volatile 
metabohtes in breath. In particular, procedural-specific sources of variability, such as the 
influence of various physiological parameters, on the delivery and airway exchange kinetics 
of volatile metabolites has yet to be established. 
One possible reason for the lack of studies in this domain may relate to the general 
assumption that most exhaled metabolites originate from alveolar gas exchange and would 
not be influenced by common respiratory variables. There is now however evidence that 
some volatile metabolites are derived predominantly from airway exchange mechanisms. An 
example for such mechanisms has been demonstrated in acetone single breath analysis [352]. 
There is also evidence based on off-line GC-MS studies suggesting that pulmonary dynamics 
of ethane, pentane and isoprene are modified by respiratory manoeuvres [191]. 
Consequently, it was hypothesised that different breathing patterns may be responsible for 
large inter-individual differences for exhaled isoprene in the clinical setting [200]. These 
issues are yet to be investigated comprehensively using on-line analytical techniques. 
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In the present study, a judiciously selected and potentially clinically relevant panel of 
metabolites was monitored in the exhaled breath of healthy subjects during prolonged 
exhalations. The primary objective was to explore the influence of respiratory variables, 
including different expiratory flow rates, hyperventilation and breatholding, on the on-line 
detection and quantification of these metabolites. Such data is essential for the consideration 
of standardisation procedures for on-line breath analysis. By directly comparing the flow 
dependency and ventilatory responses of the selected breath metabolites to exhaled NO and 
CO2 this work is intended to provide further insight into potential airway and alveolar 
exchange mechanisms for these gases. 
4.4.3 Methods 
4.4.3.1 Breath gas analysis techniques 
For experiments discussed herein the SIFT-MS instrument was operated in its MIM mode. 
4.4.3.2 On-line sampling 
On-line monitoring of multiple selected exhaled metabolites in addition to respiratory 
pressures and flows was achieved by integration of the SIFT-MS instrument with an 
independent LR2500 multiple-gas analyser [Figure 4.2]. Use of the LR2500 allowed 
simultaneous measurement of CO2 and NO, as well as allowing regulation of expiratory 
pressures and flows. Breath metabolites investigated in the present study were as follows: 
acetone, ethanol, isoprene and acetic acid. 
Breath samples were collected by asking subjects to inhale deeply, close to total lung 
capacity, and to then promptly provide a complete exhalation into the sampling manifold, 
whilst maintaining a mouth pressure >5 cmHjO. The influence of expiratory flow rate was 
determined by asking subjects to exhale into the manifold over a range of expiratory flows; 
50, 100 and 250ml/s. Subjects were also asked to perform two further independent 
respiratory manoeuvres, breathold (30 seconds) and paced hyperventilation (30 seconds), 
each immediately before exhaling into the manifold. Hyperventilation was achieved by 
asking subjects to breathe at vital capacity at a rate of 10 breaths-per-minute; verbally paced 
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by the investigator aided by an electronic metronome device (Korg MA-30, Korg, Milton 
Keynes, UK). For exhalations performed following breathold and hyperventilation a flow 
rate of 50ml/s was selected. The order in which subjects performed each of the five 
manoeuvres was assigned randomly, by drawing lots, and each manoeuvre was spaced by a 
period of two minutes tidal breathing at rest. 
4.4.3.3 Statistical analysis 
Statistical analysis was performed using the SPSS 17.0 software package (SPSS Inc., 
Chicago, USA). Breath metabolite concentrations (not normally distributed) are presented as 
median values with their associated interquartile range (IQR). Statistical differences between 
breath metabolite concentrations measured at different expiratory flows were assessed using 
the Friedman repeated measures analysis, whilst the Sign test was used for all other pair-wise 
comparisons. The level of statistical significance was assigned to P-values <0.05. 
4.4.4 Results 
4.4.4.1 Human subjects 
The sample group of 10 healthy subjects (6 male: 4 female) enrolled in the current study had 
the following characteristics: age 29 ± 7 yrs and BMI 23.8 ± 4. All subjects were non-
smokers and were fasted for a minimum of one hour prior to breath sampling. 
4.4.4.2 Flow rate 
Median concentrations of selected metabolites measured in the exhaled breath of healthy 
volunteers following different respiratory manoeuvres are given in Table 4.5. The 
concentration of exhaled NO was inversely correlated with expiratory flow (P<0.001) 
[Figure 4.5]. Of the other breath metabolites investigated, ethanol was the only one to 
demonstrate an inverse flow dependency similar to that observed for NO. This relationship 
was however only significant between the flows 50ml/s and 250ml/s (P=0.02). In contrast 
acetone levels within exhaled breath increased at higher flows (P=0.01) [Figure 4.5]. Other 
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breath metabolites investigated: isoprene, acetic acid and CO2, did not demonstrate a 
significant relationship with expiratory flow rate. 
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Figure 4.5 Influence of exi)iratory flow rate on the levels of selected breath metabolites 
Breath metabolite levels are presented as the average ratio of the difference for breath manoeuvres versus 
their respective control breath measures at flow rate 50ml/s. 
Table 4.5 Influence of respiratory manoeuvres on breath metabolite levels 
Flow rate 
Units Instrument 50 ml/s 100 ml/s 250 ml/s Breathold Hyperventilation 
NO (ppb]' LR2500 8.4 [6.3-14.7]' 7.7 [5.6-13.4] 6.1 [4.6-9.0]+ 8.5 [6.8-15.2] 8.6 [5.7-13.8] 
CO2 l%] LR2500 5.5 [5.2-5.8] 5.4 [5.1-5.8] 5.4 [5.2-5.6] 5.9 [5.7-6.1] t 4.5 [4.3-5.0] + 
Acetone [ppb] SIFT-MS 280 [250-398] 328 [277- 406] 372 [291-447] + 349 [303-464] 302 [256-426] + 
Ethanol [ppb] SIFT-MS 114 [91-123] 100[77-167] 82 [74-111] + 92 [69-134] 80 [69-100] 
Isoprene [ppb] SIFT-MS 173 [91-192] 174 [90-199] 166 [84-184] 185 [129-208] 137 [83-177] 
Acetic acid [ppb] SIFT-MS 29 [24-32] 22 [20-36] 23 [18-31] 22 [21-26] 25 [18-29] 
' ppb, parts-per-billion. Median [interquartile range], t p <0.05 
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4.4.4.3 Breathold 
After 30 second end-inspiratory breathold, the median concentration of CO2 was increased in 
the breath of healthy volunteers (P=0.05). Levels of acetone also rose significantly (P=0.021) 
[Figure 4.6]. Breathold did not significantly alter the levels of ethanol, isoprene, acetic acid 
and NO within the exhaled breath of healthy volunteers. 
4.4.4.4 Hyperventilation 
Following pretest hyperventilation the concentration of CO2 was significantly reduced in 
comparison to levels after normal breathing (P=0.001). Hyperventilation did not significantly 
alter levels of any of the other breath metabolites analysed within the exhaled breath of 
healthy volunteers. 
2.0-
0.5-
S. 1.0— 
Breathold Hyperventilation 
Figure 4.6 Influence of minute ventilation on the 
levels of selected breath metabolites 
Trace gas levels are presented as the average ratio of the 
difference for breath manoeuvres versus their respective 
control breath measured at flow rate 50ml/s. 
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4.4.5 Discussion 
This study constitutes the first concerted attempt to discern the effect of ventilatory 
parameters on the measurement of exhaled breath metabolites, with the aim of considering 
the requirement for standardisation of methods for on-line breath analysis. The principal 
novel findings of this study are: (i) SIFT-MS evidence for the flow dependency of ethanol 
and acetone within the exhaled breath of healthy volunteers, (ii) the observation that 
breathold increases the concentration of acetone and (iii) for several breath metabolites 
measured concentrations were not significantly altered by either changing expiratory flow 
rate or minute ventilation. Strengths of the study include: (i) direct comparison of trace gas 
kinetics with prototypes of respiratory gases, NO and CO2, (ii) on-line and real time analysis 
of breath metabolites, eliminating confounding factors associated with off-line sample 
collection and (iii) information on a range of distinct exhaled breath metabolites of different 
chemical classes. 
In accordance with the findings of Silkoff et al. [350] and numerous other authors, a 
significant inverse relationship between expiratory flow and NO concentration was observed. 
This is considered characteristic of a diffusion-based process for the transfer of NO between 
the airway walls and lumen [350]. Accordingly, at faster expiratory flows there is a reduced 
alveolar gas transit time that limits the transfer of NO from the airway walls to the gas-phase. 
In the current study, ethanol levels within exhaled breath also decreased at higher expiratory 
flow rates. Ethanol is highly blood-soluble and exchanges with the gas-phase in the mouth 
and airway compartment of the lungs [179, 204, 352-353]. It is therefore possible that a 
diffusion-based process, similar to that which is described for NO, is responsible for the 
observed decrease in ethanol concentration at higher expiratory flows. One model developed 
to describe the pulmonary exchange kinetics of ethanol, predicts that during inhalation, 
ethanol diffuses (i.e., is absorbed) from the airway mucosa into the airstream and that a 
proportion of this gas subsequently diffuses (i.e., is desorbed) back to the mucosa during 
exhalation [354]. Accordingly, the flux of ethanol between the airway lining and airstream 
was described by a bimodal distribution. For a control manoeuvre approximately half of the 
ethanol absorbed during inhalation was expected to be desorbed back to the airways during 
exhalation [354]. Changing expiratory flow rate is likely to disrupt this balance. In contrast to 
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NO and ethanol, breath acetone levels increased significantly at higher expiratory flow rates. 
This finding supports an earUer report by Anderson et al. [352, 355], who likewise identified 
that concentrations of acetone were positively correlated with expiratory flow. Acetone is a 
highly blood-soluble gas which exchanges with the gas-phase primarily within the airways 
[352]. Several authors have suggested that higher expiratory flows may result in shorter 
contact time between exhaled alveolar air and the airway walls, leading to a diminished re-
uptake (desorption) of compounds such as acetone [191]. This theory however remains 
unconfirmed. 
Changing minute ventilation was also shown to influence the concentration of acetone within 
breath samples. End-inspiratory breathold may prolong the time permitted for exchange of 
volatile metabolites between the alveoli and/or airway mucosa and the gas-phase, 
consequently enriching their levels within the subsequent expiratory phase. Should this prove 
to be correct, it could also be assumed that diminished minute ventilation would have a 
similar, albeit relative, effect. Thus far, attempts to satisfactorily induce graded 
hypoventilation in conscious volunteers have regrettably been unsuccessful. The findings of 
previous authors who reported ethanol levels to decrease following hyperventilation were not 
confirmed by SIFT-MS analysis [354, 356]. 
hnportantly the concentrations of other volatile metabolites, isoprene and acetic acid were 
not significantly affected by variation of either expiratory flow or minute ventilation. The 
mechanisms whereby these breath metabolites are apparently unchanged by different 
respiratory manoeuvres may be attributed to key differences in their partition between fluid-
and gas-phases. 
This study was limited to investigating the influence of on-line respiratory manoeuvres on 
the concentration of metabolites within the exhaled breath of healthy volunteers. Future 
studies should aim to include greater numbers of both healthy subjects and patient 
populations. Likewise investigation of a larger panel of breath metabolites would serve to 
provide a broader evidence base upon which to assess the requirement for standardisation. 
Regrettably, at the current time, uncertainties regarding product ion assignment and the size 
120 
of the SEFT-MS's on-line kinetics database have limited such work. Future studies should 
also aim to explain the precise exchange kinetics of important exhaled metabolites, with 
particular emphasis placed on understanding the partition of these gases between the 
systemic circulation, airway walls and gas-phase. 
4.4.6 Conclusion 
Variation of ventilatory parameters has a significant, albeit small, effect on the concentration 
of a number of exhaled metabolites when measured by SIFT-MS. Whilst these results 
suggest that standardised measurement protocols should be used for the exact quantification 
of selected breath metabolites, it remains unclear whether the adoption of guidelines similar 
to those proposed by the American Thoracic and European Respiratory Societies for the 
measurement of exhaled NO will be justified for the majority of exhaled metabolites. As 
highlighted in Experiment 2 of this chapter, the influences of intra- and inter-individual 
source of variability may yet outweigh the influence of procedural specific factors. 
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4.5 Experiment 4: Day-to-day variation in the levels of volatile trace gases within three 
hospital environments: implications for clinical breath testing 
4.5.1 Objectives 
Objectives of this study were to determine; (i) variation in the levels of trace gases within 
different clinical environments, and (ii) potential implications for breath analysis within the 
clinical setting. 
4.5.2 Introduction 
In addition to both physiological and methodological influences the levels of volatile 
metabohtes within exhaled breath may be affected by several other factors, including 
environmental exposure through inhaled air. Without reference to baseline room air levels, it 
is therefore difficult to determine whether metabolites within the breath are significantly 
altered as a result of a disease process or as a function of the local environment. The focus of 
the current study was to determine the baseline levels and variability of common breath 
metabolites, within different clinical environments in a busy teaching hospital. 
4.5.3 Methods 
4.5.3.1 Experimental design 
Gas samples were analysed using the MIM mode of the SIFT-MS instrument, a full 
description of which is provided elsewhere [218]. Room air samples were collected into 
double thickness Nalophan® sample bags (~2 litres) using a room air sampler (developed at 
Innsbruck Medical University, Innsbruck, Austria), which relies on the conduction of air 
samples along heated sample lines into a Nalophan® bag held under sub-atmospheric 
pressure within a plastic chamber. Over a period of one month room air samples were 
collected daily (after 1700) from three hospital environments. Locations were: the waiting 
room of an outpatient clinic, a surgical ward and an operating theatre used for general 
surgical procedures. Over the course of a second month room air samples were collected 
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from the same three locations between 0830 and 1000. On selected days room air samples 
were collected both in the morning and afternoon. 
Breath samples were also collected from ten hospital staff working in each of the three 
clinical environments. Breath was collected by asking subjects to exhale directly into 
Nalophan® sample bags (as described above). To reduce condensation, bag samples were 
enclosed in an incubator held at 37°C, five minutes prior to, and for the duration of analysis. 
Trace gases analysed in both room air and breath samples during the current study were as 
follows: acetone, ethanol, propanol, hydrogen cyanide, isoprene, acetic acid and ammonia. 
The concentration of trace gases was calculated by determining their levels over a 60 second 
MIM mode scan. 
4.5.3.2 Statistical analysis 
Data analysis was conducted using SPSS version 17 (SPSS Inc., Chicago, USA). Trace gas 
concentrations are presented as median values and their associated interquartile range (IQR). 
Statistical differences between trace gas concentrations measured in each of the three hospital 
locations were assessed using the Kruskal-Wallis test. All other pair-wise comparisons were 
made using the Mann-Whitney U test. The level of statistical significance was assigned to P-
values < 0.05. 
4.5.4 Results 
The levels of selected trace gases within ambient air samples collected in the evening from 
three clinical environments were determined [Table 4.6]. One-way analysis of variance 
identified that levels of acetone, ethanol and propanol were significantly different between 
the three hospital environments (P<0.05). Pair-wise comparison identified higher acetone 
levels in clinic room air compared to the operating theatre (P=0.015). hi contrast ethanol was 
found in higher concentrations within the ward compared to the clinic (P-0.003) and 
operating theatre (P<0.001). Ambient propanol levels were significantly higher in both the 
ward and clinic environments compared to the operating theatre (f<0.001). Levels of 
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hydrogen cyanide, isoprene, acetic acid and ammonia were equivalent in room air samples 
collected from each of the three locations. 
Variation in morning levels of selected trace gases between the tliree clinical environments 
were also assessed [Table 4.7]. One-way analysis of variance determined that levels of 
acetone, ethanol, propanol and ammonia were significantly different in room air samples 
collected from the three environments during the morning (P<0.05). In morning samples, the 
concentration of acetone and ethanol were higher in the ward compared to the clinic {P 
<0.001). Botli ward and clinic levels of acetone, ethanol, propanol and ammonia were greater 
than levels found in theatre air {P <0.005). Levels of hydrogen cyanide, isoprene and acetic 
acid were equivalent in room air samples collected from each of the three locations during 
die morning. 
Table 4.6 Median evening room air levels of selected trace gases 
Hospital ward 
(n=26)° 
Outpatient clinic 
(n=17) 
Operating theatre 
(n=27) 
Acetone 20 [14-26] 23 [16-32] 14 [10-20] 0.04 
Ethanol 587 [468-1245] 261 [<2-439] 269 [<2-405] <0.01 
Propanol 100 [54-150] 205 [142-275] 8 [6-11] <0.01 
Hydrogen cyanide 4 [3-8] 4 [2-7] 5 [3-7] 0.62 
Isoprene <2 [<2-6] <2 [<2-3] <2 [<2-ll] 0.66 
Acetic acid 46 [31-104] 53 [36-117] 36 [<2-61] 0.20 
Ammonia 261 [216-307] 275 [236-319] 254 [205-288] 0.53 
All values are given as parts-per-billion. Values in square brackets are interquartile range." Number of days upon 
which samples were ana lysed ,One-way analysis of variance examined by Kruskal Wallis Test. Values tiiat are 
given the prefix, <, were considered to be below the limit of detection of tire SIFT-MS instmment. 
Table 4.7 Median morning room air levels of selected trace gases 
Hospital ward 
(n=17)' 
Outpatient clinic 
(n=17) 
Operating theatre 
(n=17) 
Acetone 17 [12-20] 11 [10-13] 5 [4-6] <0.01 
Ethanol 2547 [2149-2931] 424 [210-549] 89 [55-272] <0.01 
Propanol 158 [91-228] 236 [112-302] 3 [2-3] <0.01 
Hydrogen cyanide 1 [1-2] 1 [1-2] 1 [<l-2] 0.61 
Isoprene <2 [<2-2] <2 [<2-4] <2 [<2-2] 0.20 
Acetic acid 44 [30-60] 44 [31-47] 21 [15-52] 0.11 
Ammonia 77 [62-83] 68 [66-82] 57 [52-63] <0.01 
All values are given as parts-per-bilhon. Values in square brackets are interquartile range." Number of days upon 
which samples were analysed.'' One-way analysis of variance examined by Kruskal Wallis Test. Values that are 
given the prefix, <, were considered to be below the limit of detection of the SIFT-MS instrument. 
Table 4.8 Same day median morning and evening room air levels of selected trace gases 
Hospital ward (n=5)' 
am" PM' 
Outpatient clinic (n=5) 
am pm 
Operating theatre (n=5) 
am pm 
Acetone 14 [13-16] 11 [11-13] 12 [10-13] 13 [12-13] 7 [5-12] 9 [7-12] 
Ethanol 2136 [2008-2242] 733 [521-971] 435 [240-532] 334 [143-538] 279 [109-321] 398 [109-1039] 
Propanol 115 [93-151] 95 [41-163] 301 [150-407] 124 [53-143] 2 [2-3] 5 [5-107] 
Hydrogen cyanide 2 [1-2] 2 [1-3] 1 [1-1] 1 [<1-1] 1 [1-2] 1 [1-2] 
Isoprene <2 [<2-2] <2 [<2-2] <2 [<2-2] 3 [<2-5] <2 [<2-2] <2 [<2-2] 
Acetic acid 44 [25-55] 34 [24-37] 47 [37-48] 26 [10-30] 26 [16-47] 27 [15-38] 
Ammonia 71 [60-76] 62 [47-88] 67 [66-69] 70 [61-75] 60 [52-63] 74 [48-96] 
All values are given as parts-per-billion. Values in square brackets are interquartile range. ° Number ol' days upon which samples were a n a l y s e d T ^ M , 
morning. ' PM, evening. Values that are given the prefix, <, were considered to be below the limit of detection of the SIFT-MS instrument. 
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A comparison of morning and evening samples (collected on different days) indicated the 
presence of higher ethanol levels in ward air at the beginning of the day {P <0.001). In 
contrast ammonia levels tended to be higher in all three locations towards the end of the day 
(P<0.001). On selected days room air samples were collected from all three clinical 
environments both in the morning and afternoon [Table 4.8]. Findings of these limited 
studies confirmed the presence of higher morning ethanol levels within the ward (P>0.05). A 
rise in ammonia levels was however not observed when both morning and afternoon 
sampling was performed on the same day. 
Breath samples from ten hospital staff working in each of the three clinical enviromnents 
were collected and analysed by SIFT-MS, to allow comparison with ambient levels [Table 
4.9]. At all locations breath levels of acetone, hydrogen cyanide, isoprene and ammonia were 
higher than in room air [Table 4.10]. Only in the theatre environment were breath propanol 
levels higher than in room air, whilst acetic acid was higher in breath samples collected from 
staff in both the ward and clinic, but not the theatre. At all locations ethanol was higher in 
room air compared to in the breath. 
Table 4.9 Median levels of selected trace gases within the breath of hospital staff 
Hospital ward 
{n=6)° 
Outpatient clinic 
(n=8) 
Operating theatre 
(n=6) 
Acetone 272 [174-425] 321 [298-356] 248 [227-303] 
Ethanol 678 [418-813] 249 [181-317] 128 [88-236] 
Propanol 61 [49-97] 68 [46-92] 17 [10-24] 
Hydrogen cyanide 15 [7-21] 15 [10-18] 10 [7-15] 
Isoprene 64 [42-103] 89 [69-119] 27 [11-63] 
Acetic acid 59 [48-75] 72 [45-86] 33 [26-46] 
Ammonia 583 [241-997] 1135 [569-2099] 498 [186-1279] 
All values are given as parts-per-billion. Values in square brackets are interquartile range." Number of 
breath samples analysed. 
Table 4.10 Ratios of breath and ambient trace gas levels 
Hospital 
ward 
Outpatient 
clinic 
Operating 
theatre 
All 
Acetone 0.07' 0.04 0.04 0.05 
Ethanol 2.07 1.38 1.75 1.87 
Propanol 1.86 3.33 0.32 2.37 
Hydrogen cyanide 0.16 0.13 0.31 0.18 
Isoprene <0.01 <0.01 <0.01 <0.01 
Acetic acid 0.79 0.62 1.07 0.77 
Ammonia 0.35 0.12 0.38 0.24 
° Ratio calculated as [median level within room air]\[median level within breath] 
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4.5.5 Discussion 
The principal findings of this study were: (i) that the levels of several volatile trace gases 
were markedly different in the room air of three distinct clinical environments, and (ii) that 
the consistently high levels of certain trace gases within the room air of clinical environments 
may diminish confidence in their use as breath biomarkers. 
As suggested by Schubert et al. high inspiratory concentrations of a trace gas may 
disproportionately affect the alveolar concentration gradient of that compound and hence the 
rate of elimination in the exhaled breath [357]. The same authors also suggested that, based 
on their own experimental evidence, only compounds whose inspired concentrations are <5% 
of exhaled concentrations can be confidently analysed in exhaled breath. This 
recommendation could have major implications for breath testing, especially within the 
chnical setting where there is expected to be an abundance of volatile trace gases within the 
ambient air. Furthermore background concentrations of many trace gases may vary 
significantly depending on the time and locality of breath testing, hi particular, the 
observation of a trend towards lower ambient trace gas levels in the operating theatre may be 
an indication of the efficacy of the ventilation systems used within this environment. 
Despite these acknowledgements, there currently exists no consensus agreement as to the 
most appropriate method to correct for the potential effects of inspired trace gas levels. Two 
suggested methods supported by different sets of authors for inspired air correction are: (i) 
background subtraction, and (ii) breathing air 'scrubbed' of volatiles prior to breath 
sampling. Both of these correction methods suffer from important limitations. Background 
subtraction, although relatively easy to implement, is associated with increased uncertainties 
when interpreting recalculated breath analyte concentrations, especially when room air levels 
are comparable or greater than levels in exhaled breath [358-359]. Furthermore, the 
correlation between compound concentrations in blood and breath have been demonstrated, 
in certain cases, not to be purely linear [360] and hence cannot be accounted for simply by 
background subtraction [357]. Alternatively, whilst breathing scrubbed air prior to breath 
sampling is arguably a more scrupulous method of background correction, it is laborious and 
impractical to implement routinely within the clinical setting. In addition there remains 
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considerable uncertainty as to the necessary washout period that is required prior to breath 
sampling. Some authors suggest that successful washout of the lungs can be achieved in as 
little as four minutes if the subject breathes volatile free air [361]. However depending on the 
compound, to achieve washout of the entire body, significantly longer periods may be 
required on account of latent storage of volatiles within lipid rich body compartments [360]. 
Consequently, it is of the utmost importance for researchers to produce accurate toxicokinetic 
models predicting the disposition of molecules present in inspiratory air, such that 
appropriate guidelines can be created. Until such guidelines exist it is recommended that 
samples of inspiratory air are collected and analysed in parallel to breath samples. Risby and 
Solga have suggested that if it is subsequently found that the analyte concentration of 
inspiratory air is greater than 25% of concentrations in exhaled breath then the data should be 
treated with caution [362]. Whilst it is noted that this figure of 25% is larger than the 5% 
quoted by Schubert [357], it perhaps represents a more practicable guideline, especially for 
breath sampling within the clinical setting. By this recommendation the analysis of breath 
isoprene, acetone, hydrogen cyanide and ammonia are possible in at least one of the 
environments described within this study, hi comparison high levels of ambient ethanol and 
propanol within these environments, may preclude their accurate analysis within the breath 
of human subjects. Both ethanol and propanol are common constituents of antiseptic agents, 
including alcohol hand gels, which are in widespread use within clinical environments. 
A limitation of this study was that room air samples were collected from a single hospital and 
therefore may only reflect local trends. Morning and evening experiments were also not 
performed on the same day due to the intensity of the required analysis. This hmitation was 
addressed by comparing matched morning and evening data on a restricted number of days, 
which broadly confirmed the differences observed in primary experiments. 
Further studies should now investigate the causes of intra-day variability of the levels of 
these trace gases within chosen clinical environments. Although challenging, effort should 
also be made to accurately elucidate the influence of inspiratory trace gas levels on related 
expiratory concentrations. Such information will help to inform those attempting to develop 
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clinical breath testing, allowing the establishment of consensus guidelines were deemed 
appropriate. 
4.5.6 Conclusion 
The concentrations of isoprene, acetone, hydrogen cyanide and ammonia within room air 
samples collected from at least one of the three clinical environments were less than 25% of 
levels typically found in human breath. Based on the recommendation of previous authors 
these compounds may therefore be suitable for use as exhaled markers of disease. In 
comparison high levels of ethanol, popanol and acetic acid within room air samples collected 
from each location may diminish confidence in their use as breath biomarkers. 
129 
4.6 Criteria for diagnosing pneumonia in patients following oesophagectomy 
4.6.1 Objective 
The objective of this work was to develop an evidence-based set of criteria for the diagnosis 
of pneumonia in patients following oesophagectomy. 
4.6.2 Introduction 
Respiratory complications are the most common cause of morbidity following 
oesophagectomy [363]. In particular pneumonia is reported to complicate the recovery of 
21.4% and 17.3% of patients undergoing transthoracic and transhiatal oesophagectomy 
respectively (refer to Chapter 2). There is however wide variation in reported rates of 
pneumonia following oesophagectomy that is largely attributed to inconsistency in reporting. 
There are currently no widely agreed guidelines for the diagnosis of pneumonia. In practice 
the diagnosis of pneumonia is based on the interpretation of clinical evidence including 
symptoms and signs, chest radiography, bronchoscopy and bacterial culture studies [153]. In 
cases of suspected pneumonia after transthoracic oesophagectomy the diagnosis is made 
harder by the ubiquitous finding of radiological changes on plain chest X-rays [18]. 
Consequently, due to the high incidence of pneumonia after transthoracic oesophagectomy 
and the level of variation in reporting of this complication, specific criteria were developed to 
support the accurate diagnosis of pneumonia in fixture clinical studies. 
4.6.3 Methods 
4.6.3.1 Literature review 
A literature search of the MEDLINE database (all dates) through the PubMed platform was 
conducted for studies reporting criteria for the diagnosis of respiratory complications 
following oesophagectomy. The search was limited to studies published in the English 
language until 20**^  December 2009. (Full details of the search strategy are provided as 
supplementary data in Appendix III.) 
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One reviewer (P Boshier) screened the titles and abstracts of studies identified through the 
electronic search and the full texts of potentially relevant articles were obtained. Inclusion 
criteria were, studies reporting clear criteria for the diagnosis of pneumonia in patients 
following oesophagectomy. Studies originating from the same institution were excluded, 
except for the most recent or complete publication. One reviewer (P Boshier) extracted data 
from the studies including: primary author, country of origin, year of publication and 
reported criteria for the diagnosis of pneumonia. 
4.6.3.2 Development of guidelines for the diagnosis of pneumonia after oesophagectomy 
Criteria for the diagnosis of pneumonia after oesophagectomy were developed based on the 
results of literature review and in consultation with senior clinicians familiar with the 
management of patients with pneumonia and patients after oesophagectomy. Radiological 
criteria were defined by a consultant respiratory physician who reviewed the postoperative 
radiology of patients undergoing oesophagectomy at St Mary's Hospital during 2009. 
4.6.4 Results 
4.6.4.1 Literature review 
A systematic search of the English language literature for studies reporting respiratory 
complications following oesophagectomy returned 1613 pubhcations, 35 of which presented 
clearly defined criteria for the diagnosis of postoperative pneumonia. A summary of included 
studies is presented in table 4.11. Thirty-two studies reported the use of radiological criteria 
for the diagnosis of pneumonia after oesophagectomy. Other important criteria were pyrexia 
and positive bacterial culture. The presence of leukocytosis, purulent sputum and clinical 
evidence of pneumonia were also deemed to be important by several authors. 
4.6.4.2 Review of perioperative radiology 
The perioperative chest radiographs and CT-scans of 25 patients who underwent 
transthoracic oesophagectomy were reviewed by a consultant respiratory physician, to 
determine radiological features associated with uncomplicated and complicated recovery. 
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Dependent changes, atelectasis, 'groimd glass' appearance and evidence of fluid were 
common to chest radiographs of all patients following oesophagectomy [Figure 4.7]. 
Consequently, these features were regarded as a normal response to oesophagectomy. 
Evidence of new non-dependent infiltrates and consolidation on one or more serial 
postoperative radiological studies was considered diagnostically relevant [Figures 4.7]. 
Based on these findings guidelines for the diagnosis of pneumonia were created. These 
criteria are presented in table 4.12. Radiological signs of pneumonia and/or positive bacterial 
cultures indicative of pneumonia were considered as firm criteria for the diagnosis of 
pneumonia. Clinical evidence of pneumonia (including pyrexia), production of purulent 
sputum, raised white cell count, reintubation and worsening gas exchange were considered as 
secondary criteria for the diagnosis of pneumonia. Whilst previous authors have reported 
using pyrexia alone as a marker of pneumonia, this is not acknowledged by the current 
guidelines, primarily because a raised temperature is considered a normal response to 
surgical trauma [80]. (A copy of the pro forma specifically developed to document 
radiological changes after oesophagogastric surgery is provided as supplementary material in 
Appendix III.) 
Table 4.11 Published criteria for the diagnosis of pneumonia following oesophagectomy 
Author Year Country Radiological 
signs 
Positive 
culture Leukocytosis Pyrexia 
Purulent 
sputum 
Clinical 
evidence Other criteria 
Ref. 
1 Akutsu 2010 Japan Y - Y Y Y - Raised C-reactive protein [364] 
2 Ancona 2006 Italy Y - Y Y - - Antibiotic therapy [365] 
3 Atkins 2004 USA Y - - Y - - PaCOz >50mmHg, Rl >2.5 [256] 
4 Avendano 2002 USA Y - - Y - - - [366] 
5 Azim 2007 Ireland Y Y - - - Y - [367] 
6 Bank! 2008 USA - - - - - - Reintubation [368] 
7 Buise 2009 Holland Y Y - - - - - [369] 
8 Cense 2006 Holland Y - - Y Y - Antibiotic therapy [370] 
9 Daryaei 2009 Iran Y - - - - Y - [371] 
10 D'Journo 2009 France Y Y Y Y Y - - [372] 
11 Fang 2003 Japan Y - Y Y - Y Antibiotic therapy [373] 
12 Ferguson 2002 USA Y - Y Y - - Antibiotic therapy [338] 
13 Gurkan 1991 Turkey Y - - Y - - - [374] 
14 Hsu 2009 Tiawan Y Y Y Y Y - - [375] 
15 JIao 2006 China Y - Y Y - Y - [376] 
16 Katsuta 1998 Japan Y Y Y Y - - - [97] 
17 Kinoshita 2000 Japan Y Y - - - - - [377] 
18 Kinugasa 2004 Japan Y Y - Y Y - - [378] 
19 Kusano 1997 Japan - - - - - - Mechanical ventilation >10days [379] 
20 Kuwano 1998 Japan Y Y - - - - - [380] 
21 Law 2004 Hong Kong Y Y - - - Y - [339] 
22 Motoyama 2009 Japan Y Y - - - - - [381] 
23 Nakamura 2008 Japan Y Y - - - Y - [340] 
24 Nishi 1988 Japan Y - - - - Y - [382] 
25 Ogawa 2005 Japan Y Y Y Y Y - - [383] 
26 Rizk 2004 USA Y Y Y Y - Y - [249] 
27 Sasajima 2002 Japan Y Y Y Y - - - [384] 
28 Schroder 2006 Gernnany Y Y - - - - - [385] 
29 Tandon 2001 UK Y Y - Y Y - - [121] 
30 Wang 2006 USA Y Y Y Y Y - - [386] 
31 Watanabe 2002 Japan Y - - - - - - [387] 
32 Woodail 2008 USA - Y - Y - Y - [388] 
33 Yamada 1998 Japan Y Y - - - Y - [99] 
34 Yap 2003 Hong Kong Y - Y Y Y - - [389] 
35 Zingg 2007 Switzerland Y 
-
Y Y 
- -
Raised C-reactive protein [390] 
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Table 4.12 Criteria for diagnosing pneumonia following oesophagectomy 
Firm criteria 
One or more of the following (where both firm criteria are met the diagnosis of pneumonia is confirmed) 
• One or more serial chest radiographs/CT scans with evidence of new onset, non-dependent 
consolidation or infiltrates* 
• Positive bacterial culture indicative of pneumonia 
And 
At least two of the following criteria 
• Clinical evidence of pneumonia (e.g. fever, productive cough, dyspnoea, rales or bronchial breath 
sounds on auscultation) 
• New onset of purulent sputum 
• Leukocytosis (>12000 WBC/mm^) 
• Reintubation 
• Worsening gas exchange (e.g. Pa02:Fi02 <300), increased oxygen requirement or increased 
ventilation demand 
*The presence of dependent changes, atelectasis, ground glass appearance, or fluid on postoperative chest 
radiographs or CT scans are not considered diagnostically significant unless found in the presence of one or 
more firm radiological criteria. 
4.6.5 Discussion 
Altliough pneumonia is frequently reported in patients undergoing oesophagectomy, few 
studies report a clear definition of this complication. Consequently, rates of pneumonia vary 
widely within published studies. The results of a systematic literature review do however 
indicate the perceived importance of radiological, microbiological and clinical findings 
(primarily pyrexia) as indicators of pneumonia in patients following oesophagectomy. In 
particular, almost all studies reporting definitions of postoperative pneumonia relied on the 
findings of routine radiological studies. A separate review of the postoperative radiology of 
patients who had undergone transthoracic oesophagectomy helped to determine specific 
radiological criteria upon which to base the diagnosis of pneumonia. The finding that 
dependent lung changes, atelectasis and evidence of fluid, were normal features of chest 
radiographs following oesophagectomy, proved to be important. 
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Failure to validate the proposed criteria is an acknowledged limitation of this work. As 
however there remains no gold standard test and as yet no consensus guidelines for the 
diagnosis of pneumonia, even in non-surgical patients, the opportunity for meaningful 
vahdation is diminished. 
4.6.6 Conclusion 
It is intended that the proposed criteria will form the basis for the diagnosis of pneumonia in 
fixture clinical studies. 
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Figure 4.7 Radiological studies of patients following oesophagectomy 
(A) Nonnal frontal radiograph obtained three days after transtlioracic (Ivor Lewis) oesophagectomy in a 68 year-old 
male with an uncomplicated recovery. (B) Left lower lobe pneumonia in a 65 year-old male who had undergone 
transthoracic (tliree-stage) oesophagectomy. Frontal radiograph obtained tliree days after surgery. (C) and (D) 
bilateral pneumonia and acute respiratory distress syndrome in a 58 year-old male who had undergone transthoracic 
(Ivor Lewis) oesophagectomy. (C) CT scan (3-mm section thickness) obtained three days after surgery. (D) Frontal 
radiograph obtained from the same patient on postoperative day tliree. 
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Section IV 
Clinical studies 
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5. A STUDY TO DETERMINE BASELINE LEVELS OF SELECTED VOLATILE 
METABOLITES IN THE BREATH OF PATIENTS WITH GASTROESOPHAGEAL 
TUMOURS 
5.1 Objectives 
The primary objective of the current study was to determine the normal concentrations of 
common metabolites within the exhaled breath of patients with gastroesophageal cancer, both 
before and after surgery. The secondary objective was to correlate the levels of breath 
metabolites with disease status and other routinely recorded covariates. 
5.2 Introduction 
To determine the physiological meaning and diagnostic potential of changing breath 
metabolite levels in response to disease or therapeutic intervention, the baseline levels of 
these gases within both healthy and target populations must first be determined. There is 
however, currently no formal consensus as to the 'normal' levels of even the most prominent 
metabohtes within exhaled breath. Consequently, comparisons are made on a typically ad 
hoc basis that is specific to individual study populations and analytical techniques. The work 
of Turner et al., does however offer the most complete assessment of the normal 
concentrations of common breath metabolites analysed by SIFT-MS [167, 391-393]. A 
summary of the findings of Turner and co-workers, who analysed the breath of 30 healthy 
volunteers over the course of six months, is presented in table 5.1. Results confirm high intra-
and inter-individual variability in breath metabolite levels, hi addition, breath metabolites 
were reported to exhibit distributions that were close to log-normal. These studies also made 
an attempt to correlate metabolite levels with important physiological parameters including 
age, gender and BMI. However, a small sample size as well as other methodological 
limitations meant that strong conclusions could not be drawn from these comparisons. 
Recently the same group have established the concentrations of the same metabolites in 
mouth- and nose-exhaled breath and in the oral cavity of healthy volunteers [179, 204, 206]. 
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The findings of these studies and their implications for breath analysis are discussed below 
and in other chapters. 
Table 5.1 Summary of longitudinal breath profiling studies by Turner and co-workers 
Precursor 
ion 
Product 
ion 
Mean 
(ppb) 
SD 
(ppb) 
Range 
(ppb) Disf 
CV 
(intra"*) 
CV 
(inter') 
Room air 
(ppb) Ref. 
Acetone [H30+] 88 477' (462) 1.58" 148-2744 LN 0.33 0.38 <1 [167] 
Ammonia [H30+] 18,36,54 833' (842) 1.62" 248-2935 LN 0.37 0.32 400 [167] 
Propanol [H30+] 43,61 22(18) 
-
0-135 
- - - -
[167] 
Ethanol [H30+] 47,65,83 196 (112) 244 0-1663 LN 
- -
0-145 [391] 
Acetaldehyde [H30+] 45,63,81 24 (22) 17 0-104 
- - -
0 [391] 
Methanol [H30+] 33,51,69 450' (461) 1.62" 32-1684 LN 0.43 0.29 50 [392] 
Isoprene [N0+] 68 118 68 0-474 LN 0.27 0.50 - [393] 
^ Geometric mean. Multiplicative (geometric) standard deviation.' Dist, distribution. LN, log-normal distribution. Mean intra-
individual coefficient of variability (Cv).' Inter-individual coefficient of variability (Cv). Values in parentheses are medians. 
5.3 Methods 
Local ethics committee approval was obtained for the current study and prior to breath 
sample collection both patients and control subjects provided informed written consent. (A 
copy of the letters confirming favourable ethical and local Research and Development 
Department approval is provided as supplementary material in Appendix IV.) 
5.3.1 Patients 
Both pre- and post-operative patients with biopsy proven gastroesophageal cancer and 
healthy controls were recruited from the North-West London Cancer Network. 
5.3.2 Breath sample collection 
Off-line mixed breath samples (~2 litres) were collected from patients and control subjects 
by asking them to exhale directly into double thickness Nalophan® sample bags. 
5.3.3 Breath analysis by SIFT-MS 
Samples were analysed by SIFT-MS. A detailed description of the SIFT-MS technique and 
its applications are given in otlier chapters and previous publications [218]. For a minimum 
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of five minutes prior to, and for the duration of sample analysis, breath samples were 
enclosed within an incubator held at 37°C. All breath samples were analysed using the MIM 
mode of the SIFT-MS instrument, permitting the targeted analysis of specific exhaled 
metabohtes. The following breath metabolites were targeted for MIM mode analysis: 
acetone, ethanol, propanol, hydrogen cyanide, isoprene, acetic acid and ammonia. 
5.3.4 Statistical analysis 
Statistical analysis was performed using the SPSS 17.0 software package (SPSS Inc., 
Chicago, USA). Breath metabolite concentrations (not normally distributed) are presented as 
median values with their associated interquartile range (IQR). Statistical differences between 
metabolite concentrations measured within the exhaled breath of subject groups were 
assessed using the Kruskal-Wallis test. The Mann-Whitney U test was used for all other pair-
wise comparisons. Simple linear regression was used to determine the correlation between 
continuous covariates and log-transformed breath metabolite data. The level of statistical 
significance was assigned to f-values <0.05. 
5.4 Results 
5.4.1 Patient details 
Demographic details of patient and control groups are presented in table 5.2. Pre- and post-
operative cancer patients were well matched for all demographic characteristics. Compared 
to patients (pre- and post-operative), control subjects were significantly younger, more often 
female and had been longer without oral intake (P<0.05). 
Table 5.2 Subject characteristics 
Cancer Postoperative Control 
(n=S2) (n=32) (n=33) 
Age (Mean + SD) 65.2 ±9.9 64.8 ± 9.1 59.0 ± 10.6 0.016* 
Gender {M;F) 42:10 28:4 9:24 <0.001* 
Smoking habit (current:ex:non) 12:26:14 2:20:10 5:13:15 0.119' 
Neoadjuvant therapy 32 16 
-
0.299* 
Time since last oral intake (hrs) (IVIean ± SD) 1.7 + 1.1 1.8 ±0.9 4.0 ± 3.8 <0.001* 
tOne-way analysis of variance, tpearson Chi-Squared test. 
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5.4.2 Targeted analysis of selected breath metabolites 
The median concentrations and interquartile ranges of selected volatile metabolites analysed 
in the breath of patients and control subjects are presented in table 5.3. Histograms of the 
distributions of examined metabolites in each of the three cohorts are shown in figure 5.1. 
Table 5.3 Levels of volatile metabolites in the breath of cancer patients and controls 
Cancer 
(ppb) 
Postoperative 
(ppb) 
Control 
(ppb) P ' 
Acetone 496 [252-739] 545 [429-849] 285 [217-408] <0.001 
Ethanol 275 [151-412] 231 [137-398] 461 [316-850] <0.001 
Propanol 97 [37-193] 193 [82-327] 36 [23-119] 0.001 
Hydrogen cyanide 9 [6-15] 9 [5-12] 14 [8-22] 0.008 
Isoprene 105 [69-180] 134 [98-207] 111 [71-146] 0.101 
Acetic acid 108 [44-165] 131 [90-162] 107 [91-137] 0.382 
Ammonia 635 [278-1191] 471 [256-984] 1162 [695-1563] <0.001 
All values are given as parts-per-billion. Values in square brackets are interquartile range. ° One-way analysis of 
variance examined by Kruskal Wallis Test. 
5.4.2.1 Comparison ofpre- and post-operative cancer patients with controls 
Levels of acetone were significantly higher in both the breath of pre- (f=0.003) and post-
operative (P<0.001) cancer patients compared to controls. Propanol levels were also higher 
in the breath of postoperative patients compared to controls (P=0.001). Levels of ethanol, 
hydrogen cyanide and ammonia were greater in the breath of control subjects compared to 
pre- and post-operative cancer patients (f<0.025). 
5.4.2.2 Comparison ofpre- and post-operative cancer patients 
For patients in the postoperative group, the median time interval between surgery and breath 
sampling was 238 days (IQR, 138-551). Comparison of unmatched pre- and post-operative 
breath samples demonstrated higher levels of propanol in patients following surgery 
(f=0.021). No further significant differences were observed between unmatched pre- and 
post-operative breath samples. 
Subgroup analysis was performed on the results of eight patients who provided both pre- and 
post-operative breath samples [Table 5.4]. For this group the median time since surgery was 
107 days (IQR, 58-127). Comparison of samples confirmed significantly higher levels of 
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propanol within the breath of postoperative patients (P=0.017). A significant rise in 
postoperative breath ethanol was also observed (P=0.012). 
Table 5.4 Longitudinal study of pre- and post-operative breath 
metabolites 
Preoperative 
(ppb) 
Postoperative 
(ppb) 
Acetone 820 [247-1487] 567 [493-6461] 0.263 
Ethanol 105 [52-125] 267 [216-473] 0.012 
Propanol 61 [36-116] 324 [129-345] 0.017 
Hydrogen cyanide 10 [7-11] 6 [4-9] 0.260 
Isoprene 91 [38-139] 147 [90-181] 0.069 
Acetic acid 74 [58-116] 123 [93-158] 0.123 
Ammonia 821 [332-1129] 526 [254-1012] 0.327 
All values are given as parts-per-billion. Values in square brackets are interquartile 
range." Mann-Wliitney U Test. 
5.4.2.3 Time since operation 
No correlation was observed between the time since surgery and breath metabolite levels 
(R^<0.03). 
5.4.2.4 Age 
No correlation was observed between patient age and breatli metabolite levels (R^<0.05). 
5.4.2.5 Gender 
Pair-wise comparison of the levels of metabolites within the breath of men and women from 
each subject group showed no significant differences (P>0.05). 
5.4.2.6 Smoking habit 
Metabolite levels were compared within the breath of current-, ex- and non-smokers in each 
of the three subject groups. Preoperative cancer patients who were ex-smokers were found to 
have higher concentrations of ethanol, propanol and hydrogen cyanide within their breath. 
These differences were significant between ex- and current-smokers in the case of propanol 
(145 vs. 59, f=0.042) and between ex- and non-smokers in the case of ethanol (349 vs. 189, 
f^O.042) and hydrogen cyanide (14 vs. 7, P=0.017). hi postoperative patients acetone 
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Figure 5.1 [continued] Distribution of metabolites in the breath of cancer patients and controls 
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concentrations were higher in the breath of ex-smokers compared to non-smokers (637 vs. 
451 ppb, P=0.04). As only two postoperative patients were current-smokers meaningful 
comparisons could not be made with other groups. Finally, in control subjects hydrogen 
cyanide was lower in the breath of ex-smokers (10) compared to current- (17, P=0.046) and 
non-smokers (17, P=0.004) and ammonia was higher in the breath of non-smokers (1364) 
compared to current- (922, P=0.186) and ex-smokers (701, P=0.008). 
5.4.2.7 Neoadjuvant therapy 
The breath of preoperative patients receiving neoadjuvant chemotherapy was found to 
contain significantly higher levels of hydrogen cyanide compared to other preoperative 
patients who did not receive chemotherapy (10 vs. 7, f=0.038) [Figure 5.2]. A previous 
history of neoadjuvant chemotherapy had no further significant influence on the 
concentrations of other breath metabolites. 
5.4.2.8 Time since last oral intake 
No correlation was observed between the time since last oral intake and breath metabolite 
levels (R^<0.06). 
5.4.2.9 Correlation between breath acetone andpropanol 
Only a very weak correlation (R^=0.16) was observed between the concentration of acetone 
and propanol detected within breath samples [Figure 5.3]. 
5.5 Discussion 
The primary objective of this study was to establish the normal distributions of prominent 
metabolites in the breath of patients with gastroesophageal cancers, in order to act as a 
reference-guide for future clinical trials in perioperative patients. 
In comparison to previous profiling studies, which used on-line breath sampling [167, 179, 
391-393], the current study was restricted to off-line sampling. Previous studies were also 
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longitudinal and followed healthy volunteers over the course of several months. Despite 
these methodological differences the concentrations of metabolites in the breath of control 
subjects were similar to those published by Turner and co-workers [167, 391-393]. The 
concentration range of metabolites in the breath of both patients and controls also followed 
approximately log-normal distributions. 
Baseline levels of breath metabolites were compared between patients and controls. Despite a 
shorter interval since last oral intake, acetone was observed to be significantly higher in the 
breath of both pre- and post-operative cancer patients compared to controls. In these patients, 
both underlying cachexia associated with cancer and reduced oral intake during the 
postoperative period, could lead to ketosis. A parallel rise in exhaled propanol, observed only 
in the breath of postoperative patients, may indicate either a more profound degree of ketosis 
or possibly an alteration in die metabolic pathways responsible for acetone and propanol 
biosynthesis. These findings were confirmed by a longitudinal study that included breath 
samples from eight patients. High levels of propanol in inspiratory room air may however 
diminish confidence in its use as a biomarker of (patho)physiological processes. Certainly, 
analysis of breath acetone may offer an effective method of monitoring patient's nutritional 
status both before and after major surgery. Plotting breath acetone and propanol 
demonstrated a very weak correlation, confirming the earlier findings of Turner et al [167]. 
The reaction between ions, which are a minor impurity in the HaO^ precursor ion swarm, 
and breath acetone has been suggested to be at least partly responsible for this weak 
relationship [167]. 
Levels of ethanol, hydrogen cyanide and ammonia, all of which have been previously shown 
to originate predominantly from the oral cavity [179-180, 206], were increased in the breath 
of controls. These findings may reflect the significantly shorter interval between last oral 
intake and breath sampling that was observed in controls. Alternatively, it is possible that 
cancer may disrupt the normal bacterial flora of the gastrointestinal tract that is the presumed 
origin of these metabolites. For ethanol in particular, high ambient room air levels, could also 
have influenced these findings. 
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One postoperative patient with abnormally high acetone (13461ppb) was a known diabetic. 
Another patient with breath ethanol levels equivalent to 58ppm, nearly 200 times greater than 
typically detected within the breath, was found to have consumed alcohol prior to attending 
their outpatient clinic appointment. Both of these anomalous, albeit explained results, 
demonstrate the potentially enormous influence of both endogenous and exogenous factors 
on the levels of metabolites detected within the breath. Notwithstanding, a significant 
relationship was not observed between the concentrations of breath metabolites and the time 
since last oral intake. As a rule a minimum of one hour was preferred between last oral intake 
and breath sample collection. 
The influence of smoking on the levels of breath metabolites has been investigated by several 
groups [394-395], Euler et al, whilst finding there to be no difference in the baseline levels 
of pentane, acetone and isoprene in the breath of smokers and non-smokers, reported a 
transient rise in breath pentane and isoprene immediately after smoking [394]. hi 
comparison, Senthilmohan and co-workers identified higher levels of isoprene and acetone 
and lower levels of ethanol in the breath of human subjects after smoking [395]. Previous 
SIFT-MS studies have reported higher levels of hydrogen cyanide in the breath of smokers 
[396]. The current study is the first to report the levels of prominent metabolites in the breath 
of current", ex- and non-smokers. In preoperative patients the main finding was of higher 
ethanol, propanol and hydrogen cyanide levels in the breath of ex-smokers compared to 
current- and non-smokers. Comparison of other routinely recorded covariates; age, time since 
last oral intake and neoadjuvant therapy with smoking habit revealed no further evidence to 
explain the observed variation in metabolite levels within the breath of ex-smokers. 
Regrettably it was not possible to correlate breath metabolite levels with the interval since 
last cigarette consumption, as this information was not routinely documented. It was however 
common for subjects to quit smoking at, or around, the time of cancer diagnosis, which was 
often several weeks prior to breath sampling. Whilst prolonged exposure to cigarette smoke 
might be expected to induce characteristic changes in the levels of certain breath metabolites, 
current findings seem to support this theory only in patients who are ex-smokers. 
Furthermore, there was no clear agreement between findings in pre- and post-operative 
patients and control subjects. Based on available evidence it is therefore hard to determine 
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the underlying cause of breath metabolite changes that are observed in response to smoking 
habit. Certainly, the influence of other covariates can not be ruled out. 
Neoadjuvant chemotherapy was associated with a small but significant rise in the level of 
hydrogen cyanide within the breath of preoperative patients. This finding was not readily 
explained by any of the other covariates examined. Hydrogen cyanide is known to be 
produced by bacterial species, particularly the pseudomonads [187-188]. It is possible that 
chemotherapy and related immunosuppression may lead to bacterial overgrowth within the 
upper gastrointestinal and respiratory tracts that could, in turn, cause an increase in hydrogen 
cyanide levels within the breath. It is perhaps surprising that chemotherapy, which is 
appreciated to induce considerable metabolic changes within the body and in many cases 
significant morbidity, was not observed to influence the levels of breath metabolites to a 
greater extent. As only a small panel of metabolites were examined during the current study 
it is not however possible to draw strong conclusions regarding the influence of 
chemotherapy on the levels of breath metabolites. 
5.6 Conclusion 
This is the first study to report the normal levels of metabolites within the breath of patients 
with upper gastrointestinal cancer and as such is intended to act as a reference-guide to future 
studies in this patient population. Wide variation in the concentrations of breath metabolites 
and evidence that their levels may be significantly altered by a range of confounding factors 
demonstrates the importance of carefiil evaluation of breath data to ensure correct 
interpretation of findings. 
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6. A STUDY T O DETERMINE BASELINE LEVELS OF SELECTED V O L A T I L E 
M E T A B O L I T E S I N T H E B R E A T H OF PATIENTS W I T H C O M M U N I T Y -
ACQUIRED PNEUMONIA 
6.1 Objectives 
The primary objective of the current study was to determine the concentration of common 
metabolites within the exhaled breath of patients with community-acquired pneumonia. A 
secondary objective was to correlate the levels of breath metabolites with currently used 
markers of infection and pneumonia severity. 
6.2 Introduction 
Previous studies have confirmed that postoperative respiratory complications, in particular 
pneumonia, are the commonest cause of morbidity after oesophagectomy (refer to Chapters 2 
& 3). A review of local outcomes revealed that 33% of patients who underwent transthoracic 
oesophagectomy developed pneumonia during the postoperative period (refer to Chapter 3). 
Despite its significance, both to the postoperative recovery of patients following 
oesophagectomy and to medicine as a whole, there is currently no gold standard for the 
diagnosis of pneumonia. In practice, the diagnosis of pneumonia is based on a combination 
of both clinical judgment and the sum of available clinical evidence, gathered from sources 
such as chest X-rays, pneumonia scoring systems, bronchoscopy and bacterial culture 
studies [153]. Criticisms of this approach are manifold, but most notably include; 
vulnerability to subjective interpretation of clinical data, especially chest X-rays, the 
appearance of which are invariably altered following oesophagectomy; the invasive nature of 
several techniques, including blood sampling and bronchoscopy; time delay, which is most 
apphcable to bacterial culture studies; and finally, a poorly defined correlation to real time 
lung pathology, which in turn reflects the fact that currently the diagnosis of pneumonia lacks 
a molecular basis. 
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One novel approach towards the diagnosis of pneumonia is the analysis of volatile 
metabolites within exhaled breath. Several studies have akeady reported that the gas above 
bacterial cultures contains a wide range of volatile compounds [187-188, 397-403] (see also 
references within Wang et al., 2004 [402]). Allardyce et al. recently demonstrated that SIFT-
MS analysis of volatile compounds in the headspace above bacterial cultures was able to 
discriminate between different bacterial species and that gas profiles were significantly 
altered by antibiotic therapy [397]. In vivo studies investigating the exhaled breath of 
mechanically ventilated patients in intensive care have also shown that the output of a 
commercially available electronic nose device is correlated not only with pneumonia severity 
score, but also the CT diagnosis of pneumonia [153-155]. 
The purpose of the current study was to determine the impact of community-acquired 
pneumonia on the levels of selected breath metabolites. Results are intended to support 
future studies that seek to deconvolve the gas-phase metabolic responses to surgical stress 
and postoperative pneumonia. 
6.3 Methods 
Local ethics committee approval was obtained for the current study and prior to breath 
sample collection both patients and control subjects provided informed written consent. (A 
copy of the letters confirming favourable ethical and local Research and Development 
Department approval is provided as supplementary material in Appendix IV.) 
6.3.1 Patients 
Patients with suspected community-acquired pneumonia admitted to St Mary's Hospital were 
eligible for inclusion in the current study. The same cohort of control subjects that were 
reported in Chapter 5 is used. 
The diagnosis of community-acquired pneumonia was confirmed by fulfilment of the criteria 
listed in table 6.1. All chest radiographs were independently reviewed by a consultant 
respiratory physician. Severity scoring of pneumonia was conducted using the CURB-65 
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Table 6.1 Criteria for diagnosing community-acquired pneumonia ° 
Radiological evidence on pneumonia 
One or more serial chest radiographs with evidence of at least one of the following 
• New, or progressive and persistent, infiltrates 
• Consolidation 
• Cavitation 
And 
At least two of the following criteria 
Pyrexia (>38°C) with no other recognised cause 
New onset or worsening cough, dyspnoea or tachypnoea 
Findings consistent with pneumonia upon physical examination ^ 
New onset of purulent sputum or change in the character of sputum ® 
Positive sputum culture for pneumonia-causing pathogen ' 
Leul<ocytosis (WBC>12x1oVl) ® 
^ Adapted from the CDC criteria for the diagnosis of Ventilator-Associated Pneumonia (VAP). Centers for 
Disease Control and Prevention. The National Healthcare Safety Network (NHSN) manual: patient safety 
component protocol. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/nhsn/NHSN Manual Patient 
Safety Protocol052407.pdf (last accessed 1st May 2010). ''Tachypnoea in adults is defined as a respiration 
rate >25 breaths/min. Physical examination findings consistent wi th pneumonia include dullness to 
percussion, reduced or asymmetrical chest expansion, crackles, bronchial breathing, tactile vocal fremitus 
and wheeze. ^ Laboratory confirmation of purulence is required. ^ Character of sputum refers to the colour, 
consistency, odour or quantity of the sputum. ' Pathogenic species responsible for pneumonia include 
Streptococcus pneumoniae, Chlamydia pneumoniae, Haemophilus influenzae. Mycoplasma pneumoniae, 
Legionella pneumophilia. Chlamydia spp., Moraxella catarrhalis. Staphylococcus aureus, Klebsiella 
pneumoniae, Pseudomonas aeruginosa. Chlamydia psittaci, Franciseiia tularensis and Coxiella burnetii. ® 
WBC, white blood cell count. 
score, in which one point was given where each of the following criteria were met: confusion 
(abbreviated mental test <8), blood urea concentration >7mmol/L, respiratory rate >30/min, 
blood pressure (systolic <90mmHg or diastolic <60mmHg) and age >65. 
6.3.2 Breath sample collection 
Off-line mixed breath samples (~2 litres) were collected from patients and control subjects 
by asking them to exliale directly into double thickness Nalophan® sample bags. 
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6.3.3 Breath analysis by SIFT-MS 
Breath samples were analysed, typically within one hour of collection, using the MIM mode 
of the SIFT-MS instrument. For a minimum of five minutes prior to, and for the duration of 
breath analysis, samples were enclosed within an incubator held at 37°C. The following 
breath metabolites were targeted for MIM mode analysis; acetone, ethanol, propanol, 
hydrogen cyanide, isoprene, acetic acid and ammonia. 
6.3.4 Statistical analysis 
Statistical analysis was performed using the SPSS 17.0 software package (SPSS Inc., 
Chicago, USA). Breath metabolite concentrations (not normally distributed) are presented as 
median values with their associated interquartile range (IQR). Statistical differences between 
volatile metabolite concentrations, measured within the exhaled breath of study groups, were 
assessed using the Mann-Whitney U test. Simple hnear regression was used to determine the 
correlation between continuous covariates and log-transformed breath metabolite data. The 
level of statistical significance was assigned to f-values <0.05. 
6.4 Results 
6.4.1 Patient details 
A total of 34 patients with suspected community-acquired pneumonia were recruited to the 
current study, 26 of whom met the diagnostic criteria for this condition. Of the eight patients 
who were excluded, five did not have radiological evidence of pneumonia and three were 
subsequently diagnosed with tuberculosis. Demographic details of included patients and 
control subjects are presented in table 6.2. Compared to controls, patients with pneumonia 
were significantly older, more often male and were more likely to be a current smoker 
(P<0.05). 
6.4.2 Comparison of patients wi th community-acquired pneumonia wi th controls 
The median concentrations of selected volatile metabolites analysed in the breath of 
pneumonia patients and control subjects are presented in table 6.3. Levels of hydrogen 
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Table 6.2 Subject characteristics 
Pneumonia Control 
(n=26) (n=33) 
Age (Mean ± SD) 72.5 ±13.9 59.0 ± 10.6 <0.001" 
Gender (M:F) 16:10 9:24 0.008' 
Smoking habit (current:ex:non) 11:12:3 5:13:15 0.008' 
Time since last oral intake (Mrs) (Median, IQR') 2.3 [1.6-3.0] 2.6 [2.0-4.6] 
. . . 3" . 
0.332" 
Table 6.3 Metabolite levels in the breath of pneumonia patients 
and controls 
Pneumonia Control . 
(ppb) (ppb) 
Acetone 318 [158-723] 285 [217-408] 0.516 
Etiianol 601 [409-1206] 461 [316-850] 0.328 
Propanol 55 [27-69] 36 [23-119] 0.801 
Hydrogen cyanide 6 [4-9] 14 [8-22] 0.001 
Isoprene 72 [49-103] 111 [71-146] 0.014 
Acetic acid 118 [90-142] 107 [91-137] 0.897 
Ammonia 368 [250-484] 1162 [695-1563] <0.001 
All values are given as parts-per-billion. Values in square brackets are interquartile 
range." Mann-Whitney U Test. 
cyanide, isoprene and ammonia were significantly lower in the breath of pneumonia patients 
compared to controls [Figure 6.1]. The concentrations of all remaining breath metabolites 
were equivalent in the two groups. 
All examined breath metabolites showed a very weak correlation with CURB-65 pneumonia 
severity score (R^<0.16). Likewise, hydrogen cyanide, isoprene and ammonia were not 
correlated with temperature (R^<0.04) respiratory rate (R^<0.01) and white blood cell count 
(R^<0.21). 
6.5 Discussion 
In the current study the levels of prominent volatile metabolites in the breath of 26 patients 
with community-acquired pneumonia were quantified. The principle findings of this work 
were: (i) that pneumonia induces characteristic changes in the levels of specific and 
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Figure 6.1 Levels of metabolites in the breath of pneumonia patients and controls 
Breath metabolites are as follows: (A) hydrogen cyanide, (B) Isoprene and (C) Ammonia 
identifiable volatile metabolites within the breath of affected patients, and (ii) exhaled 
metaboHtes do not correlate with pneumonia severity score and other routinely collected 
chnical parameters. 
Breath testing identified lower levels of hydrogen cyanide, isoprene and ammonia in patients 
with pneumonia compared to control subjects. Previous studies have shown that exhaled 
hydrogen cyanide originates primarily from the oral cavity and upper respiratory tract, due to 
the oxidation of thiocyanate by salivary peroxidase [186]. Disruption of this process in 
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patients with pneumonia could explain the observed change in exhaled hydrogen cyanide 
concentrations. Within the airways thiocyanate may also undergo a number of other 
important reactions that act to protect the lungs from tissue damaging species [404]. During 
pneumonia, white blood cells are recruited to the lungs and are responsible for the release of 
inflammatory mediators and oxidative species, including hydrogen peroxide [404]. 
Myeloperoxidase, which is also released by white blood cells, catalyses the reaction between 
hydrogen peroxide and thiocyanate producing hypothiocyanite and reducing the extent of 
oxidative lung damage [404]. Myeloperoxidase also catalyses the oxidation of chloride to 
hypochlorite, for which thiocyanate is a potent scavenger [404]. Consequently, increased 
oxidative stress within the lungs and airways of patients with pneumonia may promote the 
excess consumption of thiocyanate, leading to a reduction in the de novo synthesis of 
hydrogen cyanide. Simple linear regression showed only a very weak negative correlation 
between the concentration of exhaled hydrogen cyanide and white blood cell count. 
Previous authors have reported that the pneumonia causing bacteria, Pseudomonas 
aeruginosa^ is a source of hydrogen cyanide [187-188]. In the current study a rise in exhaled 
hydrogen cyanide was not observed, even in two patients with positive cultures for 
Pseudomonas. One possible explanation for these different findings is that previous studies 
focused on the release of hydrogen cyanide by Pseudomonas bacteria originating from 
children with cystic fibrosis, a disease in which normal thiocyanate regulation is known to be 
disrupted [404]. Furthermore, the most common pathogen responsible for community-
acquired pneumonia is Streptococcus pneumoniae, which has yet to be associated with 
hydrogen cyanide release [405]. 
Breath isoprene has been associated with both the mevalonic pathway of cholesterol 
synthesis and neutrophil activation [159, 190]. Previous studies have also reported reduced 
isoprene elimination from the lungs of patients with nosocomial pneumonia and ARDS [202-
203]. It was suggested that the fall in breath isoprene levels observed in these studies was a 
consequence of disruption of cell membrane repair mechanisms and impairment of 
cholesterol metabolism. 
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Ammonia is produced within the body via the deamination of amino acids and the hydrolysis 
of urea by bacteria in the gastrointestinal tract [164, 206-208]. The reduction of breath 
ammonia observed in patients with pneumonia may therefore reflect disruption of ammonia 
production within the gastrointestinal tract, caused by antibiotic therapy [207]. At the time of 
breath sampling all patients were receiving either intravenous or oral antibiotics. However, 
due to potential difficulties in off-line sampling of ammonia (refer to chapter 4.2) results 
should be interpreted with caution. 
Levels of acetone, ethanol, propanol and acetic acid within the exhaled breath of pneumonia 
patients were similar to those of healthy controls. These findings suggest that pneumonia 
does not affect the metabolic pathways underlying the production of these metabolites. 
Of the seven volatile metabolites that were analysed during the current study none were 
observed to correlate appreciably with the CURB-65 pneumonia severity score. Previously 
Hanson and co-workers have reported that the output of an electronic nose device correlated 
with the Clinical Pulmonary Infection Score (CPIS) for patients with ventilator-associated 
pneumonia [154]. Electronic nose devises, whilst offering a global profile of a breath sample 
are unable to provide information regarding the compound(s) responsible for an observed 
variation in output. Consequently, it is possible that those compounds responsible for the 
observed correlation between CPIS and electronic nose output were not considered in the 
current study. Furthermore, differences between the pathophysiology of community-acquired 
and ventilator-associated pneumonia may also explain the lack of agreement between these 
findings. Finally, unlike the CURB-65 score, the CPIS is known to have low diagnostic 
accuracy, and poor sensitivity and specificity [406-407]. 
The small number of patients and controls included in this study limit the strength of the 
conclusions that can be drawn. Selection bias was also apparent, as only patients hospitalised 
with community-acquired pneumonia were enrolled. As suggested by the results of in vitro 
studies, the initiation of antibiotic therapy prior to the collection of breath samples may 
influence potential differences between volatile metabolite levels in patients and controls 
[397]. The majority of patients were also receiving therapeutic oxygen either before or at the 
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time of sample collection. As such, this may have led to either contamination or dilution of 
trace gases within their breath. Whilst the influence of these factors is undesirable, it would 
have been unethical to interfere with patient management. Although not formally assessed, it 
was perceived that the interval between sample collect and analysis was often longer in 
control subjects compared to patients. This difference was due to the fact that several control 
samples were often collected within a short period of time, delaying the analysis of the most 
recently collected samples until the analysis of earlier samples was completed. As the water 
content of samples is known to decrease with increasing length of storage, the concentrations 
of highly water soluble compounds, particularly ammonia, may have been affected. 
Differences in age, gender and smoking habit may also have contributed to the observed 
differences between patient and control groups. Future studies with a larger sample size, 
refined methodology and matched groups are therefore recommended. 
6.6 Conclusion 
Targeted analysis of selected volatile metabolites within the breath of patients with 
community-acquired pneumonia was performed. Results provide evidence that the levels of 
several prominent breath metabolites, which are potentially related to bacterial activity and 
lung injury, are significantly altered in patients with this disease. These results are intended 
to support the interpretation of the findings of fixture studies involving surgical patients in 
whom postoperative pneumonia is commonly observed. 
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7. A STUDY TO DETERMINE CHANGES I N THE LEVELS OF SELECTED 
METABOLITES I N THE B R E A T H OF PATIENTS UNDERGOING M A J O R UPPER 
GASTROINTESTINAL SURGERY 
7.1 Objectives 
The primary objective of the current study was to determine the impact of ©esophagectomy 
on the concentrations of common breath metabolites. The secondary objective was to 
determine whether changes in breath metabolite concentrations during the postoperative 
period could reflect the development of respiratory complications. 
7.2 Introduction 
Monitoring is essential to the management of patients within the perioperative and critical 
care settings. Timely recognition of pathological processes related to abnormal metabolic and 
inflammatory stresses is necessary to prevent organ damage. Many methods routinely used to 
assess patients are expensive, laborious and invasive [149]. Furthermore, the information 
provided by these techniques is often delayed and insufficient to support clear clinical 
decisions regarding patient management [149]. 
Numerous studies have reported a close relationship between exhaled biomarkers and 
(patho)physiological status [149]. Recently there has been promising evidence that the 
analysis of compounds within exhaled breath may offer a useful non-invasive means for 
monitoring metabolic and inflammatory processes related to surgery and critical illness [161-
162, 202-203]. Furthermore, the often profound nature of the response to these injuries is 
expected to promote an excess of volatile metabolites within the breath aiding both their 
detection and differentiation between clinical states [162]. 
Specific events that are likely to induce characteristic changes in breath metabolite levels in 
response to major surgery and critical illness include: oxidative stress, the systemic 
inflammatory response syndrome, infection and starvation. In particular oxidative stress is 
one of the most important features of both critical illness and surgical stress [162]. Reactive 
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oxygen species generated as part of the normal response to microbial infections and 
ischaemia reperfiision injury cause lipid peroxidation leading to increased production of n-
alkanes that are detectable within exhaled breath [202,408-414], Lung injury that is often the 
primary cause of critical illness in both non-surgical and surgical patients is frequently the 
result of oxidative and inflammatory damage. Previous studies have reported higher levels of 
the M-alkane pentane in the breath of critically ill, mechanically ventilated patients with 
puhnonary infections [202] and lower levels of isoprene in the breath of patients with ARDS 
[202-203]. The metabolic response to severe injury and accompanying starvation is also 
anticipated to lead to significant changes in the levels of different breath metabolites. The 
influence of nutrition (and starvation) on common breath metabolite levels has been reported 
in several studies involving healthy volunteers [158, 173, 415]. The finding of elevated 
acetone in the breath of patients several months after major upper gastrointestinal surgery 
provides evidence of the influence of starvation in surgical patients (refer to Chapter 5). 
Finally, injury to specific organs including the hver [410, 416-418], kidneys [212, 419], heart 
[159, 411] and gastrointestinal tract [181, 409] is also expected to cause characteristic 
changes in the levels of certain breath metabolites. This study intends to assess the impact of 
major upper gastrointestinal surgery on breath metabolite profiles. 
7.3 Methods 
Local ethics committee approval was obtained for the current study and all patients provided 
informed written consent prior to enrolment. (A copy of the letters confirming favourable 
ethical and local Research and Development Department approval is provided as 
supplementary material in Appendix IV.) 
7.3.1 Patients 
All patients who underwent elective oesophagogastric resections at St Mary's Hospital 
during the period 26^ February 2009 to 2°^ December 2009 were invited to take part in the 
current study. 
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Perioperative variables, the same used in the retrospective case series review (refer to 
Chapter 3), were prospectively collected for all patients and recorded in a specifically 
designed database (Microsoft Office Access 2007, Microsoft Corp., Redmond, WA, USA). 
(A full list of recorded variables is available as supplementary material in Appendix II.) In 
addition the following parameters were also collected at the time of breath sampling; 
physiological variables (heart rate, respiratory rate, temperature, blood pressure, oxygen 
saturation), serum parameters (albumin, creatinine, C-reactive protein, haemoglobin, 
neutrophil count, white blood cell count, urea) and where available the results of arterial 
blood gas analysis (pH, bases excess, PaOi, PaCOa, lactate, glucose). The diagnosis of 
postoperative pneumonia was based on the criteria outlined in Chapter 4.6. ARDS/ALI was 
diagnosed using the American-European Consensus Conference definitions [120]. 
7.3.2 Breath sample collection 
Off-line mixed breath samples were collected by asking patients to exhale directly into 
double thickness Nalophan® sample bags. Breath samples were collected preoperatively 
(typically the night before surgery) and at 24, 48, 72, 96 and 168 hours following surgery. 
7.3.3 Breath analysis by SIFT-MS 
All samples were analysed by SIFT-MS within half an hour of collection. For a minimum of 
five minutes prior to, and for the duration of breath analysis, samples were enclosed within 
an incubator held at 37°C. A detailed description of the SIFT-MS technique and its 
applications are given in other chapters and previous publications [218]. All breath samples 
were analysed using the MIM mode of the SIFT-MS permitting the targeted analysis of 
specific exhaled metabolites. The following breath metabohtes were targeted for MIM mode 
analysis: acetone, ethanol, propanol, hydrogen cyanide, isoprene, acetic acid and ammonia. 
7.3.4 Statistical analysis 
Statistical analysis was performed using the SPSS 17.0 software package (SPSS Inc., 
Chicago, USA). Exhaled metabolite concentrations (not normally distributed) are presented 
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as median values with their associated interquartile range (IQR). Statistical differences 
between volatile metabolite concentrations measured within the exhaled breath of patients 
during the perioperative period were assessed using the Friedman repeated measures 
analysis. The Wilcoxen test was used for all other pair-wise comparisons. Simple linear 
regression was used to determine the correlation between continuous covariates and log-
transformed breath metabolite data. The level of statistical significance was assigned to P-
values <0.05. 
7.4 Results 
7.4.1 Patients and perioperative course 
Forty patients were recruited to take part in the current study, 25 of whom underwent 
transthoracic oesophagectomy. Details of patient characteristics, comorbidity and risk 
prediction scores are given in tables 7.1 and 7.2. With the exception of hypertension, which 
was more prevalent in patients who underwent transabdominal gastrectomy (P=0.006), 
groups were well matched for all other preoperative variables. Operative and postoperative 
details are presented in tables 7.3 and 7.4 respectively. 
There was one in-hospital death in the transthoracic group. Death occurred on the twenty-
sixth postoperative day as a result of cardiac arrest shortly after reoperation for resection of 
ischaemic bowel. Other postoperative complications contributing to this patient's death 
included ARDS and acute myocardial infarction. One other patient in the transthoracic group 
required reoperation on the fifth postoperative day to close a diaphragmatic defect through 
which a loop of large bowel had herniated into the left chest. This patient had no other major 
postoperative complications. Of those patients undergoing transthoracic resection, nine 
developed postoperative pneumonia. Four patients required reintubation, two of whom were 
diagnosed with ARDS/ALI. One additional patient, who did not meet the diagnostic criteria 
for pneumonia, required prolonged intubation until the fifth postoperative day. Postoperative 
pneumonia was diagnosed in a single patient in the transabdominal group. 
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Table 7.1 Characteristics of patient groups 
Transthoracic Transabdominal 
n* 
{n=25) (n=15) r 
Gender ratio [M:F] 17:8 12:3 0.486* 
Age (years) [mean ± SD] 59.2 ±12 .7 66.6 ± 1 0 . 1 0.062^ 
[Range] [29-80] [45-81] 
Age >70years 4(16) 7(47) 0.065* 
BMI [mean ± SD] 26 ±4 .5 27 ± 4.4 0.716^ 
[Range] [17-35] [21-38] 
Tumour location 
Oesophagus upper 1/3 1(4) -
Oesophagus middle 1/3 1(4) -
Oesophagus lower 1/3 18 (72) -
GOJ 4(16) -
Proximal stomach - 3(20) 
Middle stomach - 6(40) 
Distal stomach - 6(40) 
Histology 
Adenocarcinoma 21(84) 14 (93) 0.633* 
Squamous cell carcinoma 3(12) 0 (0 ) 0.279* 
Benign 1(4) 1(7) 1.000* 
pTNM stage 
0/1 9 (36)t 2(13) 1.000* 
11 6(24) 8(53) 0.060 
III 8(32) 3(20) 0.486* 
IV 1(4) 1(7) 1.000* 
Not applicable" 1(4) 1(7) 1.000* 
Neoadjuvant therapy 17(68) 11(73) 1.000* 
Values in parentheses are percentages unless otherwise indicated. SD, standard deviation. BMi, body mass 
index. pTNM, pathological tumour node metastasis. ^Three patients had a complete response to 
neoadjuvant chemotherapy. "Patients with benign disease. *x^ test unless otherwise indicated: *Fisher's 
exact test, ^Student's t-test. 
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Table 7.2 Comorbidity and risk prediction scores 
Transthoracic 
(n=25) 
Transabdominal 
(n=15) 
Smoking history: 
Current or ex-smoker 
Pack years 
No additional disease 
Comorbidity 
Hypertension 
Ischaemic heart disease 
Cerebral vascular disease 
Peripheral arterial disease 
Diabetes 
Chronic respiratory diseaset 
Chronic renal impairment 
[median, range] 
Charlson comorbidity score [mean ± SD] 
[Range] 
16(64) 
20 [4-40] 
10 (40) 
4 (16) 
1(4) 
0 (0 ) 
0 (0 ) 
3 (12) 
4 (16) 
0 (0 ) 
2 ± 1 
[0-6] 
7 (47) 
32 [7-80] 
3(20) 
9(60) 
2(13) 
0 (0 ) 
0 (0 ) 
3(20) 
0 (0 ) 
0(0) 
3 ± 1 . 2 
[2-6] 
0.283 
0.412* 
0.298' 
0.006" 
0.545* 
0.654' 
0.278* 
0.638^ 
ASA grade 
1 
2 
3 
POSSUM physiologic score 
<20 
>20 
O-POSSUM score (%) 
<5 
5-10 
11-20 
>21 
[mean ± SD] 
[Range] 
[mean ± SD] 
[Range] 
1(4) 
12(48) 
12 (48) 
16 ± 3 
[12-23] 
22(88) 
3 (12) 
9.0 + 6.6 
[2.1-24.0] 
11 (44) 
5 (20) 
7 (28 ) 
2(8) 
0 (0 ) 
11(73) 
4 (27) 
18 ± 5 
[12-28] 
11(73) 
4 (27) 
9.4 ±6 .6 
[1.2-23.4] 
4 (27) 
6(40) 
4 (27) 
1(7) 
1.000* 
0.187* 
0.318* 
0.152^ 
0.392+ 
0.852^ 
0.329* 
0.170 
1.000* 
1.000* 
Values in parentheses are percentages unless otherwise indicated. SD, standard deviation. ASA, American 
Society of Anesthesiologists physical status classification. O-POSSUM, Physiological and Operative Severity 
Score for the enumeration of Mortality and morbidity developed specifically for use in oesophagogastric 
surgery. ^Including chronic obstructive pulmonary disease and asthma. *x^ test unless otherwise indicated: 
*Fisher's exact test, ^ Student's t-test,"Mann-Whitney U test. 
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Table 7.3 Operative details 
Transthoracic 
(n=25) 
Transabdominal 
(n=15) P* 
Operative approach 
2-stage oesophagectomy (Ivor Lewis) 
3-stage oesophagectomy (open) 
3-stage oesophagectomy (thoracoscopic) 
Total gastrectomy (thoracolaparotomy) 
Total gastrectomy (abdominal only) 
Partial gastrectomy 
Unresectable 
Length of operation (min) [mean ± SD] 
[Range] 
15 (60) 
4 (16) 
3 (12) 
3 (12) 
0 (0 ) 
623 ± 70 
[510-750] 
4 (27) 
10(67) 
1(7) 
437 ± 1 2 6 
[165-630] 
1 .000 ' 
<0.001* 
Length of OLV (min) [mean ± SD] 
[Range] 
184 ± 64 
[0-285] 
Blood loss >1000ml 
Intraoperative transfusion 
Excised lymph nodes 
Positive lymph nodes 
[median, range] 
[mean ± SD] 
[Range] 
[median, range] 
1(4) 
1(4) 
4 
60 ±16 
[28-86] 
[0-28] 
0 (0 ) 
0 (0 ) 
75 ± 1 8 
[47-108] 
[0-16] 
1.000* 
1.000" 
0.077^ 
0,361" 
Values in parentheses are percentages unless otherwise indicated. OLV, one lung ventilation. *x test 
unless otherwise indicated: *Fisher's exact test, ^Student's t-test, "Mann-Whitney U test. 
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Table 7.4 Postoperative outcomes 
Transthoracic 
(n=25) 
Transabdominal 
(n=15) P* 
Without complications 
Mortality 
Overall technical complications^ 
10(40) 
1(4) 
2(8) 
11 (73) 
0 ( 0 ) 
1 ( 7 ) 
T 0.055 
1 .000 ' 
1.000" 
Surgical complications 
Anastomotic leak 
Chyle leak 
Haemorrhage 
Abdominal abscess 
Temporary RLN palsy 
Wound infect ion 
0 (0 ) 
0 (0 ) 
0 (0 ) 
1(4) 
1(4) 
1(4) 
0 (0 ) 
0 (0 ) 
0 (0 ) 
1(7) 
0 (0 ) 
2 (13) 
1 .000 ' 
1.000* 
0.545* 
Pulmonary complications 
Pneumothorax 
Pleural effusion 
Pulmonary embolism 
Pneumonia 
ARDS/ALI 
Reintubation 
Cardiac complications 
Arrhythmia 
MI/ACS 
1 ( 1 ) 
2 ( 8 ) 
0(0) 
9 (36)t 
2 (8) 
4 (16) 
4 (16) 
1(4) 
0 ( 0 ) 
1(7) 
0 (0 ) 
1 ( 7 ) 
0 ( 0 ) 
0 ( 0 ) 
1 ( 7 ) 
0 ( 0 ) 
1 .000 ' 
1.000* 
0.219* 
0.137* 
0.278* 
0.633' 
1.000* 
Acute renal failure 0(0) 0 ( 0 ) 
Unplanned return to theatre 
ICU stay (days) 
HDU Stay (days) 
Hospital Stay (days) 
[median, range] 
[median, range] 
[median, range] 
2 ( 8 ) 
7 [3-26] 
1 [0-5] 
16 [8-33] 
0 (0 ) 
0 [0-1] 
5 [1-12] 
11 [5-25] 
0.519' 
<0.001® 
<0.001® 
0.006® 
Values in parentheses are percentages unless otherwise indicated. SD, standard deviation. RLN, recurrent 
laryngeal nerve palsy. ARDS/ALI, acute respiratory distress syndrome/acute lung injury. MI/ACS, myocardial 
infarction/acute coronary syndrome. ICU, intensive care unit. HDU, high dependency unit, "includes: 
anastomotic leak, chyle leak, haemorrhage, abdominal abscess and temporary RLN palsy. *Two patients 
who developed pneumonia were also diagnosed as having ARDS/ALI. *x^ test unless otherwise indicated; 
*Fisher's exact test, "Mann-Whitney U test. 
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7.4.2 Routine blood parameters 
Serum creatinine, albumin and haemoglobin fell significantly after both transabdominal and 
transthoracic procedures (P<0.01). In comparison white blood cell and neutrophil counts rose 
significantly following surgery (P<0.01). There was no significant change in urea 
concentrations throughout the perioperative period [Figure 7.1]. 
On the first postoperative day neutrophil (10 vs. 7x10V l, P=0.008) and white blood cell (11 
vs. 8xlO^/L, P=0.003) counts were higher in patients who had undergone transabdominal 
resections. Neutrophil and white blood cell counts in both surgical groups were equivalent on 
the remaining postoperative days. Albumin was lower in the blood of transthoracic patients 
on postoperative days one (21 vs. 17 g/L, P=0.001), two (21 vs. 18 g/L, P=0.004) and three 
(22 vs. 17 g/L, f=0.021). Creatinine was also reduced in the blood of transthoracic patients 
on postoperative days three (80 vs. 62 mmol/L, f=0.032) and seven (82 vs. 69 mmol/L, 
P=0.023). 
In patients who developed postoperative pneumonia neutrophil count was increased on 
postoperative day three (7 vs. lOxlO^/L, P=0.020), as were both neutrophil (6 vs. 8xlO^/L, 
P=0.006) and white blood cell (7 vs. lOxlO^/L, P=0.013) counts on postoperative day four. 
C-reactive protein, whilst not routinely measured during the initial postoperative period, was 
increased in pneumonia patients one week after surgery (75 vs. 233, P=0.041). 
7.4.3 The influence of surgical approach 
Perioperative concentrations of exhaled volatile metabolites are presented in table 7.5. 
7.4.3.1 Water 
The concentration of water vapour was significantly increased within the breath of patients 
following both transthoracic and transabdominal procedures [Figure 7.2]. The highest water 
vapour levels were observed 24 hours after surgery and declined thereafter. 
167 
200-
j150-
o 
E 
3 
g 100-
u 50 
0-
•Transabdominal 
HTransthoracic 
Pre-op 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
12 
o 
E 
E 
•Transabdominal 
BTransthoracic 
I 
IT 
Pre-op 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
6 0 -
45' 
3 
•|30-
3 
15-
0-
iTransabdcminal 
^Transthoracic 
Pre-op 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
2 0 -
iTransabdominal 
BTransthoracic 
15-
1 
n 
X 
* 
i 
T 
Pre-op 24hrs 48hrs 72hrs 96 Mrs 168hrs 
Post-op 
50- iTransabdominal 
BTransthoracic 
55 40-< 
o 
Q. 
I 1101 
Pre-op 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
50-
°40 
£ • 
§30 
0 
1 
-0 20 
o 0 
a 
a 10 
1 
•Transabdominal 
^Transthoracic 
ii 
Pre-op 24hrs 48hrs 72hrs 96hrs 
Post-op 
leShrs 
Figure 7.1 Resul t s of rout ine b lood tests 
With the except ion o f urea all t rends were statistically s ignif icant (F r i edman test, P<0 .01 ) . 
Table 7.5 Perioperative changes in breath metabolite levels 
Post-op 
rreop 
24hrs 48hrs 72hrs 96hrs ISShrs 
Water [%] T f 5.47 [4.60,5.77] 6.50 [5.67,6.92] 5.70 [5.20,6.53] 5.51 [5.32,6.16] 5.99 [5.45,6.36] 5.67 [5.08,5.95] 0.008 
TA 5.41 [5.15,5.48] 6.30 [5.84,7.48] 5.81 [5.33,6.04] 6.04 [5.81,6.18] 5.58 [5.46,5.93] 5.25 [4.93,5.61] 0.053 
Acetone TT 358 [283,625] 391 [266,733] 191 [131,327] 204 [120,232] 235 [170,432] 599 [265,3054] 0.008 
TA 528 [417,609] 723[450,2370]+ 1190 [351,1307]t 641 [313,2065]t 606 [235,944] 295 [227,422] 0.604 
Ethanol TT 701 [246,1354] 366 [237,1113] 574 [245,1152] 709 [332,1114] 622 [249,1120] 585 [307,1471] 0.676 
TA 588 [302,863] 482 [179,1271] 781 [559,1108] 397 [196,742] 396 [196,777] 730 [436,1499] 0.796 
Propanol TT 40 [31,97] 52 [33,105] 66 [39,134] 32 [24,45] 92 [26,173] 90 [38,165] 0.494 
TA 42 [31,49] 100 [67,193] 72 [62,123] 80 [64,123]t 84 [64,118] 83 [38,194] 0.861 
Hydrogen cyanide TT 18 [7,25] 6 [3,11] 6 [3,10] 9 [3,17] 9 [6,21] 7 [4,14] 0.407 
TA 19 [8,23] 5 [4,9] 7 [4,15] 12 [8,18] 13 [4,18] 15 [4,22] 0.117 
Isoprene TT 130 [87,160] 163 [106,235] 139 [98,202] 156 [100,223] 176 [125,247] 176 [154,269] 0.014 
TA 150 [89,217] 145 [103,170] 156 [98,221] 128 [90,163] 114 [77,135]t 119 [97,136]t 0.350 
Acetic acid TT 108 [69,152] 121 [78.189] 146 [90,159] 90 [60,122] 99 [71,182] 110 [97,180] 0.167 
TA 109 [92,148] 76 [47,161] 87 [77,138] 103 [81,175] 98 [73,167] 92 [83,220] 0.861 
Ammonia TT 502 [282,1006] 535 [292,780] 403 [237,540] 382 [173,506] 502 [322,657] 411 [326,598] 0.032 
TA 681 [470,879] 394 [324,539] 373 [308,537] 325 [262,378] 382 [236,409] 359 [144,520] 0.942 
All concentrations are parts-per-billion with the exception of water which is given as a percentage. Values in square brackets are interquartile range. # Transthoracic [TT] 
and transabdominal [TA] resection, t Freidman test. + Mann-Whitney U test comparing of TA and TT groups P<0.05 
169 
12: 
I 
s 
8: 
4" 
^Transabdominal 
dlTransthoracic 
: X 
T 
I I I I I I 
Pre-op 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
Figure 7.2 Variation in exhaled water concentration 
7.4.3.2 Acetone 
Following transthoracic resection acetone levels initially fell significantly at 24 (f<0.011) 
and 48 hours (P<0.023), but later increased [Figure 7.3]. Although acetone levels appeared to 
transiently increase in the transabdominal group this trend was not statistically significant. 
Differences between surgical approaches were statistically significant at 24 (P<0.041), 48 
(f <0.001) and 72 hours (f<0.001) after surgery. 
7.4.3.3 Ethanol 
Exhaled ethanol concentrations did not change significantly following either transthoracic or 
transabdominal resections [Figure 7.4]. Comparison of transthoracic and transabdominal 
patients also showed no significant difference in exhaled ethanol concentrations at any of the 
perioperative time points. 
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Figure 7.5 Variation in exhaled propanol concentration 
7.4.3.4 Propanol 
There was no significant change in propanol levels after either transthoracic or 
transabdominal resections [Figure 7.5]. However, compared to transthoracic patients 
propanol levels were higher in the breath of transabdominal patients 72 hours after surgery 
(P=0.001). Exhaled propanol and acetone levels were not correlated (R^=0.095). 
7.4.3.5 Hydrogen cyanide 
A non-significant decline in the concentration of hydrogen cyanide was observed in the 
breath of both transthoracic and transabdominal patients 24 and 48 hours following surgery 
[Figure 7.6]. In the transthoracic group levels of this metabolite tended to remain low for the 
duration of the study whilst in the transabdominal group, concentrations returned to what 
were essentially preoperative levels by postoperative day seven. 
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7.4.3.6 Isoprene 
Whilst in the transabdominal group exhaled isoprene levels fell slightly after surgery, levels 
of this metabolite increased significantly in the breath of transthoracic patients [Figure 7.7]. 
In comparison to patients from the transabdominal group, isoprene levels were significantly 
elevated in the breath of transthoracic patients at postoperative time points 96 (P=0.023) and 
168 hours (P=0.024). 
7.4.3.7 Acetic acid 
Although there was a slight increase in the concentration of acetic acid within the breath of 
transthoracic patients during the first 48 hours after surgery, levels of this metabolite did not 
change significantly after either surgical approach [Figure 7.8]. Comparison of transthoracic 
and transabdominal patients also showed no significant difference in exhaled acetic acid 
concentrations at any of the perioperative time points. 
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Figure 7.9 Variation in exhaled ammonia concentration 
7.4.3.8 Ammonia 
Ammonia levels were observed to fall significantly at 48 (f=0.041) and 72 hours (f=0.008) 
after transthoracic resection [Figure 7.9]. Despite a similar trend being observed in the 
transabdominal group, this proved not to be statistically significant. Breath ammonia did not 
correlate with urea (R^=0.04) or creatinine (R^=0.08). 
7.4.3.9 The influence ofpostoperative pneumonia on breath metabolite levels 
The breath samples of those patients who developed postoperative pneumonia were 
compared to patients without respiratory complications. The concentrations of water, ethanol, 
propanol, isoprene, acetic acid and ammonia were not significantly influenced by 
postoperative pneumonia. However, on postoperative day three acetone levels were 
significantly reduced in the breath of patients who developed pneumonia (276 vs. 168, 
P=0.038). Correlations between breath acetone and markers of infection including white 
blood cell count, neutrophil count and C-reactive protein were not deemed significant 
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(R <0.021). The concentration of hydrogen cyanide tended to be lower in the breath of 
patients who developed serious postoperative respiratory complications at all perioperative 
time points, although this relationship was only significant 72 hours after surgery (13 vs. 
4ppb, P=0.008). No correlation was observed between hydrogen cyanide and the markers of 
infection; white blood cell count, neutrophil count and C-reactive protein (R^<0.123). 
7.4.4 Anaesthetic gases 
A review of count rate data recorded during MIM analysis provided evidence of high levels 
of anaesthetic gases within the breath of patients following surgery. In particular, patients 
anaesthetised with the volatile anaesthetic gases isoflurane and desflurane exhibited a marked 
increase in the intensity of the product ion at m/z 117, detected in breath collected shortly 
after surgery and analysed using the precursor [Figure 7.10]. For those patients 
receiving isoflurane an additional product ion at m/z 153 (HsO^) was also observed [Figure 
7.11]. hi patients anaesthetised with isoflurane the product ions m/z 117 and 153 showed a 
strong correlation (R^=0.914) [Figure 7.12]. Other potential anaesthetic gas markers were 
noted at m/z 49 and 67 [Figure 7.13 and 7.14]. 
100001 
I 100i 
* t 4 
ISevoflurane 
llsoflurane 
I Desflurane 
1 1 1 1 1 1 1 1 
Pre-op 2hrs 6hrs 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
Figure 7.10 Level of m/z 117 (counts s"^ ) analysed using the precursor ion 
1 7 6 
100.0-
B 
i 
1.0-
1.0E-12i 
m- lll'li'lll 
ISevoflurane 
llsoflurane 
lOesflurane 
Pre-op 2hrs 6hrs 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
Figure 7.11 Level of m/z 153 (counts s"') analysed using the HjO^ precursor ion 
1000-
800-
N 600-
N 
E 4 0 0 -
200-
oi 
0 
0 
0 ® - ' ' ' 
QS 
(9 Linear = 0.914 
% h° 
5 0 1 0 0 1 5 0 2 0 0 2 5 0 
mz 153 
Figure 7.12 Correlation between m/z 117 and 153 analysed using the H3O* 
precursor ion 
177 
lOOOOi 
<1 
9 _ 
N 1001 
1l 
a ^ # 
Sevoflurane 
Isoflurane 
Desflurane 
'V * I 
IJ J i .i' s i Pre-op 2hrs 6hrs 24hrs 48hrs 72hrs 96hrs 168hrs Post-op 
Figure 7.13 Level of m/z 49 (counts s ') analysed using the precursor ion 
1007 ! 
G 
I 
1.E-12^ 
Sevoflurane 
Isoflurane 
Desflurane 
Pre-op 2hrs 6hrs 24hrs 48hrs 72hrs 96hrs 168hrs 
Post-op 
Figure 7.14 Level of m/z 67 (counts s"') analysed using the precursor ion 
178 
7.5 Discussion 
Metabolic and inflammatory disturbances that are associated with major surgery are 
predicted to induce characteristic changes in the molecular profile of exhaled breath. For this 
reason breath analysis has been proposed as a novel non-invasive approach to the early 
detection of pathological processes during the perioperative period. During the current study 
SIFT-MS was used to investigate the gas-phase metabolic response to major upper 
gastrointestinal surgery. The principal findings were: (i) major surgery is responsible for 
significant changes in the levels of several prominent breath metabolites associated with 
(patho)physiological processes within the body, (ii) the extent of surgical trauma and the 
development of pneumonia are both associated with specific changes in breath metabolite 
levels and (iii) breath metabolites correlated weakly with a number of routinely used clinical 
parameters. 
Patients recruited to the current study were representative of normal populations undergoing 
oesophagogastric cancer resection (refer to Chapters 2 and 3). In accordance with the 
findings of previous studies, respiratory complications were identified as the most common 
cause of postoperative morbidity in patients undergoing transthoracic resection. The rate of 
pneumonia in patients undergoing transthoracic resection was 36%, which is equivalent to 
previous reports. 
The results of routine blood tests performed in all patients during the perioperative period 
provide confirmation of the metabolic and inflammatory response to surgery. Leukocytosis is 
a common feature of the early postoperative period, reflecting the mobilisation of white 
blood cells to support tissue repair and a normal response to infective sequelae [80,420-421]. 
Furthermore, inflammatory and oxidative stress induced by the accumulation of neutrophils 
within the lungs is recognised to be a key characteristic of the pathogenesis of lung injury 
after oesophagectomy [421]. Depletion of serum albumin following major surgery has been 
linked to higher rates of complications and early mortality [422-423]. Possible causes of 
postoperative hypoalbuminaemia include: continued protein depletion, protein 
reprioritisation, hepatic dysfunction, capillary leakage and haemodilution [80, 423-424]. The 
finding of reduced haemoglobin following both transthoracic and transabdominal procedures 
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is most likely attributed to intraoperative blood loss (typically <500ml) and perioperative 
haemodilution. Whilst raised serum creatinine is often associated with renal dysfimction, a 
significant fall in the level of this metabolite was observed in the current study, possibly 
resulting from perioperative fluid loading [425]. 
Postoperative catabolism is common after major surgery and in cancer patients often occurs 
on a background of preoperative cachexia. Depletion of hepatic glycogen stores and initiation 
of lipolysis, which occurs in response to surgical stress and perioperative starvation, promote 
the formation of ketone bodies, including acetone [172-173]. Also, as suggested by Pabst et 
al., a rise in both endogenous and exogenous catecholamine levels during the perioperative 
period may trigger an increase in lipolysis and acetone production [161]. Whilst not 
statistically significant, postoperative acetone levels were increased in the breath of patients 
who had undergone transabdominal resection. As those patients within the transabdominal 
group are kept nil by mouth and without supplementary nutrition typically until the second or 
third postoperative day, starvation is the most likely cause of the observed increase in breath 
acetone. In comparison acetone levels fell significantly by the second postoperative day in 
patients who had undergone transthoracic resection. Although all patients within the 
transthoracic group remained nil by mouth for a minimum of five days after surgery, the 
majority (19/25) did receive supplementary nutrition during the early postoperative period 
either parenterally or via feeding jejunostomy. The observed fall in acetone in those patients 
receiving nutritional support therefore most likely reflects the inhibition of both lipolysis and 
ketogenesis. This also explains why acetone levels were found to be significantly lower in 
those patients who developed pneumonia, the majority of whom received supplementary 
nutrition. Importantly in those patients who did not receive supplementary nutrition, a normal 
acetone response to starvation was preserved. Based on these findings breath analysis may 
therefore have a future role in monitoring nutritional status in patients during the 
perioperative period. 
Propanol is generated within the body through the reduction of acetone [184]. Despite this 
association only a very weak correlation has been reported, both in current and previous 
studies, between acetone and propanol. Moreover changes in propanol levels measured in the 
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breath of patients during the postoperative period did not accurately reflect concurrent 
changes in breath acetone. In patients from both surgical groups propanol appeared to 
increase after surgery, although this relationship did not reach statistical significance. At least 
in the transabdominal group, the increase in propanol observed during the postoperative 
period, may partly be explained by ketogensis secondary to starvation [183-185]. An 
alternative explanation may however derive 6om the fact that propanol is also a common 
constituent of cleaning products used within the clinical setting, including antiseptic alcohol 
hand gels. A previous study investigating ambient room air levels of selected trace gases in 
different hospital environments, found high levels of propanol (greater than typically found 
within exhaled breath) in the hospital ward where patients resided during the postoperative 
period (refer to Chapter 4). Accordingly a rise in exhaled propanol following surgery may be 
a consequence of environmental exposure. 
Previous studies have associated exhaled isoprene with oxidative stress, inflammation and 
impaired cholesterol metabolism in patients with ARDS [157, 159, 203]. Li the current study 
higher levels of isoprene were recorded in the breath of transthoracic patients shortly after 
surgery and stayed elevated for the remainder of the period of investigation. The only other 
study to have examined exhaled isoprene levels in the perioperative setting also reported a 
significant increase in this metabolite shortly after the start of cardiac surgery [161]. Whilst 
the authors postulated that the accumulation of neutrophils within the myocardium may have 
contributed to this observation, the concurrent finding of a positive correlation between 
exhaled isoprene and cardiac output offered, as they suggested, a more probable explanation. 
Isoprene was however found not to be significantly correlated with any of the cardiac 
parameters routinely recorded during the current study. It is possible therefore that raised 
isoprene levels that were observed following transthoracic oesophagectomy may reflect the 
influence of surgical stress and lung injury that is known to be associated with this surgery 
[157,161]. Whilst the precise mechanisms mediating this effect remain unknown an increase 
in cholesterol biosynthesis secondary to oxidative and inflammatory damage is one 
hypothesis. 
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Ammonia is a common breath metabolite that is linked to protein deamination and urea 
hydrolysis by bacteria within the gastrointestinal tract [206-208], In the absence of 
hepatocellular damage the majority of ammonia is converted to urea by the liver. In the 
current study patients showed a decrease in exhaled ammonia concentration following both 
transthoracic and transabdominal surgery. This finding may be explained by a disruption of 
gastrointestinal ammonia metabolism, specific causes of which may include either the 
restriction of protein substrate or the routine use of antibiotic therapy in all patients during 
the perioperative period [207, 426]. Substrate restriction would not however explain the 
significant fall in exhaled ammonia that was observed in the majority of transthoracic 
patients who received enteral nutrition, which typically contained 55.5 g/L of protein. 
Alternatively, the observed decrease in breath ammonia might be explained by the increased 
conversion of ammonia to glutamine, which occurs mainly in skeletal muscle [207]. 
Glutamine that is produced in this way may subsequently be used in de novo protein 
synthesis. In contrast to the findings of previous studies [212-213] ammonia was found not to 
be correlated with serum urea and creatinine. 
Breath metabolites ethanol, hydrogen cyanide and acetic acid demonstrated no significant 
response to major surgery. Recent experiments that have analysed these metabolites within 
the mouth- and nose-exhaled breath and oral cavity of healthy volunteers identified that they 
were each largely generated within the mouth, with minimal systemic contribution [179, 
206]. Accordingly their potential role as biomarkers of systemic disease remains uncertain. 
The high levels of ethanol that were found in the ward environment (refer to Chapter 4) could 
also explain the lack of association between this compound and clinical status. Despite not 
showing a significant relationship with surgical stress, hydrogen cyanide was observed, on 
postoperative day three, to be significantly lower in the breath of patients who developed 
respiratory complications. Because of the relatively low level of hydrogen cyanide within the 
breath (typically ~10ppb), that is close to the detection limit of the current SIFT-MS 
instrument, this finding must be interpreted with due caution. Notwithstanding, this result 
appears to support the previous finding of lower hydrogen cyanide in the breath of patients 
with community-acquired pneumonia (refer to Chapter 6). In those patients who developed 
postoperative pneumonia increased consumption of thiocyanate secondary to inflammatory 
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and oxidative stress may prevent the de novo synthesis of hydrogen cyanide. Bacterial 
production of hydrogen cyanide may also have been disrupted by the routine use of antibiotic 
therapy in these patient populations. 
In both patients who underwent transthoracic and transabdominal procedures the 
concentration of exhaled water vapour was initially increased following surgery, decreasing 
thereafter to preoperative levels. An increase in the water content of exhaled breath following 
surgery could reflect a concurrent rise in core temperature that is associated with both the 
hypermetabolic and systemic inflammatory response to surgical trauma [421]. An alternative, 
explanation for the observed trend in exhaled water levels after surgery concerns the 
influence of the volatile anaesthetic gases that are used for the induction and maintenance of 
intraoperative anaesthesia [427]. Experimental evidence has demonstrated that partially 
associates with anaesthetic gases, M, to produce a transient ion HsO^M, which then reacts 
rapidly with H2O molecules to produce H3O H2O at m/z 37. In effect, the anaesthetic gas 
catalyses the production of HgO^HzO. Since the water vapour level is calculated from the 
distribution of the hydrated ions then this anomalous level of m/z 37 gives an abnormally 
high water level. 
The chosen methodology of breath sampling suffered from some limitations, including the 
reliance on off-Kne analysis. Whilst desired, the opportunity for on-line sampling remains 
limited within the perioperative and critical care setting, primarily as a result of the severity 
of patients medical condition, patient immobility, issues of infection control and the limited 
portability of current breath analysis instruments. The possible negative implications of off-
hne sampling have been discussed in previous chapters, but principally relate to sample 
decay and contamination. To minimise these effects off-line samples collected during the 
current study were analysed within half an hour of collection. 
Due to the small number of patients included in this study the strength of conclusions are 
hmited, especially those drawn from multiple statistical comparisons. Despite recruitment of 
all eligible patients during the study period sample size remained low. The main reason for 
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low subject accrual was the relative infrequency of oesophagogastric resections, even in 
regional centres like the one in which the current study was conducted. 
7.6 Conclusion 
Targeted analysis of selected volatile metabolites within the breath of patients undergoing 
major upper gastrointestinal surgery was performed. Results give evidence that the level of 
several prominent metabolites related to aspects of energy metabolism, nutrition and tissue 
injury are significantly changed in response to surgery. Moreover, correlation between the 
levels of some exhaled metabolites and the severity of surgical stress and 
(patho)physiological processes provides an indication of the potential of breath testing within 
the perioperative setting. 
184 
8. G L O B A L M E T A B O L I C SIGNATURES OF SURGICAL STRESS I N THE FLUID-
PHASE F O L L O W I N G OESOPHAGECTOMY 
8.1 Objectives 
The objective of this study was to employ a NMR-based metabonomics approach to 
distinguish serum and urine metabolic markers of surgical stress following oesophagectomy. 
Secondary objectives were; (i) to determine whether changes in fluid-phase metabolite 
concentrations during the postoperative period could reflect respiratory complications, (ii) to 
assess how changes in metabolite levels detected by 'H NMR relate to established clinical 
parameters measured routinely within the perioperative setting and (iii) where possible, to 
correlate serum and breath metabolite levels. 
8.2 Introduction 
In addition to those experiments examining biomarkers of surgical stress in exhaled breath, 
serum and urine samples were collected from patients undergoing oesophagectomy, for the 
purpose of fluid-phase metabolic profiling. At the current time several metabolites are 
akeady routinely measured within the critical care and perioperative setting, including: CO2, 
lactate, glucose and creatinine. Whilst providing useful information regarding a range of 
(patho)physiological processes these metabolites may not fully represent the complexity of 
the underlying immunoinflammatory response to surgical trauma and critical illness. For this 
reason further insight may be gained through the adoption of holistic metabolic phenotyping. 
Metabolic profiling has already shown considerable potential as a diagnostic tool in a number 
of disorders characterised predominantly by inflammatory processes, including: sepsis, the 
systemic inflammatory response syndrome, multiple organ dysfunction syndrome and 
ischaemia reperfusion injury [232, 428-430]. Whether the findings of these studies are 
apphcable to other forms of injury, such as that which is associated with major surgery, 
remains to be determined. Furthermore, metabolic signatures of postoperative complications 
involving specific organs remain unknown. 
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8.3 Methods 
Local ethics committee approval was obtained for the current study and all patients provided 
informed written consent prior to enrolment. (A copy of the letters confirming favourable 
ethical and local Research and Development Department approval is provided as 
supplementary material in Appendix IV.) 
8.3.1 Patients and sample collection 
Samples that were collected from ten subjects (5 male, median age 61.3 years) undergoing 
transthoracic oesophagectomy form the basis of the current study. Serum and urine samples 
were collected throughout the perioperative period. Collection times were: preoperative 
(immediately prior to skin incision), at the end of OLV (immediately prior to expansion of 
the collapsed lung) and 2, 12, 24, 48, 72 and 96 hours after surgery. Approximately 8-10 mL 
of arterial blood was drawn directly from a radial arterial catheter into an untreated (red-
topped) Vacutainer® tube. Urine samples were drained from an indwelling urinary catheter 
using a sample port proximal to the catheter bag. After allowing 15 minutes for the blood to 
clot, serum and urine samples were centriftiged at 3000 rcf for 15 minutes. A 500 |iL aliquot 
of each sample was stored at -80°C until NMR analysis. 
8.3.2 Sample preparation 
Prior to sample preparation all solvents were checked by 'H NMR and the recorded spectra 
were retained for future reference. 
8.3.2.1 Serum 
After being allowed to defrost at room temperature for no longer than 20 minutes a 200 jiL 
aliquot of serum was diluted in 400 |iL saline buffer solution (0.9% solution of NaCl in 10% 
D20:90% H2O) and the resultant mixture was centriftiged at 13000 rpm for five minutes. A 
550 |iL aliquot of the resulting supernatant was pipetted into a 5 mm NMR tube and frozen at 
-40°C until NMR analysis. 
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8.3.2.2 Urine 
After being allowed to defrost at room temperature for no longer than 20 minutes a 400 i^L 
aliquot of urine was added to 200 (iL phosphate buffer solution (0.2M Na2HP04, 0.043M 
NaH2P04, ImM TSP, 3mM NaNs, in 8:2, H20:D20, pH 7.4) and the resultant mixture was 
centrifuged at 13000 rpm for 5 minutes. A 550 \iL aliquot of the resulting supernatant was 
pipetted into a 5 mm NMR tube and frozen at -40°C until NMR analysis. 
8.3.3 N M R analysis 
'H NMR spectra of serum and urine were acquired on a Bruker DRX600 spectrometer 
(Bruker Biospin, Germany) operating at 600.29-MHz NMR frequency and 300 K. 
Samples were automatically inserted into a 5 mm TXI probe and gradient shimming was 
performed prior to the acquisition of each spectrum. 
8.3.4 Statistical analysis 
Raw spectra were phased, baseline corrected, calibrated to the alpha-glucose doublet 
resonance (5H = 5.233ppm) and imported into MATLAB (Student Version, 2007, The 
MathsWorks, USA). Isolated spectral regions were defined through visual inspection and 
their peak areas were determined. Statistical analysis was performed using the SPSS 17.0 
software package (SPSS Inc., Chicago, USA). Group medians were compared by Friedman 
repeated measures analysis. All other pair-wise comparisons of independent samples were 
performed using the Mann-Whitney U test. Median fold change (mfc) was determined as the 
median intensity of a spectral resonance divided by the median preoperative intensity of the 
same resonance. Simple linear regression was used to determine the correlation between 
continuous covariates. The level of statistical significance was assigned to f-values <0.05. 
8.3.4.1 Multivariate pattern recognition analysis 
Full resolution spectra were used as independent variables (X) and perioperative time point 
was considered as the response variable (Y). After removal of the regions containing the 
residual water signal (4.66-5.OOppm) and the extremes of the spectrum (<0.80 and >8.00 
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ppm) this produced a data table of 21,906 spectral variables. Principal component analysis 
(PCA) was conducted using SIMCA 11.5 (Umetrics, Sweden) in which class variables were 
allocated according to perioperative time point. Each sample was centred to a mean of zero 
prior to analysis. 
8.4 Results 
Details of patient characteristics and postoperative complications are presented in tables 8.1 
and 8.2 respectively. There were five cases of postoperative pneumonia meeting the criteria 
outline in chapter 4.6, two of which met the criteria for ARDS/ALI [120]. 
8.4.1 Routine blood parameters 
The results of routine blood tests performed on patients during the perioperative period are 
presented in figure 8.1. Levels of creatinine, albumin and haemoglobin fell significantly after 
surgery (P<0.01). In comparison, white blood cell and neutrophil counts rose significantly 
immediately following surgery (P<0.01). Levels of urea did not vary significantly during the 
perioperative period. 
Table 8.1 Patient characteristics Table 8.2 Postoperative complications 
Oesophagectomy (n=10) Range Complication (n=10) 
Demographics Mortality 1 
Gender (M:F) 5:5 Surgical 
Age (years)* 61.3 [48-78] Anastomotic leak 0 
BMI 27.8 [18.7-34.9] Abdominal abscess 1 
Neoadjuvant therapy 6 Haemorrhage 0 
Significant comorbidity 4 Chyle leak 0 
ASA grade 2 5 RLN palsyt 1 
ASA grade 3 5 Wound infection 0 
O-POSSUM (%) 9.2 [2.7-21.2] Unplanned return to theatre 1 
Operative details Respiratory 
2-stage oesophagectomy 6 Pleural effusion 0 
3-stage oesophagectomyt 4 Pneumothorax 1 
Duration of surgery (mins) 642 [540-735] Pulmonary embolism 0 
Duration of OLV (mins) 198 [75-260] ARDS/ALI 2 
Postoperative details Pneumonia* 5 
ITU stay (days) 9 [3-26] Cardiac 
Hospital stay (days) 
i 
18 [12-32] MI/ACS 
Atrial fibrillation 
1 
1 
All continuous variables are presented as medians and their 
associated range. tThoracoscopic 3-stage oesophagectomy was 
performed in two patients. BMI, body mass index. ASA, American 
Society of Anesthesiologists physical status classification. O-
POSSUIVl, Physiological and Operative Severity Score for the 
enumeration of Mortality and morbidity developed specifically for 
use in oesophagogastric surgery. OLV, one lung ventilation. ICU, 
intensive care unit. 
RLN, recurrent laryngeal nerve palsy. ARDS/ALI, acute respiratory 
distress syndrome/acute lung injury. MI/ACS, myocardial 
infarction/acute coronary syndrome, t i n this patient RLN palsy was 
temporary. ^Included two patients with ARDS/ALI. 
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F i g u r e 8 . 1 R e s u l t s o f r o u t i n e b l o o d t e s t s 
W i t h t h e e x c e p t i o n o f u r e a a l l t r e n d s w e r e s t a t i s t i c a l l y s i g n i f i c a n t ( F r i e d m a n t e s t , P < 0 . 0 1 ) . 
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8.4.2 H NMR analysis 
8.4.2.1 Multivariate analysis of patient serum 
PCA was performed on acquired data sets in order to summarise global metabolic changes 
that occurred during the perioperative period. The results of PCA showed evidence of 
separation of the pre- and post-operative metabohc profiles of oesophagectomy patients 
[Figures 8.2 and 8.3]. For a PCA model constructed from samples collected preoperatively 
and at 2, 24 and 168 hours postoperatively, the fraction of X-variation modelled in the first 
three components was 82%. The largest differences in the global metabolic phenotype were 
seen during the early postoperative period. With the exception of patients who developed 
significant complications the metabolic phenotype had recovered within seven days of 
surgery. 
3E+07 
2E+07 
1E+07 
OE+00: 
-1E+07 
-2E+07 
a 
—' 
/ a • 
• 
* * 
• • • \ 
I _ a • * y 
• * / 
; a ^ a y 
• / 
• Pre-op 
• 2hrs post-op 
• 24hrs post-op 
• 168hrs post-op 
- 3 . 0 0 0 7 - 2 . 0 0 0 7 - 1 . 0 0 0 7 O .OOOO 1 . 0 0 0 7 2 . 0 0 0 7 3 . 0 0 0 7 
t[1] 
Type: PCA-X Observations (N)=40, Variables (K)=21906 (X=21906, Y=0) 
A R2X R2X(cum) Eigenvalues Q2 Limit Q2(cum) Sig. Iterations 
1 0.433 0.433 17.3 0 .381 0.025 0 .381 R1 22 
2 0.247 0.679 9.86 0.240 0.0257 0.530 R1 19 
3 0.137 0.816 5.48 0.363 0.0264 0 .701 R1 14 
Figure 8.2 Results of principal component analysis of 'H NMR data sets 
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Figure 8.3 Principal component loading for p i and p2 
Principal component loading for p i and p2 are the weights that combine the variable to form 
PC-scores t l and t2 respectively. The scores tl and t2 are mainly a weighted combination of 
those variables that have a large positive or negative loading in die corresponding pi and p2. 
Labelled metabolites are as follows; (a) volplex (intravenous colloid), (b) alpha-D-glucose, (c) 
beta-D-glucose, (d) lactate, (e) succinate, (f) pyruvate, (g) alanine, (h) P-hydroxybutyrate. 
8.4.2.2 Targeted analysis of patient serum 
Metabolite assignment was made using Chenomx NMR Suite Version 6.0 (Chenomx, 
Canada), the Madison Metabolomics Consortium Database (available at; http://mmcd. 
nmrfam.wisc.edu) [431] and the Human Metabolome Database (available at: 
http://www.hmdb.ca) [432-433]. Further confirmation of metabolite assignment was sought 
through two-dimensional NMR experiments including correlation spectroscopy (COSY) and 
J-resolved spectroscopy (J-res). (An assigned NMR spectrum of serum collected prior to 
oesophagectomy and an example of a COSY spectrum is presented as supplementary 
material in Appendix V.) 
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Supported by the findings of multivariate analysis, visual inspection of the median spectra of 
serum collected during the perioperative period indicated systematic differences in several 
metabolites in response to oesophagectomy. The chemical shifts and intensities of those 
metaboHtes found to change significantly in response to oesophagectomy are reported in 
table 8.3. Important metabolic determinants of the response to surgery were: pyruvate (mfc 
2.34 at 2hrs PO) [Figure 8.4], lactate (1.67 at End OLV) [Figure 8.5], glycerol (2.12 at 2hrs 
PO), creatine (1.98 at 2hrs PO), acetone (0.55 at 48hrs PO), alanine (0.64 at 72hrs PO), 
phenylalanine (4.54 at 24hrs PO) and mannitol (3.87 at 24hrs PO). Three currently 
unassigned metabolites that are potentially markers of drugs or drug metabolites were also 
elevated following surgery. 
8.4.2.2.1 The influence of postoperative pneumonia 
Serum metabolite levels of patients who developed postoperative pneumonia (n=5) were 
compared to those of patients without respiratory complications. Patients who developed 
pneumonia had lower levels of serum choline (70x10^ vs. 45x10^ intensity, P=0.016) and 
acetone (24x10^ vs. 14x10^, f=0.032) at the end of OLV. In these patients a diagnosis of 
pneumonia was made either on postoperative day two (n=l), three (n=2) or four (n=2). Due 
to this variability serum metabolites detected within samples collected both on the day of 
pneumonia diagnosis and on the preceding day were compared to those of other samples 
collected from non-pneumonia patients on postoperative days two and three. Analysis 
revealed no significant difference in metabolite levels between the two subgroups. 
Significantly lower Hb (10.3 vs. 7.9 g/dL, ^=0.029) and pH (7.36 vs. 7.41, P=0.029) were 
however recorded in patients with pneumonia on the day of diagnosis. 
8.4.2.2.2 Correlation of serum metabolites with established clinical parameters and exhaled 
biomarkers 
Pyruvate's central position within energy metabolism pathways was supported by its weak 
correlation with lactate (R^=0.571, f<0.001) and alanine (R^=0.359, P<0.001). Serum and 
breath acetone were also positively correlated (R^=0.576, P<0.001). 
Table 8.3 Perioperative changes in serum metabolite levels 
Metabolite <y'H 
Intensity' (10^) 
M' (ppm)° 
Pre-op End-OLV 2hrs post-op 12hrs post-op 24hrs post-op 48hrs post-op 72hrs post-op 96hrs post-op 
Unassigned A 8.06 s 1 [1-3] 2 [1-3] 3 [2-5] 4 [3-5] 3 [2-6] 2 [1-2] 1 [1-2] 1 [0-1] 0.003 
Phenyalanine 7.42 t 10 [8-12] 12 [10-15] 17 [15-19] 20 [17-21] 20 [19-21] 17 [17-21] 17 [13-24] 23 [18-27] <0.001 
Unassigned B 7.15 d 4 [2-5] 5 [4-8] 10 [7-15] 13 [7-23] 18 [14-20] 17 [15-19] 12 [8-15] 16 [12-18] <0.001 
Mannose 5.18 s 19 [19-19] 20 [18-22] 23 [23-24] 25 [23-27] 26 [24-28] 26 [24-28] 26 [25-30] 26 [24-31] <0.001 
Mannitol 3.80 s 28 [26-34] 36 [32-45] 58 [42-93] 88 [38-177] 108 [88-136] 101 [87-216] 89 [39-107] 100 [91-148] <0.001 
Glycerol 3.64 d 76 [44-110] 99 [91-122] 161[125-169] 144 [113-163] 137 [125-157] 120[99-134] 97 [79-139] 112 [98-121] 0.007 
myo-lnosotoi 3.28 t 6 [5-7] 7 [7-8] 8 [8-11] 11 [8-13] 8 [8-9] 6 [5-6] 6[5-6] 5[5-6] <0.001 
Choline 3.22 s 107 [85-115] 100 [94-116] 124 [106-144] 140 [131-153] 147 [129-165] 124 [103-129] 98 [88-106] 88 [78-107] <0.001 
Creatine 3.03 s 23 [20-26] 28 [25-34] 42 [30-60] 51 [37-59] 51 [38-61] 36 [26-56] 25 [21-47] 29 [23-35] <0.001 
Pyruvate 2.37 s 31 [23-38] 58 [39-91] 72 [62-95] 60 [52-78] 59 [43-73] 41 [38-49] 35 [28-38] 36 [27-39] <0.001 
Acetone 2.23 s 55 [34-75] 76 [51-96] 89 [63-113] 55 [51-69] 42 [34-52] 30 [23-33] 27 [17-34] 25 [18-40] <0.001 
Unassigned C 2.16 s 17 [9-23] 19 [15-23] 28 [25-35] 33 [22-43] 33 [29-37] 30 [27-34] 21 [17-24] 22 [19-27] <0.001 
Alanine 1.47 d 185 [162-194] 201 [157-270] 195 [159-274] 181 [170-241] 181 [139-229] 133 [121-162] 118 [107-159] 150 [116-181] 0.001 
Lactate 1.33 d 683 [624-742] 1138 [859-1786] 1191 [869-1412] 927 [858-1080] 794 [592-864] 652 [557-706] 604 [562-735] 697 [534-967] <0.001 
Propylene glycol 1.12 d 7 [6-8] 9 [8-11] 11 [10-12] 9[8-10] 11 [7-11] 9 [7-10] 9 [7-12] 12 [10-16] 0.014 
Isobutyrate 1.07 d 7 [6-9] 9 [8-10] 12 [8-16] 9[8-10] 10 [9-11] 9 [8-10] 9 [6-11] 9 [8-14] 0.001 
° Chemical shifts are reported with reference to the alpha-glucose doublet resonance at 5.233 ppm. Multiplicity.' Data are medians and interquartile range. Freidman test. 
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Figure 8.5 Time course of serum lactate (1.33 ppm) 
8.4.2.3 Targeted analysis of patient urine 
Visual inspection of the median spectra of urine collected during tlie perioperative period 
revealed many broad resonances. Comparison of the NMR spectra of urine and several 
xenobiotic agents routinely administered to patients during the perioperative period showed 
that Volplex® (succinylated gelatine), a colloidal plasma substitute, was the main source of 
these additional resonances [Figure 8.6]. (An assigned 'H NMR spectrum of urine collected 
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prior to oesophagectomy is presented as supplementary material in Appendix V.) Whilst a 
limited number of the spectral resonances from small molecular weight metabolites could be 
clearly resolved, the majority were obscured by the influence of Volplex®. A restricted 
analysis of the data did reveal several metabolites whose concentrations changed 
significantly following oesophagectomy. The chemical shifts and intensities of these 
metabolites are reported in table 8.4. As well as several unassigned metabolites, both alpha-
D-glucose (27.3, 24hrs PO) and creatinine (2.15, 24hrs PO) increased during the 
postoperative period [Figure 8.7 and 8.8]. 
6 4 2 
Chemical shift (ppm) 
Figure 8.6 Example of 'H NMR spectrum of Voplex® 
Median 'H NMR spectra of: (a) urine collected at tlie end of OLV and (b) 
Volplex®, a colloid that is given intravenously as a plasma substitute to all 
patients during tlie early perioperative period. 
Table 8.4 Perioperative changes in urine metabolite levels 
Intensity' ( l o ' ) 
nneiaooiiie (ppm)' IVI Pre-op End-OLV 2hrs post-op 12hrs post-op 24hrs post-op 48hrs post-op 72hrs post-op 96hrs post-op 
r 
Unknown D 6.65 q 0 [0-3] 7 [5-8] 5 [2-6] 11 [5-21] 4 [1-8] 1 [0-1] 0 [0-0] 0[0-1] <0.001 
Unknown E 5.11 d 1 [0-1] 1 [1-1] 4 [1-8] 3 [1-12] 17 [12-25] 17 [10-32] 16 [4-31] 17 [10-27] <0.001 
Alpha-D-Glucose 3.77 m 15 [11-30] 31 [21-39] 81 [63-195] 74 [45-242] 423 [149-508] 230 [162-443] 271 [108-457] 225 [169-308] <0.001 
Creatinine 3.04 s 44 [26-68] 30 [26-36] 54 [38-72] 72 [51-85] 95 [65-130] 95 [66-136] 86 [55-108] 71 [36-82] 0.03 
Unknown F 2.18 d 3 [2-6] 9 [6-12] 23 [18-45] 18 [13-39] 46 [27-73] 31 [24-35] 31 [12-35] 24 [20-47] <0.001 
Unknown G 1.17 q 11 [6-39] 16 [14-21] 69 [37-144] 211 [90-457] 103 [65-137] 48 [28-73] 31 [28-75] 61 [15-189] <0.001 
' Chemical shifts are reported with reference to the alpha-glucose doublet resonance at 5.233 ppm. Multiplicity.' Data are medians and interquartile range. Freidman test. 
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Figure 8.8 Time course of urine creatinine (3.04 ppm) 
8.5 Discussion 
In tlie previous chapter gas-phase metabolic profiling was used to detect perturbations in the 
levels of selected volatile metabolites within the breath of patients following major upper 
gastrointestinal surgery. Although breath testing represents a promising field of research, 
current technological limitations may mean that breath analysis cannot provide the most 
complete interpretation of global metabolic responses to (patho)physiological processes. 'H 
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NMR-based metabonomics, which allows unbiased analysis of a wide range of fluid-phase 
metabolites, may however serve as an alternative method for this purpose. 
Several recent studies adopting a metabonomics approach have investigated the global 
metabohc alterations associated with sepsis [428-429] and severe trauma [430]. These studies 
confirmed in principle that such methods can distinguish between the metabolic phenotypes 
of critically ill patients and healthy controls. Moreover, assigned metabolites that were 
influential in the systemic inflammatory response syndrome were related mainly to energy 
metabolism pathways and as such were consistent with existing descriptions of the metabolic 
response to critical illness. However, methods similar to those used by these previous studies 
have not been widely adopted in the context of surgical stress. Consequently, in the current 
study ' h NMR spectroscopy was used to investigate the global metabolic response to 
oesophagectomy, through the analysis of perioperative serum and urine samples. Results 
confirmed that the levels of several prominent metabolites were significantly altered 
following major surgical stress. 
Initial examination of the acquired NMR data sets using PCA, provided evidence that 
perioperative serum samples could be broadly separated based on their global metabolic 
phenotype. Examination of the loadings for the first two principal components identified that 
variability in the intensities of resonances assigned to lactate, succinate, glucose and pyruvate 
were principally responsible for observed differences between groups. Although 
contributing to the PCA model succinate and glucose levels were found not to change 
significantly in serum collected at different times during the perioperative period. Common 
to all these metabolites however is their relationship to cellular respiration and intracellular 
pathways of energy metabolism. 
Cellular respiration is the process whereby biochemical energy in the form of carbohydrates, 
Hpids and proteins is converted, via a series of catabolic reactions, to the universal energy 
carrier adenosine triphosphate (ATP). Under aerobic conditions cellular respiration can be 
divided into three main steps: (i) glycolysis, (ii) the tricarboxylic acid (TCA) cycle and (iii) 
oxidative phosphorylation [Figure 8.9]. Glycolysis is the central pathway for the conversion 
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Figure 8.9 Pathways of aerobic and anaerobic energy metabolism 
of glucose into free energy and occurs in the cell cytosol where one mole of glucose is 
oxidised in a 10 step process to two moles of ATP, two moles of NADH and two moles of 
pyruvate [434-435], Where there is an adequate supply of oxygen, pyruvate is converted to 
acetyl-CoA, which enters the TCA cycle, leading to the production of NADH that is itself 
oxidised to CO2 and 36 moles of ATP [434]. Alternatively, under anaerobic conditions 
200 
pyruvate is converted to lactate in a process that regenerates cofactors necessary for 
glycolysis [434]. 
Disruption of normal glucose metabolism in patients undergoing major surgery may 
therefore account for observed changes in key energy metabolites involved in these 
pathways. Blood lactate is already routinely measured within the clinical setting. Raised 
lactate is conventionally thought to indicate anaerobic metabolism and tissue hypoperfusion 
that may, in turn, be a consequence of either global (e.g. sepsis) or focal (e.g. bowel 
ischaemia) processes [435-436]. Non-hypoxic hyperlactatemia may also occur under specific 
circumstances including; (i) pyruvate dehydrogenase dysfunction, (ii) impairment of hepatic 
lactate clearance, (iii) accelerated aerobic glycolysis that exceeds the oxidative capacity of 
the mitochondria, and (iv) excessive proteolysis and conversion of amino acids to pyruvate 
[435-436], Analysis of patient serum by NMR confirmed that oesophagectomy was 
associated with an early rise in lactate and pyruvate levels, that occurred most likely in 
response to intraoperative episodes of intestinal, hepatic and pulmonary ischaemia [18, 143]. 
Administration of catecholamines throughout the perioperative period could also explain the 
observed increase in lactate production via a process of accelerated glycolysis. 
Alanine, which is one of the most abundant amino acids within the body, may undergo 
reversible transamination to pyruvate, thus influencing a number of metabolic pathways, 
including: glycolysis, gluconeogenesis, and the TCA cycle [429, 437] [Figure 8.9]. Using an 
NMR-based metabonomics approach Lin et al., reported finding higher levels of serum 
alanine in septic rats which the authors attributed to enhanced metabolism of glucose and 
pyruvate [429]. Whilst current results did show evidence of a small initial rise in serum 
alanine following oesophagectomy, the principal finding was of a delayed fall in levels of 
this metabolite, occurring on either the second or third postoperative day. Variation in 
alanine levels following surgery may therefore reflect its increased consumption via either 
hepatic gluconeogenesis [438], or possibly enhanced protein synthesis that is reported in 
patients following oesophagectomy [439]. In contrast to alanine, levels of serum 
phenylalanine increased following surgery. This result confirms the earlier report of Tashiro 
et al., who found elevated phenylalanine and tyrosine within the femoral-venous blood of 
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patients following oesophagectomy indicating, as the authors suggested, evidence of 
enhanced breakdown of skeletal muscle protein [87]. Variation observed in the levels of both 
alanine and phenylalanine may therefore indicate the existence of a dynamic balance between 
the processes of protein catabolism and protein synthesis in patients following 
oesophagectomy. 
Acetone, produced through the decarboxylation of excess ketone bodies, was initially 
elevated in the serum of patients following oesophagectomy, but subsequently declined to 
levels below those which were observed preoperatively. The early rise in acetone may 
indicate an increase in fatty acid metabolism in an attempt to meet energy demands. As 
suggested in the previous chapter, a fall in acetone levels after the second postoperative day 
could reflect the inhibition of lipolysis and ketogenesis secondary to the provision of 
supplementary nutrition that was provided to ahnost all patients during the postoperative 
period. Importantly, serum and breath acetone levels were found to be correlated, providing 
the first evidence of the comparability of SIFT-MS and 'H NMR profiling techniques. It is 
noted that the levels of other ketone bodies, acetoacetate and 3-hydroxybutyrate were not 
significantly changed in response to surgery. 
The finding that creatine, an important intermediate of intracellular metabolism [440-441], 
was increased within the serum of patients after oesophagectomy possibly indicates either a 
decrease in creatine clearance secondary to kidney dysfunction or, alternatively, increased 
utihsation of creatine phosphate to regenerate ATP [442-443]. Whilst often not considered 
chnically significant, the urine output of patients after oesophagectomy is commonly 
observed to decline during the early postoperative period, indicating a degree of renal 
dysfunction. Several studies have demonstrated creatine to exhibit cytoprotective effects 
towards oxidative agents [444-445] and to have anti-inflammatory activities against 
endothelial cells, including the inhibition of endothelial permeability, the expression of 
adhesion molecules and neutrophil adhesion [446]. Whether the observed increase in serum 
creatine levels after oesophagectomy confers similar cytoprotective effects remains 
unknown. 
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The increase in serum glycerol that was observed two hours after the completion of surgery 
(before supplementary nutrition was commenced), does provide tentative evidence of 
enhanced lipolysis during the early postoperative period, possibly in order to provide 
substrate for hepatic gluconeogenesis. The results of the current study also demonstrate 
increased levels of the metabolites myo-inositol, choline and isobutyrate. These metabolites 
are associated with a number of important functions within the body that are related to 
membrane integrity, neurotransmission and signal transduction. Isobutyrate, like other short 
chain fatty acids, is produced in the gastrointestinal tract by the action of bacteria [447], 
therefore intestinal ischemia and mechanical disruption of the bowel could be factors 
contributing to the observed rise in serum levels of this metabolite. 
The sugar alcohol mannitol is produced by many plants and microorganisms [448]. Although 
frequently used as a sweetener or stabilising agent in foods and pharmaceuticals, mannitol is 
non-cariogenic and has a low-glycaemic, energy and insulinaemic potential. As mannitol is 
not metaboUsed by the body, 75% of ingested mannitol is fermented by intestinal flora while 
the remaining 25%, that is absorbed, is excreted in the urine [449]. Raised mannitol levels 
that were found in the serum of patients after oesophagectomy most likely reflect either 
exogenous administration via supplementary nutrition or medications or, alternatively, as a 
result of increased intestinal permeability. 
NMR analysis of urine revealed hmited evidence of the metabolic response to major 
surgery, primarily due to the unanticipated influence of Volplex®, a plasma substitute 
routinely given intravenously to all patients. This finding highlights the inherent vulnerability 
of metabonomic techniques to exogenous factors, which as in the case of the current study 
may prove detrimental to the accurate interpretation of global profiling experiments. Analysis 
of urine samples collected from patients undergoing oesophagectomy did however provide 
evidence that the levels of glucose and creatinine increased significantly during the first 24 
hours after surgery. Fluid retention in combination with a fall in urine output that is 
commonly seen after major surgery may explain these findings. Four currently unassigned 
metabohtes, that are possibly markers of drugs or drug metabolites, were also found to be 
elevated in the urine of patients following surgery. 
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The small number of samples included in the current study limits the strength of the 
conclusions that can be drawn. As demonstrated by Herbert, the interpretation of the results 
of (NMR) experiments performed on small sample sizes can be misleading based on the 
underestimation of the breadth of confidence intervals [450]. 
8.6 Conclusion 
'H NMR-based metabonomics profiling has helped to provide deeper insight into the 
metabolic pathways altered under surgical stress. Initial multivariate analysis of acquired data 
sets was able to differentiate patient groups based on their global metabolic profiles at 
different times during the perioperative period. Assigned metabolites influential for surgical 
stress were mainly those with close links to energy metabolism pathways and as such were 
consistent with known responses to surgical trauma. The finding that NMR analysis of 
urine was significantly disrupted by specific xenobiotic agents given during the perioperative 
period, whilst limiting the conclusions of this study, does at least provide vital evidence 
which will support future investigations. These results indicate that 'H NMR-based 
metabonomics offers a promising approach to evaluate patient responses to major surgical 
trauma that may prove relevant for prognostic evaluation. 
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9. FINAL CONCLUSIONS 
Adequate primary resection of tumours following oncological principals remains the best 
therapy for oesophageal cancer. Access trauma related to oesophageal resection is however 
considerable and has a profound influence on patient outcome. This was confirmed by a 
meta-analysis of studies comparing the results of transthoracic and transhiatal 
oesophagectomy. Critically, this review established respiratory complications as the most 
common cause of postoperative morbidity following oesophagectomy and that these 
problems more often affected the recovery of patients undergoing transthoracic procedures. 
Conclusions drawn from this meta-analysis were regrettably weakened by poor reporting, 
low surgical quality and confounding exhibited by many studies. These factors were 
expected to have contributed to the wide variation observed between different studies. A 
subsequent audit of local outcomes revealed that whilst radical transthoracic oesophagectomy 
could be performed without operative mortality, respiratory complications, in particular 
pneumonia, remained the most common cause of postoperative morbidity. A multivariate 
logistic regression model based on this data set however failed to correctly predict new cases 
of postoperative pneumonia. 
Evidence discussed herein has indicated that oesophagectomy provides a prelude to the 
induction of a potent metabolic inflammatory response, signs of which are readily 
identifiable both systemically and locally within the lungs. As well as the general extent of 
surgical trauma, it has been proposed that single lung ventilation, which is a requirement of 
transthoracic oesophagectomy, may also have a significant role in promoting lung injury 
after this surgery. Whilst those who have previously investigated the metabolic inflammatory 
response to oesophagectomy have relied almost exclusively on characterisation of fluid-
phase cytokines and acute phase proteins, this thesis has sought to develop a novel approach 
through the application of gas- and fluid-phase metabolic profiling. 
The analysis of volatile metabolites within exhaled breath, although an attractive area of 
research, is subject to continued uncertainties and possible Hmitations. For this reason a 
considerable proportion of this thesis was given to the investigation of sources of 
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confounding that may affect the collection and analysis of breath samples within the clinical 
setting. 
For those breath metabolites investigated, initial experiments determined that SIFT-MS 
analysis was both reliable and repeatable. Although sampling methodology did appear to 
have a role in influencing the level of observed repeatability and variability, metabolite 
concentration and physiological variability remained the principal determinants of these 
parameters. Based on these finding there is still a degree of uncertainty as to the requirement 
for standardised measurement protocols for the analysis of the majority of volatile 
metabolites within the breath. This thesis does however highlight several areas where future 
developments are needed in order to increase confidence in breath analysis. These areas are 
discussed below. 
On-line sampling, whilst desirable, is not currently feasible within the clinical setting due to 
the size of mass spectrometry based breath analysers, as well as issues relating to patient 
access, health and safety and infection control. As such there remains a requirement for off-
hne sampling. In the experiments presented herein sample bags constructed from Nalophan® 
were used for the collection and short term storage of breath samples. Despite Nalophan® 
having been suggested as a suitable material for the construction of gas sample bags, it is 
evident that the effective storage time for selected breath metabolites is limited to only a few 
hours. In an attempt to minimise the possible adverse affects of off-line storage, all breath 
samples were analysed as soon after collection as possible, which in the majority of cases 
was within one hour. Other materials, including Tedar®, can also be used to construct breath 
sample bags. Whilst Tedar® bags are commercially available, their relative price in 
comparison to Nalophan® bags, which are constructed on-site, is such that in order for their 
use to become economical they must be reused. To facilitate the repeated use of Tedlar® 
bags, a rigorous cleaning process has to be adopted, that itself requires considerable time and 
cost. Ultimately, future efforts should be made to help make breath sampling devices smaller 
and more portable, thus allowing wider access to on-line sampling. 
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The influence of inspiratory room air remains a potential barrier to future studies 
investigating exhaled biomarkers within the clinical setting. Current results demonstrate high 
levels of certain trace gases in the ambient air of both a hospital ward and outpatient 
department, two environments in which breath samples are routinely collected. In particular, 
high levels of ethanol and propanol within these locations are tentatively attributed to 
hospital cleaning products and antiseptic hand gels. As there is currently no consensus as to 
the most appropriate method to account for the influence of ambient levels of volatile trace 
gases, it is essential that future studies determine the affect of inspiratory trace gas levels on 
the partition of endogenous volatile metabolites between the lungs and the expiratory-phase. 
Although breath is recognised to contain a mixture of as many as 500 different compounds, 
that are both of endogenous and exogenous origins [149], current investigations have 
primarily focused on the detection of a panel of seven volatile breath metabolites. The 
decision to investigate only these metabolites was based on a number of important factors, 
including: (i) the extent of the current SIFT-MS MIM mode kinetic database, (ii) their 
prominence within exhaled breath, (iii) existing knowledge of their endogenous origins, and 
(iv) their association with both normal and abnormal human physiology. It is likely that 
current studies, by favouring a targeted approach to breath analysis, have not been able to 
provide the most complete interpretation of global gas-phase metabolic responses to 
(patho)physiological processes. As such possible markers of the metabolic and inflammatory 
processes associated with major surgery and the development of postoperative complications 
were not assessed. Whilst it is possible to acquire a complete mass spectrum of an ionised 
gas samples via the SIFT-MS's 'full scan' mode, the accuracy of this approach is limited by 
tbe scarce production of product ions that is currently observed. Breath biomarkers that can 
not currently be assessed by SIFT-MS, but have been previously linked with surgical stress 
and lung injury, include: nitric oxide, pentane and ethane [161, 202-203, 351]. Future studies 
must therefore seek to exploit the full diagnostic potential of exhaled breath by targeting 
known biomarkers and by adopting a more holistic profiling strategy. To achieve this 
requires either advancement of SIFT-MS or the adoption of allied techniques including PTR-
MS and GC/MS. For the findings of future studies to have true scientific value there must 
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also be parallel efforts to greater understand the origins and possible physiological meaning 
of those trace gases that can be detected within the breath. 
The site of release of breath metabolites within the respiratory tract and its relation to the 
chosen sampling methodology is likely to contribute to observed variability. Several recent 
publications, comparing metabolite levels within the mouth- and nose-exhaled breath and in 
the oral cavity, contribute new evidence relevant to this hypothesis [179, 204, 206]. Based on 
the findings of these studies, certainly the recommendation that nose-breath analysis should 
be carried out to avoid oral contamination of breath samples, deserves fiirther consideration 
[179]. 
The analysis of breath samples collected from healthy controls, pre- and post-operative 
cancer patients and patients with community-acquired pneumonia was intended to provide a 
reference-guide for subsequent clinical studies in the perioperative setting; helping to 
deconvolve responses to surgery and postoperative pulmonary injury. Current studies 
confirm the findings of previous authors who reported wide variation in the levels of breath 
metabolites that were described by a typically log-normal distribution [167, 391-393]. 
Methodological as well as endogenous and exogenous factors all were deemed to contribute 
to the wide variability that was observed in breath analysis data. Because of this finding, 
major difficulties may arise when it is desired to draw clear distinction between different 
physiological or disease states. Notwithstanding, studies investigating the levels of 
metabohtes within the breath of pre- and post-operative cancer patients compared to controls 
identified significantly higher levels of acetone in patient groups, that was suggested to 
reflect cancer and post-surgical cachexia. Whilst other significant differences were also 
observed between these groups, the influence of inspiratory room air, varying intervals since 
last oral intake and disruption of the normal gastrointestinal flora may have had some part to 
play in these findings. Concurrent studies also identified lower levels of hydrogen cyanide 
and isoprene within the breath of patients with community-acquired pneumonia, two 
metabohtes that are linked with inflammation and oxidative stress within the lungs. 
208 
Critically, several of the most important findings of these preliminary investigations were 
also reflected in patients during the early postoperative period after oesophagectomy. In 
particular, patients who developed postoperative pneumonia were observed to have lower 
levels of hydrogen cyanide within their breath. Whilst there remains uncertainty as to the 
precise mechanisms responsible for the observed change in exhaled hydrogen cyanide levels 
in response to pneumonia, it was hypothesised that the recruitment of white blood cells to the 
lungs and a concurrent rise in oxidative stress may be an important factor. The influence of 
antibiotic therapy can not be ruled out either. Although isoprene levels did not change 
significantly in patients who developed postoperative pneumonia, its levels were elevated in 
the breath of patients after transthoracic oesophagectomy. This finding confirms the results 
of several previous authors who suggest isoprene levels within the breath are linked to 
increased oxidative stress [157, 161]. Also in accordance with previous studies, exhaled 
acetone levels appeared to correlate closely with nutritional status during the postoperative 
period. 
In addition to those experiments examining biomarkers of surgical stress and lung injury in 
exhaled breath, serum and urine samples collected from patients undergoing oesophagectomy 
were analysed by NMR. Strengths of this approach are its unbiased and quantitative 
assessment of the dynamic multiparametric metabolic changes of an entire living system in 
response to (patho)physiological stimuli [231]. These experiments have provided new insight 
into the global metabolic processes that are altered in response to major surgical stress. 
Assigned determinants of metabolic responses were for the most part known intermediates of 
prominent intracellular energy pathways. 
An important outcome of studies conducted during the perioperative period was the finding 
of a modest correlation between breath and serum acetone levels. This result provides the 
first evidence of the comparability of SIFT-MS and NMR profiling techniques. Moreover 
it offers support to the widely held belief that breath analysis can serve as a non-invasive 
method for the assessment of systemic metabolite levels. However, the generally poor 
correlation of breath and serum metabolites with routinely collected clinical covariates is a 
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finding that deserves further investigation, as it may have imphcations for the acceptance of 
future proposed biomarkers as indicators of (patho)physiological processes. 
Both gas- and fluid-phase studies have provided clear evidence of the potential influence of 
xenobiotic agents on the results of profiling experiments. Notable exogenous agents readily 
detectable within collected samples include; volatile anaesthetic gases, the plasma substitute 
Volplex® and maimitol. In the majority of patients who underwent oesophagectomy the 
routine provision of supplementary nutrition during the early postoperative period was also 
recognised to influence both breath and serum levels of acetone. These findings highlight the 
vulnerability of metabolic profiling techniques to the influence of exogenous factors. This 
problem may be especially relevant to studies conducted in the perioperative and critical care 
settings, where patients are frequently exposed to large numbers of pharmaceutical agents. 
In conclusion these findings represent an advancement of our understanding of factors 
influencing breath gas analysis in human subjects. Furthermore, results potentially 
underscore the requirement for the adoption of standardised practices relating to breath 
collection, storage and analysis within the clinical setting. Investigations exploring the 
metabolic response to major surgical stress have yielded important insight into the metabolic 
pathways altered in response to these injuries that may have future diagnosis and prognostic 
value. 
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11. APPENDICES 
Appendix I: Meta-analysis 
1(a). Characteristics of included studies comparing transthoracic (TTE) and transhiatal 
(THE) oesophagectomy 
1. 
Author: Areja D 2006 
Methods Prospective randomised study 
Participants 30 patients with oesophageal cancer. 
Interventions Transthoracic (TTE) & transhiatal (THE) 
Outcomes Operative mortality, morbidity 
Notes Method of randomisation not stated. TTE approach was 2-stage (n=15). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Method of randomisation not stated. 
2. 
Author: Berdejo L 1995 
Methods Retrospective case series 
Participants 41 patients with stage 1 oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality 
Notes Rationale for operative assignment not stated. TTE approaches were 2-stage (3), 3-stage (11), 
thoracoabdominal (6). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
3. 
Author: Bolton JS 1994 
Methods Retrospective case series 
Participants 82 patients with cancer of the GOJ and thoracic oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality 
Notes Study divided in to early and late periods [THE favoured in the later period and for patients 
with higher ASA grades].TTE approaches were 2-stage (29), total thoracic (2), 
thoracoabdominal (3). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
4. 
Author; Bonavina L 1995 
Methods Retrospective case series 
Participants 253 patients with early oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, 5 year survival 
Notes Multicentre study. 
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Risk of bias 
Item 
Allocation concealment? 
Authors' judgment 
Unclear 
Description 
Not used 
5. 
Author: Bousamra M 2002 
Methods Retrospective case series 
Participants 63 patients with benign and malignant oesophageal disease 
Interventions TIE & THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Case specific surgical approach was used, based on tumour location, stage and physiological 
state of the patient. Cases of benign (21) disease and emergency oesophagectomy (4) are 
excluded from the analysis. TTE approach, 2-stage (47). 
Risi<ofbias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
6. 
Author: Boyle MJ 1999 
Methods Retrospective case series 
Participants 65 patients with oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for operative assignment not clearly stated - 2 patients assigned to undergo TTE 
based on pre-operative radiological findings. Study includes patients treated at two centres. 
Five patients not reported: lost records (3), colon interposition (2).TTE approaches were 2-
stage, thoracoabdominal. 
Risi<ofbias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
7. 
Author: Braghetto 1 2006 
Methods Retrospective case series 
Participants 166 patients with oesophageal cancer 
Interventions TTE & THE & minimally invasive oesophagectomy 
Outcomes Operative mortality, morbidity, 3 year survival 
Notes TTE indicated for tumours above the levels of the tracheal bifurcation. Minimally invasive 
oesophagectomies (47) are excluded from the analysis. Stage IV patient excluded. TTE 
approach was 3-stage. 
Risl( of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
8. 
Author: Caracci B 1983 
Methods Retrospective case series 
Participants patients with oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for operative assignment not stated - likely that THE was chosen for more recent 
patients. THE split into two groups (i) reverse gastric tube (13) and (ii) isoperistaltic tube (9). 
Includes patients treated at two centres. TTE approach, 2-stage (13). 
Risl( of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
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9. 
Author: Cariati A 2002 
Methods Retrospective case series 
Participants 63 patients with oesophageal cancer 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for operative assignment not stated. Patients with jejunal and colon interposition 
were not reported. TTE approaches were 2-stage, 3-stage. 
Risk of bias 
Item Authors'judgment Description 
Allocation concealment? Unclear Not used 
10. 
Author: Chan WH 2000 
Methods Retrospective case series 
Participants 67 patients with oesophageal cancer 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, overall 5 year survival 
Notes Surgical approach was left to the discretion of the surgeon, although THE was favoured for 
tumours of the lower 1/3. TTE approaches were 2-stage (7), 3-stage (26). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
11. 
Author: Chang AC 2008 
Methods Retrospective population based cohort study 
Participants 868 patients with oesophageal cancer 
Interventions TTE&THE 
Outcomes Operative mortality, 5 year survival 
Notes Rationale for operative assignment not stated. Patients undergoing TTE were however less 
likely to have localised disease. This paper constitutes the largest population based study to 
date. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
12. 
Author: Chou SH 2005 
Methods Retrospective case series 
Participants 73 patients with middle and lower 1/3 oesophageal cancer 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 2 year survival 
Notes Rationale for operative assignment not stated. Both THE and TTE employed retrosternal 
reconstruction. TTE approach was 3-stage. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
13. 
Author: Chou SH 2009 
Methods Prospective randomised study 
Participants 87 patients with stage II and III oesophageal cancer. 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 2 year survival 
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Notes Inadequate randomisation. Conversion of 3 patients from THE to TTE. Both THE and TTE 
employed retrosternal reconstruction. TTE approach vi/as 3-stage. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? No Alternate patients 
14. 
Author: Chu KM 1997 
Methods Prospective randomised study 
Participants 39 patients w/ith oesophageal cancer. 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, median survival 
Notes Method of randomisation not stated. TTE approach was 2-stage (19). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Method of randomisation not stated. 
15. 
Author: Fok M 1989 
Methods Retrospective case series 
Participants 210 patients with cancer of the middle and lower oesophagus. 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 3 year survival 
Notes THE was indicated for tumours at any level of the oesophagus when thoracotomy was not 
desirable on medical grounds. Four patients who were selected for THE were converted to 
TTE. TTE approach was 2-stage (172). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
16. 
Author: Gluch L1999 
Methods Retrospective case series 
Participants 98 patients with oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Selection of operative approach was individualised - generally TTE was preferred for large. 
fixed tumours and for early tumour in young patients, whilst THE was favoured for frailer 
patients. One patient with leiomyoma was excluded by the author from further staging and 
survival analysis. TTE approach was 2-stage (33). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
17. 
Author: Gockel 1 2005 
Methods Retrospective case series 
Participants 150 patients with adenocarcinoma of the oesophagus (Siewert type 1 only) 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes TTE selected for transmural tumours, patients with suspected intrathoracic lymph node 
involvement and patients with justifiable risk. Patients drawn from the same cohort as 
Junginger 2006. TTE approach was 2-stage. 
Risk of bias 
Item Authors' judgment Description 
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Allocation concealment? Unclear Not used 
18. 
Author; Goldfaden D 1986 
Methods Retrospective case series 
Participants 153 patients with adenocarcinoma of the distal oesophagus and cardia. 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for operative assignment not stated. TTE approach was 2-stage. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
19. 
Author: Goldmine M 1993 
Methods Prospective randomised study 
Participants 67 patients with cancer of the oesophagus 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 3 year survival 
Notes Three patients randomised to receive THE were converted to TTE as it was not possible to 
remove the tumour via the former route. TTE approach was 3-stage (35). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Method of randomisation not stated. 
20. 
Author; Graham A 1998 
Methods Retrospective case series 
Participants 153 patients with adenocarcinoma of the cardia. 
Interventions TTE & THE & transabdominal oesophagectomy 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for operative assignment not stated. Includes patients treated at two centres. Two 
patients undergoing transabdominal oesophagogastrectomy are excluded from the analysis. 
TTE approaches were thoracoabdominal (21), 3-stage (7), total thoracic (3). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
21. 
Author; Gupta NM 2000 
Methods Retrospective case series 
Participants 82 patients with squamous cell carcinoma of the distal 1/3 of the oesophagus. 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Study divided in to two time periods during each of which either TTE or THE was exclusively 
performed. The postoperative outcomes of 16 patients with unresectable disease are not 
reported. TTE approach was 2-stage. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
22. 
Author; HankinsJR 1989 
Methods Retrospective case series 
Participants 96 patients with carcinoma of oesophagus and cardia 
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Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 3 year survival 
Notes Rationale for selecting operative approach was not clearly defined. 18 patients who 
underwent oesophagectomy for carcinoma of the cardia are not reported. TTE approaches 
were 2-stage (48), 3-stage (3), left-throacotomy only (1). 
Risk of bias 
Item Authors'judgment Description 
Allocation concealment? Unclear Not used 
23. 
Author: Homesh NA 2006 
Methods Prospective non-randomised observational study 
Participants 118 patients with carcinoma of oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, patient follow-up 
Notes Selection of surgical approach was determined by tumour location, patient risk, and surgeon 
preference. 34 patients who were unsuitable for either TTE or THE are not reported. TTE 
approach was 2-stage. 
K/sk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
24. 
Author: Horstmann 0 1995 
Methods Prospective non-randomised observational study 
Participants 87 patients with oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 3 year survival 
Notes The type of operation was chosen on clinical grounds 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
25. 
Author: Hulscher JBF2002 
Methods Prospective randomised study 
Participants 220 patients with adenocarcinoma of the mid/distal oesophagus or of the gastric cardia 
involving the distal oesophagus. 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 3 year survival 
Notes Includes patients treated at two centres. TTE approach was 3-stage (114). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Randomisation was stratified according to hospital and 
tumour site 
26. 
Author: Ikeguchi M 2000 
Methods Retrospective case series 
Participants 33 patients with T1 squamous cell carcinoma of the oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Patients >70yrs or with preoperative complications were selected for THE. TTE approach was 
3-stage (14). 
241 
Risk of bias 
Item 
Allocation concealment? 
Authors' judgment 
Unclear 
Description 
Not used 
27. 
Author: Jacobi CA 1996 
Methods Prospective randomised study 
Participants 32 patients with cancer of the oesophagus 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 1 year survival 
Notes TTE approach was 3-stage (16). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Method of randomisation not described 
28. 
Author: Jauch KW 1992 
Methods Retrospective case series 
Participants 86 patients with cancer of the oesophagus 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not clearly defined - progressively more TTEs 
were performed owing to a trend towards more radical surgery (not Influenced by tumour 
stage, spread or site). TTE approaches were 2-stage (34) was 3-stage (3). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
29. 
Author: Johansson J 2004 
Methods Retrospective case series 
Participants 49 patients with T3 N1 adenocarcinoma of the distal oesophagus 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes TTE was performed in patients younger than 75yrs who did not have significant 
cardiorespiratory comorbidity (FEVl >1.25L, ejection fraction >40% at rest, that increased on 
exercise without evidence of motion wall defects). THE was performed in patients older than 
75yrs who did have significant cardiorespiratory comorbidity. In three patients who died 
post-op the surgical approach is not defined. Patients for the same cohort as Oh 2006 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
30. 
Author: Junginger T 2006 
Methods Retrospective case series 
Participants 229 patients with squamous cell carcinoma of the oesophagus 
Interventions TTE&THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes TTE approach was 2-stage. THE selected for patients with more distal tumour and patients 
with higher risk (ASA lll-IV). Patients drawn from the same cohort as Gockel 2005. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
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31. 
Author: Kudo T1990 
Methods Retrospective case series 
Participants 100 patients vi/ith cancer of the oesophagus 
Interventions TTE & THE & 2-phase oesophagectomy 
Outcomes Operative mortality 
Notes Rationale for selecting operative approach was not defined. 28 patients operated on by 2-
stage approach (where each stage was 43hrs apart) are not included in the analysis. TTE 
approach was 3-stage (35). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
32. 
Author: Makela AJ1991 
Methods Retrospective case series 
Participants 89 patients with cancer of the oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not defined. Review divided in to early and 
late periods with THE being performed during the most recent period. TTE approaches were 
3-stage (40), thoracoabdominal (6). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
33. 
Author: Marton S 2005 
Methods Prospective non-randomised observational study 
Participants 83 patients with cancer of the oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity 
Notes Rationale for selecting operative approach was not clearly defined -assignment of surgical 
approach was based on 'established guidelines'. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
34. 
Author: Millikan KW 1995 
Methods Retrospective case series 
Participants 157 patients with cancer of the oesophagus and/or cardia 
Interventions TTE & THE & transabdominal oesophagectomy 
Outcomes Operative mortality, morbidity, 5-year survival 
Notes Rationale for selecting operative approach was not clearly defined (surgeon preference). 5 
patients with incomplete postoperative histology were excluded from the survival analysis. 
19 patients who underwent abdominal only oesophagectomy are not included in the 
analysis. Includes patients treated at two centres. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
35. 
Author: Mohsen H 1992-1993 
Methods Retrospective case series 
Participants 65 patients with cancer of the oesophagus 
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Interventions TTE & THE & endoesophageal pull through 
Outcomes Operative mortality, morbidity 
Notes Rationale for selecting operative approach w/as not defined. Where possible the outcomes of 
6 patients who were presented separately as TTE 2-stage procedures are included in the 
analysis. Two endoesophageal pull through procedures are excluded from the analysis. TTE 
approaches were: 2-stage (6), 3-stage (35). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
36. 
Author: Moon MR 1992 
Methods Retrospective case series 
Participants 88 patients with adenocarcinoma of the distal oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not clearly defined (surgeon preference). One 
patient who underwent a substernal bypass is excluded from the analysis. TTE approaches 
were 2-stage (13), 3-stage (4), thoracoabdominal (7). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
37. 
Author: Morgan MA 2007 
Methods Prospective non-randomised observational study 
Participants 151 with oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Surgeons selected patients with associated significant cardiorespiratory comorbidity (ASA III-
IV) for THE. All patients received neoadjuvant therapy. It is stated that the study is 
prospective, however no details of data collection are provided. TTE approach was 2-stage 
(119) 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
38. 
Author: Muller JM 1989 
Methods Retrospective case series 
Participants 136 patients with carcinoma of the oesophagus 
interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes TTE was favoured during the early part of the study and during the later period for tumours 
of the middle and upper 1/3 where extramural tumour invasion is indicated preoperatively. 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
39. 
Author: Naunheim KS 1993 
Methods Retrospective case series 
Participants 38 with oesophageal cancer 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
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Notes 
Risk of bias 
Item 
Allocation concealment? 
Rationale for selecting operative approach was not defined. Study includes only patients 
aged 70yrs or older. Patients were treated in one of four hospitals. TTE approaches were 2-
stage, 3-stage (5), thoracoabdominal. 
Authors' judgment 
Unclear 
Description 
Not used 
40. 
Author: Oh DS 2006 
Methods 
Participants 
Interventions 
Outcomes 
Notes 
Risk of bias 
Item 
Allocation concealment? 
Retrospective case series 
78 patients with intramucosal adenocarcinoma of the oesophagus 
TTE & THE & vagal sparing oesophagectomy 
Operative mortality, morbidity, 5 year survival 
Choice of surgical approach constitutes an evolution in practice towards less invasive 
techniques. Study limited to only patients with intramucosal adenocarcinoma. 20 patients 
who underwent vagal sparing oesophagectomy are excluded from the analysis. Where 
possible the outcomes of 4 patients who were presented separately as non-en bloc TTE are 
included in the analysis. Patients from the same cohort as Johannson 2006 
Authors' judgment 
Unclear 
Description 
Not used 
41. 
Author: Omloo JMT 2007 
IVIethods 
Participants 
Interventions 
Outcomes 
Notes 
Prospective randomised study 
220 patients with adenocarcinoma of the mid-to distal oesophagus or of the gastric cardia 
involving the distal oesophagus. 
TTE& THE 
5 year survival 
5 year survival of patients reported in Hulscher 2002 
Risk of bias 
Item 
Allocation concealment? 
Authors' judgment 
Unclear 
Description 
Randomisation was stratified according to hospital and 
tumour site 
42. 
Author: Pac M 1993 
Methods 
Participants 
Interventions 
Outcomes 
Notes 
Risk of bias 
Item 
Allocation concealment? 
Retrospective case series 
238 patients with carcinoma of the oesophagus or cardia 
TTE& THE 
Operative mortality, morbidity, 5 year survival 
THE introduced partway through the study. In the later period THE was the first choice 
procedure for all tumours except where firm fixation to mediastinal structures was present. 
TTE approaches were 2-stage (115), 3-stage (5). 
Authors' judgment 
Unclear 
Description 
Not used 
43. 
Author: Pommier RF 1998 
Methods 
Participants 
Interventions 
Outcomes 
Retrospective case series 
78 patients with carcinoma of the oesophagus 
TTE& THE 
Operative mortality, morbidity, 5 year survival 
2 4 5 
Notes Rationale for selecting operative approach was not defined. Includes patients treated at two 
centres. TTE approach was 2-stage (40). 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
44. 
Author; Putman JB 1994 
Methods Retrospective case series 
Participants 221 patients with carcinoma of the oesophagus 
Interventions TTE & THE & total thoracic oesophagectomy 
Outcomes Operative mortality, morbidity, 5 year survival. 
Notes Rationale for selecting operative approach was not defined. Where possible the outcomes of 
45 patients who underwent total thoracic oesophagectomy (3-stage procedure) are included 
in the analysis. THE approaches were 2-stage (134), 3-stage (45). 
Rfek of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
45. 
Author: Saha AK 2009 
Methods Retrospective case series 
Participants 44 patients with pTl carcinoma of the oesophagus 
Interventions TTE & THE + laparoscopic THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not clearly defined (surgeon preference). 
Patients undergoing laparoscopic THE (16) are excluded from the analysis. TTE approach was 
2-stage (24) 
Risl( of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
46. 
Author; Sato N 
Methods Prospective non-randomised observational study 
Participants 19 men with carcinoma of the thoracic oesophagus 
Interventions TTE& THE 
Outcomes Resting energy expenditure, operative mortality, morbidity. 
Notes THE was only performed for patients with stage 0/1 disease. TTE approach was 3-stage (14) 
/?/sk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
47. 
Author: Shahian DM 1986 
Methods Retrospective case series 
Participants 95 patients with cancer of the oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not clearly defined - "no conscious bias 
influenced selection", patients were not selected based of patient risk or tumour 
classification. TTE approaches were 2-stage, 3-stage, thoracoabdominal. 
R/sfe of bias 
Item Authors'judgment Description 
Allocation concealment? Unclear Not used 
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48. 
Author: Stark SP 1996 
Methods Retrospective case series 
Participants 48 patients w/ith adenocarcinoma of the distal oesophagus and cardia 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not clearly defined (surgeon preference). 
Includes patients treated at two centres. TTE approach was 2-stage (16) 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
49. 
Author: Steiger Z1981 
Methods Retrospective case series 
Participants 41 patients vifith cancer of the distal oesophagus 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not defined. Patients presented were 
primarily affected by squamous cell carcinoma (39/2) TTE approaches were 2-stage, 3-stage. 
Ristiofbias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
50. 
Author: SuttieSA 
Methods Retrospective case series 
Participants 104 patients with cancer of the distal oesophagus and GOJ (Siewert type 1 and II) 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes THE was used for tumours <6cm in length and when the whole tumour could be dissected 
under direct vision from an abdominal incision. The outcomes of 2 patients who were not 
resected are not presented. Where possible the outcomes of 42 patients who were 
presented separately as left-thoracoabdominal procedures are included in the analysis. 
During the early study period patients were randomised to receive either no neo-adjuvant 
therapy or neo-adjuvant chemotherapy as part of the OE02 trial. In the latter period of the 
study all patients received neo-adjuvant chemotherapy. TTE approaches were 2-stage (29), 
thoracoabdominal (42) 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
51. 
Author: Svanes K1995 
Methods Retrospective case series 
Participants 83 patients with cancer of the oesophagus and cardia 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Rationale for selecting operative approach was not clearly defined - THE was frequently 
selected for patients with adenocarcinoma of the lower 1/3 and cardia, and in patients with 
significant risk. Postoperative follow-up was prospective. TTE approaches were 2-stage (2), 3-
stage (3). 
Risk of bias 
Item Authors' judgment Description 
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Allocation concealment? Unclear Not used 
52. 
Author: Tilanus HW 
Methods Retrospective case series 
Participants 293 patients with cancer of the oesophagus and GOJ 
Interventions TTE& THE 
Outcomes Operative mortality, morbidity, 5 year survival 
Notes Study was divided in to early and late periods [TTE first period, THE second period], TTE 
approach was 2-stage (152) 
Risk of bias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
53. 
Author: Yekebas EF 2006 
Methods Prospective non-randomised observational study 
Participants 120 patients with squamous cell carcinoma of the oesophagus 
Interventions TTE& THE 
Outcomes 5 year survival 
Notes Surgical approach was dictated by the condition of the patient-THE chosen for patients with 
"severe" comorbidity, TTE approach was 3-stage (79) 
Risl<ofbias 
Item Authors' judgment Description 
Allocation concealment? Unclear Not used 
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1(b). Characteristics of excluded studies 
Author Reason for exclusion 
1 Bolger C 1991 Results could not be analysed with respect to surgical approach 
2 Bolton JS 1992 Overlap of patients with Bolton 1994 
3 Casson AG 2002 Results could not be analysed with respect to surgical approach 
4 Chatoopadhyay TK 1993 Unable to separate benign and malignant disease 
5 Connors RC 2007 Unable to separate benign and malignant disease 
6 Courrech Staal EFW 2009 Results could not be analysed with respect to surgical approach 
7 Daniel TM 1992 Unable to separate benign and malignant disease 
8 de Boer A6EM 2002 Same patients as Hulscher 2002 
9 de Boer AGEM 2004 Same patients as Hulscher 2002 
10 de Graaf PW 1991 Opinion paper 
11 Deshmane VH 1994 Unable to separate benign and malignant disease 
12 Fok M 1993 Overlap of patients with Chu 1997 
13 Fok M 1995 Overlap of patients with Chu 1997 
14 Forshaw MJ 2008 Unable to separate benign and malignant disease 
15 Goan Y-G 2007 Overlap of patients with Chou SH 2005 & 2009 
16 Gockel 1 2005 Results could not be analysed with respect to surgical approach 
17 Gupta NM 2000 Unable to separate benign and malignant disease 
IS Gupta V 2009 Case report 
19 Holscher AH 1995 Results could not be analysed with respect to surgical approach 
20 Hulscher JBF 2000 Overlap of patients with Hulscher 2002 
21 Idelevlch E 2008 Results could not be analysed with respect to surgical approach 
22 Ikeguchi M 2002 Same patients as Ikeguchi 2000 
23 Kauer WK 2003 Same patients as Ikeguchi 2000 
24 Lagarde SM 2005 Overlap of patients with Hulscher 2002 
25 Lagarde SM 2007 Overlap of patients with Hulscher 2002 
26 Lee PC 2009 Results could not be analysed with respect to surgical approach 
27 MaJ-Y 2006 Results could not be analysed with respect to surgical approach 
28 Meneu-Diaz JC 2000 Results could not be analysed with respect to surgical approach 
29 Nguyen NT 2000 Unable to separate benign and malignant disease 
30 Osinowo O 1992 Unable to separate benign and malignant disease 
31 Parshad R 1999 Results could not be analysed with respect to surgical approach 
32 Peracchia A 1994 Overlap of patients with Bonavina 1995 
33 Rahamim J 1993 THE approach not reported 
34 Rakic S 1993 Results could not be analysed with respect to surgical approach 
35 Rao DVLN 2004 Unable to separate benign and malignant disease 
36 Rentz J 2003 Unable to separate benign and malignant disease 
37 Rindani R 1999 Review article 
38 Sarela Al 2008 Overlap of patients with Saha 2009 
39 Siewert JR 1988 Delayed reconstruction 
40 Stewart FM 1989 Results could not be analysed with respect to surgical approach 
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41 Streitz JM 1992 Review article 
42 Szucs G 2003 Results could not be analysed with respect to surgical approach 
43 Tsui SL 1991 Overlap of patients with Chu 1997 
44 VanDeSchootL 2009 Results could not be analysed with respect to surgical approach 
45 van Heljl M 2010 Same patients as Hulscher 2002 
46 VanSandlckJW 2003 Same patients as Hulscher 2002 
47 Viklund P 2006 Results could not be analysed with respect to surgical approach 
1(c). Results of Methodological Quality Scoring 
Selection of treatment Comparability of groups in studies Outcome assessment Total score 
8 10 11 12 13 14 
Are] a D 2006 2 1 1 1 1 1 2 9 
Berdejo L 1995 1 1 1 1 1 1 1 1 8 
Bolton J 1994 1 1 1 1 1 1 1 1 8 
Bonavina L 1995 1 1 1 1 1 1 1 1 8 
Bousamra M 2002 1 1 1 1 1 5 
Boyle MJ 1999 1 1 1 1 1 1 1 1 1 2 11 
Braghetto 1 2006 1 1 1 1 1 2 7 
Caracci B 1983 1 1 1 1 1 1 1 1 8 
Cariati A 2002 1 1 1 1 1 1 1 1 1 9 
Chan WH 2000 1 1 1 1 1 1 1 1 1 9 
Chang A 2008 1 1 1 1 1 1 1 1 1 1 10 
Chou S-H 2005 1 1 1 1 1 1 1 1 1 9 
Chou S-H 2009 1 1 1 1 1 1 1 1 1 9 
Chu K-M 1997 2 1 1 1 1 1 1 1 1 1 1 1 2 15 
FokM 1989 1 1 1 1 1 1 6 
Gluch L 1999 1 1 1 1 1 1 1 1 1 2 11 
Gockel 1 2005 1 1 1 1 1 1 1 1 2 10 
Goldfaden D 1986 1 1 1 1 1 1 1 1 1 2 11 
Goldmine M 1993 2 1 1 1 1 1 1 1 1 1 2 13 
Graham AJ 1998 1 1 1 1 1 1 2 8 
Gupta NM 2000 1 1 1 1 1 1 1 1 1 1 1 2 13 
HankinsJR 1989 1 1 1 1 1 1 1 2 9 
Homesh NA 2006 1 1 1 1 1 1 1 1 1 1 10 
Horstmann O 1995 1 1 1 1 1 1 1 1 2 10 
Hulscher JBF 2002 2 1 1 1 1 1 1 1 1 1 1 1 2 1 16 
Ikeguchi M 2000 1 1 1 1 1 1 1 1 1 1 10 
Jacob! CA 1997 2 1 1 1 1 1 1 1 1 1 1 1 1 14 
Jauch KW 1992 1 1 1 1 1 1 1 1 1 1 1 2 13 
Johansson J 2004 1 1 1 1 1 1 1 1 1 1 10 
Junginger T 2006 1 1 1 1 1 1 1 1 2 10 
Kudo T 1990 1 1 1 1 1 5 
Makela J 1991 1 1 1 1 1 1 1 1 1 1 10 
Marton S 2005 1 1 1 1 1 1 1 1 8 
Milllkan KW 1995 1 1 1 1 1 2 7 
Mohsen H 1993 1 1 1 1 1 5 
Moon MR 1992 1 1 1 1 1 1 1 1 1 1 1 11 
Morgan MA 2007 1 1 1 1 1 1 1 1 1 1 1 2 13 
Muller JM 1989 1 1 1 1 1 1 1 2 9 
Naunheim KS 1992 1 1 1 1 1 1 6 
Oh DS 2006 1 1 1 1 1 1 1 1 1 9 
Omioo 2007 - - - - - -
Pac M 1993 1 1 1 1 1 1 1 1 2 10 
Pommier RF 1998 1 1 1 1 1 1 6 
Putman JB 1994 1 1 1 1 1 1 2 8 
Saha A! 2009 1 1 1 1 1 1 1 1 1 1 1 11 
Sato N 1993 1 1 1 1 1 1 1 1 8 
Shahlan DM 1986 1 1 1 1 1 1 1 1 1 1 2 12 
Stark SP 1996 1 1 1 1 1 1 1 1 1 1 1 2 13 
Steiger Z 1981 1 1 1 1 1 1 1 7 
Suttie SA 2007 1 1 1 1 1 1 1 1 1 1 1 11 
Svanes K 1995 1 1 1 1 1 5 
Tllanus HW 1993 1 1 1 1 1 1 1 7 
Yekebas EF 2006 1 1 1 1 1 1 1 1 1 9 
2. Inclusion criteria reported 
3. Representability of patients undergoing THE to all patients undergoing surgery for oesophageal cancer 
4. Representability of patients undergoing TTE to all patients undergoing surgery for oesophageal cancer 
5. Age 
6. Sex 
7. Co-morbidity 
8. Tumour site 
9. Tumour histological type 
10. Tumour stage 
11. Pathological grade of tumours 
12. Time period of management (years of recruitment) 
13. One star if 1-11 outcomes are clearly recorded (2-stars if >11 outcomes are clearly recorded 
14. One star if 90% of patients were followed up for 5 years 
1(d). Results of Surgical Quality Scoring 
First Author Year Surgeon case load Hospital volume Lymph nodes Technical complications Anastomotic leak Early mortality Total s 
Areja D 2006 1 1 1 0 3 
Berdejo L 1995 1 2 2 0 5 
Bolton J 1994 1 1 2 
Bonavina L 1995 2 1 1 4 
Bousamra M 2002 0 0 0 2 2 
Boyle MJ 1999 1 1 0 2 
Braghetto 1 2006 1 2 0 0 3 
Caracci B 1983 0 0 0 0 
Cariati A 2002 0 1 0 0 1 
Chan WH 2000 0 0 0 1 1 
Chang A 2008 0 0 
Chou S-H 2005 1 0 1 0 2 4 
Chou S-H 2009 1 1 0 0 2 
ChuK-M 1997 0 2 1 3 
FokM 1989 2 1 2 0 5 
Gluch L 1999 1 0 1 1 3 
Gockel 1 2005 1 1 0 1 3 
Goldfaden D 1986 0 1 1 0 2 
Goldmine M 1993 1 1 1 1 4 
Graham AJ 1998 2 2 0 2 6 
Gupta NM 2000 0 0 0 0 0 
Hankins JR 1989 1 0 1 1 3 
Homesh NA 2006 1 0 0 1 2 
Horstmann O 1995 1 0 0 0 1 
Hulscher JBF 2002 2 1 0 0 2 5 
Ikeguchi M 2000 0 1 0 0 1 
Jacobi CA 1997 1 0 1 2 
Jauch KW 1992 1 0 0 0 1 
Johansson J 2004 1 2 1 4 
Junginger T 2006 2 1 0 0 3 
Kudo T 1990 2 2 2 6 
Makela J 1991 0 2 0 1 3 
Marton S 2005 1 2 0 3 
Millikan KW 1995 1 2 1 1 5 
Mohsen H 1993 1 0 0 0 1 
Moon MR 1992 0 0 0 0 0 
Morgan MA 2007 1 0 1 1 2 5 
Muller JM 1989 1 0 0 0 1 
Naunheim KS 1992 0 0 0 0 0 
Oh DS 2006 0 1 1 1 2 5 
Omioo 2007 2 1 0 0 2 5 
Pac M 1993 2 2 2 1 7 
Pommler RF 1998 0 1 2 3 
Putman JB 1994 2 1 1 1 5 
Saha A! 2009 2 0 0 1 3 
Sato N 1993 2 0 2 4 
Shahian DM 1986 1 0 1 2 
Stark SP 1996 1 0 1 0 2 4 
Steiger Z 1981 1 2 1 2 6 
Suttle SA 2007 1 1 0 1 2 5 
Svanes K 1995 1 0 0 1 1 3 
Tilanus HW 1993 1 0 0 1 2 
Yekebas EF 2006 1 0 1 
Surgeon case load: 0 star = unknown or < 10 cases/year, 1 star = >10 cases/year, 2 stars = > 30 cases/year or > 100 cases in total 
Hospital volume: 0 star = unknown or < 10 cases/year, 1 star = > 10 cases/year, 2 stars = > 30 cases/year 
Lymph nodes: 0 star = unknown or < 20 lymph nodes on average, 1 star = > 20 lymph nodes on average, 2 stars = > 30 lymph nodes on average 
Technical complications (including only: chyle leak, laryngeal nerve palsy, haemorrhage and splenectomy): 0 star = unknown or > 10%, 1 star = < 10%, 2 stars = < 5% 
Anastomotic leak (including radiological/asymptomatic, conservatively managed, managed with a drain and managed with an operation): 0 star = unknown or > 10%, 1 star = < 10%, 2 stars = < 5% 
Early mortality (<30 day or in-hospital): 0 star = unknown or > 10%, 1 star = < 10%, 2 stars = < 5% 
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1(e). Sensitivity analysis performed for studies comparing transthoracic and transhiatal 
esophagectomy: prospective randomized control trials 
No. of 
studies 
No. of 
patients OR/WMD 95%CI P-value 
HGx' 
P-value 
HG 
I ' 
Tumour histology 
Adenocarcinoma 2 252 2.19 0.96, 5.00 0.06 0.33 0 
Squamous cell carcinoma 1 32 1.00 0.17,5.90 1 - -
Tumour site 
Upper 1/3 and cervical oesophagus 1 67 0.17 0.01, 3.72 0.26 - -
Middle 1/3 1 67 0.92 0.35, 2.42 0.87 - -
Lower 1/3, GOJ and cardia 1 67 1.40 0.53, 3.73 0.5 - -
Tumour stage 
O/l 4 358 0.77 0.32, 1.81 0.54 0.15 43 
11 4 358 0.60 0.31,1.15 0.12 0.31 17 
III 4 358 1.54 1.00, 2.38 0.05 0.64 0 
IV 3 319 1.84 0.89, 3.83 0.1 0.43 0 
Neoadjuvant therapy - - - - - - -
Lymph nodes excised 1 220 15.00 11.91,18.09 <0.001 - -
Operative and hospital details 
Operative time (mins) 1 39 36.00 17.94, 54.06 <0.001 - -
Operative blood loss (ml) 1 39 -53.00 -199.33, 93.33 0.48 - -
Mean length of ICU stay (days) - - - - - - -
Mean length of hospital stay (days) 1 39 9.00 4.19,13.81 <0.001 - -
Postoperative complications 
Mortality 5 388 1.07 0.43, 2.65 0.89 0.38 5 
All respiratory complications 5 388 0.99 0.28, 3.46 0.98 <0.001 82 
All cardiac complications 5 388 1.34 0.77, 2.34 0.3 0.42 0 
Anastomotic leak 4 349 1.23 0.65, 2.34 0.52 0.79 0 
Chyle leak 1 220 5.55 1.20, 25.67 0.03 - -
Vocal cord paralysis 4 356 1.48 0.76, 2.87 0.24 0.53 0 
Haemorrhage 2 106 0.98 0.10, 9.74 0.99 0.36 0 
Wound infection 3 289 1.36 0.58, 3.18 0.48 0.9 0 
Pneumothorax 2 62 0.45 0.05, 3.71 0.46 0.42 0 
Pleural effusion 4 168 0.43 0.20, 0.94 0.03 0.6 0 
Anastomotic stricture 3 136 0.75 0.09, 6.05 0.79 0.11 54 
Pneumonia 4 168 1.18 0.54, 2.61 0.68 0.54 0 
ARDS/AU 2 106 0.95 0.13, 6.84 0.96 0.4 0 
Atelectasis 2 62 3.72 0.46, 29.80 0.22 0.19 42 
Pulmonary embolism 1 67 0.91 0.05,15.21 0.95 - -
Myocardial infarction 3 129 0.37 0,07, 2.02 0.25 0.97 0 
Arrhythmia 2 71 0.85 0.25, 2.86 0.8 0.73 0 
Renal insufficiency - - - - - - -
5-year survival 1 220 1.09 0.63,1.90 0.76 - -
OR, odds ratio; WIVID, weiglited mean difference; CI, confidence interval; 
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1(f). Sensitivity analysis performed for studies comparing transthoracic and transhiatal 
esophagectomy: studies published after and including the year 2000 
No. of 
studies 
No. of 
patients OR/WMD 95%CI P-value 
HGx' 
P-value 
HG 
I ' 
Tumour histology 
Adenocarcinoma 5 620 1.30 0.71, 2.39 0.39 0.21 32 
Squamous cell carcinoma 4 400 0.96 0.55,1.67 0.89 0.41 0 
Tumour site 
Upper 1/3 and cervical oesophagus 8 867 1.26 0.38, 4.17 0.71 <0.001 73 
Middle 1/3 9 937 2.26 1.46, 3.52 <0.001 0.21 26 
Lower 1/3, GOJ and cardia 10 1027 0.47 0.28, 0.80 0.006 0.01 57 
Tumour stage 
0/1 9 1559 0.62 0.37, 1.01 0.06 0.22 25 
II 13 1954 1.03 0.83, 1.28 0.8 0.63 0 
III 13 2250 1.22 0.92, 1.60 0.16 0.09 36 
IV 9 1961 1.62 1.13,2.34 0.01 0.85 0 
Neoadjuvant therapy 3 305 0.96 0.51,1.82 0.9 0.52 0 
Lymph nodes excised 3 413 9.98 1.96,18.00 0.01 <0.001 96 
Operative and hospital details 
Operative time (mins) 4 259 126.25 72.45, 180.05 <0.001 <0.001 92 
Operative blood loss (ml) 3 193 -17.00 -91.99, 58.00 0.66 0.97 0 
Mean length of ICU stay (days) - 0 - - - - -
Mean length of hospital stay (days) 4 289 7.18 4.93, 9.44 <0.001 0.37 5 
Postoperative complications 
Mortality 18 2511 1.64 1.18,2.29 0.003 0.83 0 
All respiratory complications 16 1476 1.4 0.97, 2.02 0.07 0.08 36 
All cardiac complications 9 906 1.28 0.76, 2.16 0.36 0.56 0 
Anastomotic leak 14 1243 0.94 0.67,1.32 0.73 0.58 0 
Chyle leak 5 559 1.06 0.24, 4.77 0.94 0.05 58 
Vocal cord paralysis 10 923 0.55 0.21, 1.47 0.24 0.008 60 
Haemorrhage 6 520 0.54 0.24, 1.21 0.13 0.61 0 
Wound infection 5 551 2.03 1.16, 3.54 0.01 0.58 0 
Pneumothorax 3 248 0.52 0.13, 2.19 0.38 0.73 0 
Pleural effusion 2 149 0.50 0.17, 1.50 0.22 0.48 0 
Anastomotic stricture 4 1083 0.72 0.54, 0.98 0.04 0.48 0 
Pneumonia 10 812 1.38 0.95,1.99 0.09 0.58 0 
ARDS/AU 3 225 1.28 0.49, 3.38 0.61 0.94 0 
Atelectasis 2 96 11.32 1.32, 96.97 0.03 0.73 0 
Pulmonary embolism 3 336 1.13 0.23, 5.57 0.88 0.73 0 
Myocardial infarction 3 154 0.44 0.08, 2.38 0.34 0.99 0 
Arrhythmia 2 160 0.20 0.02, 2.00 0.17 0.79 0 
Renal insufficiency - - - - - - -
5-year survival 13 2167 0.98 0.67, 1.41 0.9 0.02 52 
OR, odds ratio; WIVID, weighted mean difference; CI, 
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1(g). Sensitivity analysis performed for studies comparing transthoracic and transhiatal 
esophagectomy: high quality studies > / i stars 
No. of 
studies 
No. of 
patients OR/WMD 95%CI P-value 
HGx' 
P-value 
HG 
I' 
Tumour histology 
Adenocarcinoma 8 849 1.23 0.66, 2.30 0.51 0.02 57 
Squamous cell carcinoma 7 629 0.87 0.44,1.73 0.7 0.03 57 
Tumour site 
Upper 1/3 and cervical oesophagus 5 464 0.29 0.10, 0.84 0.02 0.7 0 
Middle 1/3 5 464 1.01 0.63, 1.60 0.98 0.63 0 
Lower 1/3, GOJ and cardla 5 464 1.34 0.85, 2.12 0.2 0.51 0 
Tumour stage 
0/1 13 1057 0.75 0.53,1.08 0.13 0.71 0 
It 14 1208 0.76 0.57, 1.02 0.07 0.53 0 
III 13 1180 1.36 1.05, 1.75 0.02 0.58 0 
IV 9 882 1.37 0.84, 2.24 0.2 0.72 0 
Neoadjuvant therapy 4 348 0.74 0.44, 1.24 0.26 0.62 0 
Lymph nodes excised 2 268 7.71 -6.89, 22.31 0.3 <0.001 96 
Operative and hospital details 
Operative time (mins) 4 251 86.43 -10.23,183.08 0.08 <0.001 99 
Operative blood loss (ml) 1 39 -53.00 -199.33, 93.33 0.48 - -
Mean length of ICU stay (days) 2 184 -1.21 -6.90, 4.47 0.68 0.01 85 
Mean length of hospital stay (days) 5 384 1.69 -4.38, 7.77 0.58 <0.001 87 
Postoperative complications 
Mortality 15 1256 1.13 0.72,1.77 0.6 0.71 0 
All respiratory complications 14 1228 1.35 0.80, 2.28 0.26 <0.001 72 
All cardiac complications 13 1130 1.16 0.76,1.77 0.49 0.78 0 
Anastomotic leak 13 1189 0.60 0.35,1.01 0.05 0.07 40 
Chyle leak 2 371 1.15 0.05, 26.48 0.93 0.003 89 
Vocal cord paralysis 11 1029 0.69 0.34, 1.39 0.3 0.18 28 
Haemorrhage 7 623 0.47 0.16, 1.37 0.17 0.53 0 
Wound infection 8 827 2.00 1.17, 3.41 0.01 0.75 0 
Pneumothorax 3 248 1.82 0.31, 10.58 0.5 0.53 0 
Pleural effusion 3 138 0.46 0.20,1.02 0.06 0.47 0 
Anastomotic stricture 6 404 0.57 0.29, 1.10 0.09 0.53 0 
Pneumonia 7 529 1.54 0.78, 3.02 0.21 0.11 42 
ARDS/ALI 4 273 1.01 0.44, 2.34 0.98 0.74 0 
Atelectasis 2 98 2.40 0.61, 9.35 0.21 0.4 0 
Pulmonary embolism 7 564 0.86 0.29, 2.54 0.78 0.77 0 
Myocardial infarction 5 323 0.54 0.16, 1.83 0.32 0.77 0 
Arrhythmia 3 119 0.90 0.33, 2.45 0.83 0.93 0 
Renal Insufficiency 3 253 0.81 0.21, 3.10 0.76 0.82 0 
5-year survival 10 963 0.85 0.56, 1.31 0.47 0.12 36 
OR, odds ratio; WMD, weighted mean difference; CI, confidence interval; HG, heterogeneity; Chi squared 
Appendix II: Case series 
n(a). List or recorded variables 
Patient Details 
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1 Surname 
2 Forename 
3 NHS Number 
4 Hospital Number 
5 Date of Birth 
6 Postcode 
7 Phone Number: Patient 
8 Phone Number: Next Of Kin 
9 Phone Number: GP 
10 Sex 
11 Height (cm) 
12 Weight (Kg) 
13 BMI 
14 Occupation 
15 Ethnic Origin 
16 Smol<ing 
17 Smoking History (pack years) 
18 Additional Smoking Details 
19 Alcohol Consumption (units per week) 
20 Additional Details of Alcohol Consumption 
Referral and Diagnostic Details 
Referral Details: 
Staging Details: 
21 Presenting Complaint 
22 Source of Initial Referral 
23 Priority of Referral (GP only) 
24 Date of First Referral to St Mary's Upper Gl Team 
25 Date of Diagnosis 
26 Unit Where Cancer Was First Diagnosed 
27 Cancer Site 
28 Gastro-Oesophageal Junction: Siewert Class 
29 Diagnostic Histology 
30 Staging Investigations 
31 Date of 1st CT Scan 
32 Date of 2nd CT Scan 
33 Date of 3rd CT Scan 
34 Date of 1st EUS 
35 Date of 2nd EUS 
36 Date of 3rd EUS 
37 Date of 1st EUS Fine Needle Aspiration 
38 Date of 2nd EUS Fine Needle Aspiration 
39 Date of 3rd EUS Fine Needle Aspiration 
40 Date of 1st MRI Scan 
41 Date of 2nd MRI Scan 
42 Date of 3rd MRI Scan 
43 Date of 1st OGD 
44 Date of 2nd OGD 
45 Date of 3rd OGD 
46 Date of 1st PET/PET-CT Scan 
47 Date of 2nd PET/PET-CT Scan 
48 Date of 3rd PET/PET-CT Scan 
49 Date of 1st Staging Laparoscopy 
50 Date of 2nd Staging Laparoscopy 
51 Date of 3rd Staging Laparoscopy 
52 Details and Dates of Other Investigations 
53 Pre-treatment Stage (T) 
54 Pre-treatment Stage (N) 
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55 Pre-treatment Stage (M) 
Treatment Plan: 56 Date Final Care-Plan Agreed 
57 Treatment Intent 
58 Details of Treatment (Curative) 
59 Details of Treatment (Palliative) 
60 Reason for Palliative Treatment 
Pre-operative Treatment: 
Neo-Adjuvant Chemotherapy: 
Neo-Adjuvant Radiotherapy: 
61 Modality 
62 Number of Cycles Prescribed 
63 Actual Number of Cycles Given 
64 Chemotherapy Treatment Protocol 
65 Date of First Cycle 
66 Date of Last Cycle 
67 Significant Side Effects 
68 Completed as Prescribed 
69 Reason if Incomplete 
70 Date of First Fraction 
71 Date of Last Fraction 
72 Total Dose Prescribed 
73 Number of Fractions Prescribed 
74 Actual Number of Fractions Given 
75 Significant Side-Effects 
76 Treatment Completed As Prescribed 
77 Reason (if incomplete) 
78 Responded to Neo-Adjuvant therapy 
Clinical Response to Neo-Adjuvant Therapy: 79 Weight Change (Kg) 
80 Pain 
81 Food Intake 
82 Vomiting 
83 Post Neo-Adjuvant Therapy Stage (T) 
84 Post Neo-Adjuvant Therapy Stage (N) 
85 Post Neo-Adjuvant Therapy Stage (M) 
Preoperative Risk: 
86 
87 
89 
90 
ECOG (WHO) Performance Status 
Comorbities 
Details of Other Significant Conditions 
Medications 
ASA Grade 
O-POSSUM 
91 Age 
92 Cardiac Signs/ Chest Radiograph 
93 Respiratory History/Chest Radiograph 
94 Systolic Blood Pressure (mmHg) 
95 Pulse (bpm) 
96 Glasgow Coma Scale 
97 Hb (g/100 ml) 
98 WBC (xlO'^12 /L) 
99 Urea (mmol/L) 
100 Na + (mmol/L) 
101 K + (mmol/L) 
102 ECG 
103 Operation Type 
104 Malignant Status 
105 Urgency (CEPOD) 
106 Physiology Score 
107 Predicted Mortality (%) 
Preoperative: 
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Lung Function Tests: 
Additional Blood Results: 
108 FVC (L) 
109 FEVl (L) 
110 FEVl % predicted 
111 FVC % predicted 
112 PEF (L/sec) 
113 TLC(L) 
114 RV(L) 
115 Albumin 
116 Creatinine 
117 INR 
118 APTR 
Operative: 
Admission and Surgical Details: 119 Hospital where operation took place 
120 Lead Surgeon 
121 Date of Admission 
122 Date of Operation 
123 Preoperative intent of surgery 
124 Priority of surgery (NCEPOD) 
Procedural Details: 125 Procedure: Oesophageal 
126 Procedure: Gastric 
127 Surgical Access (Thoracic) 
128 Surgical Access (Abdominal) 
129 Feeding Adjunct 
130 Other Organ(s) Removed 
131 Oesophagectomy Nodal Dissection 
132 Gastrectomy Nodal Dissection 
133 Skin Closure 
134 Skin Closure: Sutures 
135 Length of Operation: Induction to Skin Closure (hrs) 
136 Length of First Period of One Lung Ventilation (hrs) 
137 Length of Second Period of One Lung Ventilation (hrs) 
Additional Operative Details: 138 Anaesthetic 
139 Inotropes 
140 Insulin Requirement 
141 Blood loss (ml) 
142 Heart Rate: Low/est (bpm) 
143 Heart Rate: Highest (bpm) 
144 Blood Pressure: Lowest (mmHg) 
145 Blood Pressure: Highest (mmHg) 
146 Urine Output: Lowest (ml/hr) 
147 Urine Output: Highest (ml/hr) 
148 Total Urine Output (L) 
149 Total Crystalloids Given (L) 
150 pH: Lowest 
151 Base Excess: Lowest 
152 Temperature: Lowest (°C) 
153 Lactate; Highest 
154 Glucose: Highest 
155 Total Colloids Given (L) 
156 Transfusion Packed Cells (units) 
157 Cell Products 
158 Extubation (post-operative day) 
159 Additional Intraoperative Details 
End Operative Arterial Blood Gas Result: 160 Temperature (°C) 
161 FI02 
162 pH 
163 PC02 (kPa) 
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164 P02 (kPa) 
165 HC03- (mmol/L) 
166 BE (mmol/L) 
167 tHb (g/dL) 
168 S02 (%) 
169 F02Hb(%) 
170 FCOHb (%) 
171 FMetHb (%) 
172 FHHb (%) 
173 Na+ (mmol/L) 
174 K+ (mmol/L) 
175 Ca++ (mmol/L) 
176 CI- (mmol/L) 
177 AnGap (mmol/L) 
178 Glucose (mmol/L) 
179 Lactate (mmol/L) 
Postoperative complications: 
180 Anastomotic Leak (post-op day) 
181 Sepsis 
182 Sepsis WBC 
183 Pneumonia (post-op day) 
184 Pneumonia Antibiotic Therapy 
185 ARDS (post-op day) 
186 Pulmonary Embolism (post-op day) 
187 Pleural Effusion (post-op day) 
188 Chyle Leak (post-op day) 
189 Duodenal Stump Leak (post-op day) 
190 Haemorrhage (post-op day) 
191 Wound Infection (post-op day) 
192 Cardiac Complication (post-op day) 
193 Acute Renal Failure (post-op day) 
194 DVT (post-op day) 
195 Laryngeal Nerve Palsy (post-op day) 
196 Abdominal Abscess (post-op day) 
197 Pancreatic Fistula (post-op day) 
198 Details of Significant Events 
199 Unplanned Return to Theatre 
200 Unplanned Return to Theatre (post-op day) 
201 Reason for Unplanned Return to Theatre 
202 In-hospital Death (post-op day) 
203 Primary Reason for In-hospital Death 
Postoperative management: 
204 Pain Management 
205 Epidural Stopped (post-op day) 
206 Days In ITU 
207 Days in HDU 
208 Hospital Stay (days) 
209 Mobility Sitting Out of Bed (post-op day) 
210 Mobility Walking (post-op day) 
211 Contrast Study (post-op day) 
212 Result of Contrast Study 
213 Imaging 
214 Oral Fluid Intake (post-op day) 
215 Oral Solids Intake (post-op day) 
216 Removal of N6 tube (post-op day) 
217 Removal of N6 tube 
218 Removal of Abdominal Drain(s) (post-op day) 
219 Removal of Chest Drain(s) (post-op day) 
220 Removal of Urinary Catheter (post-op day) 
221 Date of Discharge 
222 Weight on Discharge 
223 Hb on Discharge (g/100 ml) 
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224 Albumin on Discharge 
Postoperative: 
225 Adjuvant Therapy 
226 Date of Last Follow-Up 
227 Disease Free at (postoperative month) 
228 Recurrence 
Date Recurrence First Diagnosed 
Diagnostic modality Used to Confirm Recurrent 
Disease 
231 Alive at (postoperative month) 
232 Date of Death 
233 Other Relevant Details 
229 
230 
Postoperative Histology: 
234 Report Number 
235 Received Date 
236 Other Reports 
237 Hospital 
238 Surgeon 
239 Pathologist 1 
240 Pathologist 2 
241 Specimen Type 
242 Operation 
243 Stomach Greater Curvature Length 
244 Stomach Lesser Curvature Length 
245 Stomach Length 
246 Stomach Width 
247 Oesophagus Length 
248 Oesophagus Width 
249 Duodenum Length 
250 Specimen Length 
251 Tumour Site 
252 Tumour Length 
253 Tumour Width 
254 Tumour Thickness 
255 Tumour Diameter 
256 Distal Margin 
257 Proximal Margin 
258 Minimum Margin 
259 Macroscopic Assessment 
260 Oesophageal Stent in-situ 
261 Histology 
262 Differentiation 
263 Other Findings 
264 H-Pylori Type Organisms 
265 Siewert's Type 
266 Proximal Histology 
267 Distal Histology 
268 Proximal Invasion 
269 Distal Invasion 
270 Circumferential Margin 
271 Circumferential Distance (mm) 
272 Serosal Invasion 
273 Vascular Invasion 
274 Perineural Invasion 
275 Barretts Oesophagus 
276 Barretts Length 
277 Lymphnodes Excised 
278 Lymphnodes Positive 
279 Celiac Metastasis 
280 Cervical Metastasis 
281 Other Metastasis 
282 History Neoadjuvant Chemotherapy 
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283 Complete Resection 
284 Pathological Stage (T) 
285 Pathological Stage (N) 
286 Pathological Stage (M) 
287 Resection 
288 MANDARD SCORE 
289 Additional Comments 
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11(b). Multivariate logistic regression model validation: validation using test date set 
Patient Pneumonia 
no. approach (yrs) (mins) Predicted risk Observed 
1 TT 71 600 0.40 1 
2 TT 64 660 0.37 1 
3 TA 71 450 0.24 0 
4 TA 67 450 0.20 1 
5 TT 75 690 0.57 1 
6 TT 45 600 0.12 0 
7 TA 56 480 0.13 1 
8 TA 80 540 0.46 0 
11 TT 68 540 0.29 0 
12 TT 58 570 0.21 0 
13 TT 48 540 0.11 1 
14 TT 65 690 0.42 0 
15 TA 77 630 0.52 0 
16 TT 58 630 0.26 1 
17 TA 57 600 0.22 0 
18 TA 74 420 0.24 0 
19 TA 72 435 0.24 0 
20 TA 69 390 0.17 0 
21 TA 60 480 0.16 0 
22 TT 52 630 0.20 0 
23 TT 59 600 0.24 0 
24 TT 56 615 0.22 0 
25 TT 51 600 0.17 0 
26 TT 78 540 0.43 0 
27 TA 81 390 0.30 0 
28 TT 51 680 0.23 0 
29 TT 69 660 0.44 0 
30 TT 41 510 0.07 0 
31 TT 74 750 0.63 0 
32 TA 45 540 0.09 0 
33 TT 52 735 0.29 0 
34 TT 59 705 0.35 0 
35 TT 48 735 0.25 1 
36 TT 75 570 0.42 0 
37 TT 54 600 0.19 0 
38 TA 54 420 0.09 0 
39 TA 69 510 0.27 0 
Surgical approach: TT, transthoracic. TA, transabdominal. 
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Appendix III: Criteria for diagnosing pneumonia following oesophagectomy 
Ill(a). Electronic search strategy 
Search no. Search [20.12.09] No. of citations 
#1 Oesophagectomy 4991 
#2 Postoperative complications 287840 
#3 Postoperative respiratory complications 7294 
#4 Pulmonary complications 123414 
#5 Respiratory complications 51046 
#6 Pneumonia 65718 
#7 Nosocomial pneumonia 2387 
#8 Hospital acquired pneumonia 4091 
#9 Ventilator-associated pneumonia 2023 
#10 Lung injury 33699 
#11 Acute lung injury 8448 
#12 Ventilator-induced lung injury 3406 
#13 Acute respiratory failure 11137 
#14 Acute respiratory distress syndrome 14544 
#15 ALI 13712 
#16 ARDS 4587 
#17 Atelectasis 5316 
#18 Pleural effusion 13962 
#19 Pulmonary oedema 17071 
#20 Pulmonary embolism 24751 
#21 Pneumothorax 10952 
#22 Lung inflammation 82101 
#23 Pulmonary inflammation 77283 
#24 Reperfusion injury 29118 
#25 Hyperoxia 4416 
#26 hypoxic pulmonary vasoconstriction 1984 
#27 Tracheal tear 201 
#28 Tracheobronchial tear 47 
#29 Postoperative complications [MeSH] 247435 
#30 Lung injury [MeSH] 15338 
#31 Pneumonia [MeSH] 41910 
#32 Reperfusion injury [MeSH] 20732 
#33 Pulmonary atelectasis [MeSH] 3235 
#34 Pleural effusion [MeSH] 10051 
#35 Pulmonary embolism [MeSH] 18598 
#36 Pulmonary oedema [MeSH] 10141 
#37 #2 0R#3....0R#36 579362 
#39 #1 AND #37 1613 
265 
Ill(b). Data sheet 
Imperial College imperial College Healthcare 
London NHS Trust 
Pneumonia diagnosis in patients who have undergone gastro-esophaeeal resection 
NHS 
Patient surname: 
Patient forename: 
Date of operation: 
DOB: 
Hospno: 
Surgical approach: 
Radiological cr i ter ia; 
1 or m o r e serial chest radiographs w i t h evidence of at least 1 on the fo l l ovv ing t : 
Nsw non-dspsndentinfiltrotss 
New rion-dspsndsnt consolidotion 
OR 
A least one CT scan showing evidence of at least 1 on t he fo l lowing: 
New infiltro ts: 
Nsw consolidotion 
Please mark areas of new in f i l t ra te/consol idat ion: 
u 
Tick if 
opp'spriote 
Lateral Right Left 
• 
• 
• 
• 
Date on which changes f i rst observed : / / 
Lateral 
Descript ion of changes/addit ional comments 
tTTje presence of atelectasis, ground glass appearance, or fluid on postoperative cttest radiograph are iwt considered 
diagnostically significant unless found in the presence or one or more of the firm criteria 
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Appendix IV: Ethics approval letters 
06/Q0403/63 Page 1 
07 July 2006 
St Mary's Research Ethics Committee 
Internal Mail Box 121 
St Marys Hospital 
Paddinglon 
London 
WZ 1NY 
Telephone: 020 7886 6514 
Facsimile; 020 7886 1529 
Mr George B Hanna 
Clinical Reader in Sui^ery 
Imperial College London 
Department of Biosurgery & Surgical Technology 
•fOth Roor, QEQM Buifding 
St Mary's Hospital, Praed Street, London 
W2 1NY 
Dear Mr Hanna 
Full title of study: 
REG reference number. 
The use of breath-gas analysis for molecular oriented 
detection of gastric and oesophageal cancer 
06/Q0403/63 
Thank you for your letter of 07 June 2006. responding to the Committee's request for further 
information on the above research and submitting revised documentation. 
The farther information was considered at the meeting of the Sub-Committee of the REC 
held on 07 July 2006. The members who reviewed (he Information were Vassilios Papalois 
and Mark Turkish. 
Confirmation of ethical opinion 
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described In the application form, protocol and supporting 
documentation as revised. 
Ethical review of research sites 
The favourable opinion applies to the research sites listed on the attached form. 
Conditions of approval 
The fevourabie opinion is given provided that you comply with the conditions set out in the 
attached document. You are advised to study the conditions carefully. 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Document:i \ L " v 'Vernon : \ : iDaife. if--
Application 1 26 April 2006 
Protocol 1 27 April 2006 
Letter from Sponsor email i 26 April 2006 
2 6 7 
06/Q0403JB3 Page 2 
Peer Re^ew Dr M Harrison 01 May 2006 
Peer Review Dr Hadiiminas PR 27 April 2006 
Compensation Arrangements email 26 April 2006 
Participant Information Sheet leaflet 2 05 June 2006 
Participant information Sheet 1 27 April 2006 
Participant Information Sheet Control 1 27 April 2006 
Participant Consent Form Control 1 27 April 2006 
Participant Consent Form 1 27 April 2006 
Response to Request for Further Information fetter 07 June 2006 
Research governance approval 
The study should not commence at any NHS site until the local Principal Investigator has 
obtained final research governance approval from the R&D Department for the relevant NHS 
care organisation. 
Statement of compliance 
The Committee is constituted In accordance with the Governance Arrangements for 
Research Ethics Committees (July 2001) and complies fulfy with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
06/Q0403/63 Please quote thts number on all correspondence 
With the Committee's best wishes for the success of this project 
Yours sincerely 
Mr Barrie Newton 
Chairman 
Email: Ros.Cooke@st-marys-nhs.uk 
Enchsures: Stsndard approval conditions 
Site approval form 
Copy to: Imperial College London 
Faculty of Medicine. Imperial College London 
Faculty Building, South Kensington Campus 
London 
R&D Department for NHS care organisation af lead site 
06/Q0403/63 Page 1 
00 \o 
<N 
St Mary's Research Ethics Committeo 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
For all studies requiring site-specific assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and 
following subsequent notificatiorts from site assessors. For Issue 2 onwards, all sites with a favourable opinion are listed, adding the new sites approved. 
REC reference number: 
Chief Investigator: 
Full title of study: 
06/00403/63 Issue number: 
T 
Date of issue: 07 July 2006 
Mr George B Hanna 
The use of breath-gas analysis for molecular oriented detection of gastric and oesophageal cancer 
This study was given a favourable ethical opinion by SI Mary's Research Ethics Committeo on 07 July 2006. The favourable opinion is extended to each of the sites 
listed botoiv. The research may commence at each NHS site when management approval from the relevant NHS care organisation has been confirmed. 
Ivir George B Hanna Clinical Reader In 
Surgery 
St Mary's NHS Trust St Mary's Research 
Ethics Committee 
iiRiSttg^ igigligp 
07/07/2006 
••'•"''iiiiri;' 
Approved by the Cfiair on behalf of the REC: 
../!% (Signature of-€t»ir/Admlnlstrator) 
(delete as applicable) 
. (Name) 
(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notitiod by the Chief Investigator or sponsor), the 
suspension of termination of the favourable opinion for an individual site, or any o(/ier relevant development. The date should be recorded. 
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St Mary's 
NHS Trust 
NHS 
A 
St Mary^ Hospital 
Praed Street 
London 
W2 1NY 
19** September 2006 
Tel: 020 7386 6666 
Mr George Hanra Fax: 020 7886 6200 
Imperial College London Website: www.st-marys.org.uk 
D^r tment of Blosurgery and Surgical Technology 
10* Floor QEQM 
St Marys NHS Trust 
Dear Mr Hanna 
Project title: The use of breath-gas analysis for molecular oriented 
diagnosis and management of gastro-oesophageai cancer 
RAD Number 06/CD/0020E St Marys REC no 06q0403/63 (SSA) 
Principal Znvestlgaton Mr George Hanna 
I confirm that this project has now been approved by the Research & Development 
Department. The project may now start at St Marys site. 
Before you commence your research, please note that you must be aware of your 
obligations to comply with the minimum requirements for compliance with the 
Research Governance Indicators 17 (Data Protection); 25 (Health and Safety) and 22 
(Bnandaf Probity). Details of the requirements to be met can be found in the Trust 
Research Governance Policy in the current R&D Annual Report, R&D Management 
Office, or on the Trust Intranet under Research & Development. Please also refer to 
the Research Governance Framework available on www.dh.gov.ufc. 
I wish you well In your research, and look forward to seeing regular annual progress 
reports, and funding details, as well as Information about any publications resulting 
from the study. 
Under Research Governance regulations participant consent forms for all recruited 
participants on the study, and Serious Adverse Event Reports must be forwarded to 
the Research & Development Office, using the R&D number above. 
I wish you well In your research, and look forward to seeing regular annual progress 
reports, and funding details, as well as information about any publications resulting 
from the study. 
Yours sincerely 
Professor Myra McClure / , , 
Director of R and D / r * * ' 
St Marys NHS Trust 
St Mary's NHS Trust indudes St Mary% Hospital, Paddlngton, acute services at 
St Charles Hospital the Western Eye Hosfrital 
Ctiairman: Baroness Joan Hanham 
2 7 0 
NHS 
The Joint UCL/UCLH Committees on the Ethics ofnuman Research (Comminee 
Alpha) 
ICH R&D office, 1st Floor 
3 Long Yard 
London 
Tel: 020 7599 4130 
Fax: 020 7599 4138 
Website: http:/Awww.nrss.npsa.nhs.uk/index.htm 
WC1N 3LU 
Telephone: 020 7599 4130 
Facsimile: 020 7599 4138 
16 February 2009 
Professor George Hanna 
Professor of Surgical Sciences / Consultant Surgeon 
Imperial College London, St Mary's Hospital 
Department of Biosurgery and Surgical Technology 
10th Floor QEQM Wing St Mary's Hospital, 
Praed Street, London 
W21NY 
Dear Professor Hanna 
Full title of study: Use of gas and fluid phase metabolic profiling to predict, 
diagnose and monitor the development of postoperative 
pneumonia in patients undergoing elective 
oesophagectomy 
REG reference number: 08/H0715/122 
Thank you for your letter of 30 January 2009, responding to the Committee's request for 
further information on the above research and submitting revised documentation. 
The further information was considered at the meeting of the Sub-Committee of the REC 
held on 12 February 2009. A list of the memljers who were present at the meeting is 
attached. 
Confirmation of ethical opinion 
On behalf of the Committee. I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised, subject to the conditions specified below. 
Ethical review of research sites 
The favourable opinion applies to the research sites listed on the attached form. 
Conditions of the favourable opinion 
The favourable opinion is subject to the following conditions being met prior to the start of 
the study. 
Management permission or approval must be obtained from each host organisation prior to 
the start of the studv at the site concerned. 
Management permission at NHS sites ("R&D approval") should be obtained from the 
This Research Ethics Committee is an advisory committee to London Strategic Health Authority 
The National Research Ethics Service (NRES) represents the NRES Directorate within 
the National Patient Safety Agency and Research Ethics Committees in Bngiand 
2 7 1 
relevant care organisation(s} in accordance vi/ith NHS research governance an^ngements. 
Guidance on applying for NHS permission is available in the Integrated Research 
Application System or at http://www.rdforum.nhs.uk. 
Approved documents 
The final list of documents reviewed and approved by the Committee is as follows: 
Letter from Sponsor 01 December 2008 
Protocol 1,1 26 November 2008 
Investigator CV 
Application 05 December 2008 
Covering Letter 05 December 2008 
Insurance details 04 December 2008 
Response to Request for Further Information 30 January 2009 
Participant Consent Form: Surgical Consent 1.2 29 January 2009 
Participant Consent Fonn: Non-Ventilated 1.2 29 January 2009 
Participant Information Sheet: Surgical 1.2 29 January 2009 
Participant Information Sheet: Non-Ventilated 1.2 29 January 2009 
Statement of compliance 
The Committee is constituted in accordance with the Governance An-angements for 
Research Ethics Committees (July 2001) and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
After ethical review 
Now that you have completed the application process please visit the National Research 
Ethics Website > After Review 
You are invited to give your view of the service that you have received from the National 
Research Ethics Service and the application procedure. If you wish to make your views 
known please use the feedback form available on the website. 
The attached document "After ethical review -guidance for researchers" gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including: 
• Notifying substantial amendments 
• Progress and safety reports 
• Notifying the end of the study 
The NRES website also provides guidance on these topics, vi/hich is updated in the light of 
changes in reporting requirements or procedures. 
We would also like to inform you that we consult regularly with stakeholders to improve our 
service. If you would like to join our Reference Group please email 
referenceqroup@nres.npsa.nhs.uk. 
108/H0715/122 Please quote this number on all correspondence 
With the Committee's best wishes for the success of this project 
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Yours sincerely 
C W -
| j Mrs Patricia Orwell 
Chair 
Email: Tom.Lucas@lch.ucl.ac.uk 
Enclosures: List of names and professions of members who were present at the 
meeting and those who submitted written comments 
Copy to: Mr Gary Roper 
Clinical Research Governance Office G02 
Sir Alexander Fleming Building, 
Imperial college, 
South Kensington Campus 
London 
SW7 2AZ 
The Joint UCL/UCLH Committees on the Ethics of Human Research (Committee 
Alpha) Attendance at Sub-Committee of the REC meeting on 12 February 2009 
Committee Members: 
Mr Robin Offord Director of Clinical 
Pharmacy / Clinical 
Pharmacist 
Yes 
Mrs Patricia Orwell Yes 
M r-(N 
The Joint UCUUCLH Committees on the Ethics of Human Research (Committee Alpha) 
LIST OF SITES WITH A FAVOURABLE ETHICAL OPINION 
For a// studies requiring sUe-specinc assessment, this form is issued by the main REC to the Chief Investigator and sponsor with the favourable opinion letter and 
fbllowina subsequent notifications from site assessors. For issue 2 onwards, all sites with a favourable opinion are listed, addinq the new sites approved. 
REC reference number 08/H0715/122 Issue number: 0 Date of issue: 16 February 2009 
Chief Investigator: Professor George Hanna 
Full title of study: Use of gas and fluid phase metabolic profiling to predict, diagnose and monitor the development of postoperative pneumonia in patients 
undergoing elective oesophaqectomv 
This study was given a favourable ethical opinion by The Joint UCUUCLH Committees on the Ethics of Human Research (Committee Alpha) on 12 February 2009. 
The favourable opinion is extended to each of the sites listed below. The research may commence at each NHS site when management approval from the relevant 
NHS care organisation has been confirmed. 
Tfindf^l Invesiiuator; J l ~ , i l W ' ',1 
Professor George 
Hanna 
Professor of Surgical 
Sciences / Consultant 
Upper Gl Surgeon 
St Mary s Hospital, 
Imperial College 
Healthcare NHS Trust 
St Mary's REC 16/02/2009 
Approved by the Chair on behalf of the REC: 
eiitriiyCo-ordlnator) 
(delete as applicable) 
(1) The notes column may be used by the main REC to record the early closure or withdrawal of a site (where notified by the Chief Investigator or sponsor), 
the suspension of termination of the favourable opinion for an individual site, or any other relevant development. The date should be recorded. 
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Imperial College Healthcare L'-LtZf 
Research & Development Management Office 
Mailbox 121 
St Mary's Hospital 
Praed Street 
London 
W21NY 
Tel: 020 7886 7952 
25 February 2009 
Professor George Hanna 
Professor of Surgical Sciences / Consultant Surgeon 
Imperial College London - St Mary's Hospital 
Department of Biosurgery and Surgical Technology 
10''' Floor QEQM Wing 
Praed Street 
London W2 1NY 
Dear Professor Hanna, 
Project Title: Use of gas and fluid phase metabolic profiling to predict, diagnose and 
monitor the development of postoperative pneumonia in patients undergoing elective 
oesophagectomy 
R&D reference number: 08/CD/006 Ethics reference number: 08/H0715/122 
Principal Investigator: Professor George Hanna, 
I confirm that this project has now been approved by the Research & Development 
Department. The project may now start at Imperial College Healthcare NHS Trust 
sites. Please note that the start date of the project is the date of this letter and the 
duration is the same as that provided in your application form. 
Before you commence your research, please note that you must be aware of your 
obligations to comply with the minimum requirements for compliance with the 
Research Governance indicators 17 (Data Protection): 25 (Health and Safety) and 22 
(Financial Probity). Details of the requirements to be met can be found in the Trust 
Research Governance Policy in the current R&D Annual Report, R&D Management 
Office, or on the Trust Intranet under Research & Development. Please also refer to 
the Research Governance Framework available on .v.w.dh.aov.uk. 
Under the Research Governance regulations, Serious Adverse Event Reports, 
Adverse Reactions and amendments to the protocol or other supporting documents 
must be forwarded to the Research & Development Office and Ethics Committee 
In accordance with the Research Governance Framework, research projects carried 
out in the Trust will be randomly chosen by the R&D team for auditing. Please see 
the attached checklist for documentation that will be required during the audit. 
I wish you well in your research. 
Yours sincerely, 
A '^1 L. r. 
Professor Myra McClure 
Research and Development Management Office 
St Mary's Hospital 
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Appendix V: Metabolite assignments 
a. b. c. a. c. 
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Two-dimensions COSY spectra showing cross-peaks. Metabolite responsible for tlie labelled 
cross peaks are as follows: (a) liistidine, (b) phenylalanine, (c) tyrosine, (d) 3-hydroxybutyrate, (e) 
lactate, (f) creatinine, (g) alanine, (h) valine, (i) citrate, and (j) glutamine. 
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Chemical shift (ppm) 
Typical 'H NMR spectrum recorded from the serum of a patients before oesophagectomy. Assignment of peaks was made using Chenomx nmr suite 
(Version 6.0). The black line represents the NMR spectrum of serum whilst the red line represents assignments derived from the Chenomx database. 
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Typical 'H NMR spectrum recorded from the urine of a patient before oesophagectomy. Assignment of peaks was made using Chenomx nmr suite (Version 
6.0). The black line represents the NMR spectrum of urine whilst the red line represents assignments derived from the Chenomx database. 
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